<SEC-DOCUMENT>0001096906-25-000816.txt : 20250515
<SEC-HEADER>0001096906-25-000816.hdr.sgml : 20250515
<ACCEPTANCE-DATETIME>20250515150053
ACCESSION NUMBER:		0001096906-25-000816
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		44
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250515
DATE AS OF CHANGE:		20250515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UTAH MEDICAL PRODUCTS INC
		CENTRAL INDEX KEY:			0000706698
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				870342734
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12575
		FILM NUMBER:		25951694

	BUSINESS ADDRESS:	
		STREET 1:		7043 S 300 WEST
		CITY:			MIDVALE
		STATE:			UT
		ZIP:			84047
		BUSINESS PHONE:		8015661200
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>utmd-20250331.htm
<DESCRIPTION>UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:fil="http://www.utahmed.com/20250331" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:i="http://www.xbrl.org/2003/instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<head>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK5GW761L0VEWPD92X]. www.edgarsuite.com -->
<title>UTAH MEDICAL PRODUCTS INC - Form 10-Q SEC filing</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body>
<div style="display:none">
<ix:header>
<ix:hidden>
<ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="Y25Q1" id="fact1">0000706698</ix:nonNumeric>
<ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="Y25Q1" id="fact2">--12-31</ix:nonNumeric>
<ix:nonNumeric name="dei:AmendmentFlag" contextRef="Y25Q1" id="fact3">false</ix:nonNumeric>
<ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="Y25Q1" id="fact4">2025</ix:nonNumeric>
<ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="Y25Q1" id="fact5">Q1</ix:nonNumeric>
</ix:hidden>
<ix:references>
<link:schemaRef xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="utmd-20250331.xsd" xlink:type="simple"/>
</ix:references>
<ix:resources>
<i:unit id="USD">
<i:measure>iso4217:USD</i:measure>
</i:unit>
<i:unit id="Shares">
<i:measure>xbrli:shares</i:measure>
</i:unit>
<i:unit id="UsdPerShare">
<i:divide>
<i:unitNumerator>
<i:measure>iso4217:USD</i:measure>
</i:unitNumerator>
<i:unitDenominator>
<i:measure>xbrli:shares</i:measure>
</i:unitDenominator>
</i:divide>
</i:unit>
<i:unit id="Pure">
<i:measure>xbrli:pure</i:measure>
</i:unit>
<i:context id="Y25Q1">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="E25Q1">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2025-03-31</i:instant>
</i:period>
</i:context>
<i:context id="I250512">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2025-05-12</i:instant>
</i:period>
</i:context>
<i:context id="E24">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2024-12-31</i:instant>
</i:period>
</i:context>
<i:context id="Y24Q1">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q1_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q1_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q1_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q1_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="E24_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E24_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E24_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E24_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E25Q1_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2025-03-31</i:instant>
</i:period>
</i:context>
<i:context id="E25Q1_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2025-03-31</i:instant>
</i:period>
</i:context>
<i:context id="E25Q1_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2025-03-31</i:instant>
</i:period>
</i:context>
<i:context id="E25Q1_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2025-03-31</i:instant>
</i:period>
</i:context>
<i:context id="E23">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2023-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E23_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E23_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E23_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E23_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-12-31</i:instant>
</i:period>
</i:context>
<i:context id="Y24Q1_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q1_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q1_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q1_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="E24Q1">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2024-03-31</i:instant>
</i:period>
</i:context>
<i:context id="E24Q1_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-03-31</i:instant>
</i:period>
</i:context>
<i:context id="E24Q1_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-03-31</i:instant>
</i:period>
</i:context>
<i:context id="E24Q1_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-03-31</i:instant>
</i:period>
</i:context>
<i:context id="E24Q1_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-03-31</i:instant>
</i:period>
</i:context>
<i:context id="Y25Q1_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q1_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q1_ProductOrService-Obstetrics">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q1_ProductOrService-Obstetrics_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q1_ProductOrService-Obstetrics_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q1_ProductOrService-GynecologyElectrosurgeryUrology">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q1_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q1_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q1_ProductOrService-Neonatal">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q1_ProductOrService-Neonatal_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q1_ProductOrService-Neonatal_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q1_ProductOrService-BloodPressureMonitoringAndAccessories">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q1_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q1_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q1_StScenario-SingleOperatingSeg">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">fil:SingleOperatingSegmentMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q1_StScenario-SingleOperatingSeg">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">fil:SingleOperatingSegmentMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
</ix:resources>
</ix:header>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">UNITED STATES</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">Washington, D.C. &#160;20549</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><b>FORM </b><ix:nonNumeric name="dei:DocumentType" contextRef="Y25Q1" escape="true" id="ixv-4854">10-Q</ix:nonNumeric></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0"><ix:nonNumeric name="dei:DocumentQuarterlyReport" contextRef="Y25Q1" format="ixt-sec:boolballotbox" id="ixv-4855">&#9746;</ix:nonNumeric> &#160;&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center">For the quarterly period ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="Y25Q1" format="ixt:date-monthname-day-year-en" id="ixv-4856">March 31, 2025</ix:nonNumeric><span style="-sec-ix-hidden:fact2"></span></p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center">OR</p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0"><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="Y25Q1" format="ixt-sec:boolballotbox" id="ixv-4857">&#9744;</ix:nonNumeric> &#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to &#160;</p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center">Commission File No. <span style="border-bottom:1px solid #000000"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="Y25Q1" escape="true" id="ixv-4858">001-12575</ix:nonNumeric></span></p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="Y25Q1" escape="true" id="ixv-4859">UTAH MEDICAL PRODUCTS INC</ix:nonNumeric></span></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">(Exact name of Registrant as specified in its charter)</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="Y25Q1" escape="true" id="ixv-4860">UT</ix:nonNumeric>AH</span></p>
</td><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="Y25Q1" escape="true" id="ixv-4861">87-0342734</ix:nonNumeric></p>
</td></tr>
<tr><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0;text-align:center">(State or other jurisdiction of incorporation or organization)</p>
</td><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0;text-align:center">(I.R.S. Employer&#160;Identification No.)</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="Y25Q1" escape="true" id="ixv-4862">7043 South 300 West</ix:nonNumeric></p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="Y25Q1" escape="true" id="ixv-4863">Midvale</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="Y25Q1" format="ixt-sec:stateprovnameen" id="ixv-4864">Utah</ix:nonNumeric> &#160;<ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="Y25Q1" escape="true" id="ixv-4865">84047</ix:nonNumeric></span></p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center">(Address of principal executive offices) (Zip Code)</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="Y25Q1" escape="true" id="ixv-4866">801</ix:nonNumeric>) </span><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="Y25Q1" escape="true" id="ixv-4867">566-1200</ix:nonNumeric></p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center">(Registrant&#8217;s telephone number, including area code)</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0">Securities registered pursuant to Section 12(b) of the Act:</p>
</td><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:33.32%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:33.32%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0;text-align:center">Title of each class:</p>
</td><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0;text-align:center">Trading Symbol:</p>
</td><td valign="top" style="width:33.32%"><p style="font:10pt Times New Roman;margin:0;text-align:center">Name of each exchange on which registered:</p>
</td></tr>
<tr><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="Y25Q1" escape="true" id="ixv-4868">Common stock, $0.01 par value</ix:nonNumeric></p>
</td><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="Y25Q1" escape="true" id="ixv-4869">UTMD</ix:nonNumeric></p>
</td><td valign="top" style="width:33.32%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="Y25Q1" id="ixv-4870">NASDAQ</ix:nonNumeric></p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt"> &#160;</kbd><kbd style="margin-left:18pt"></kbd>Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;<ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="Y25Q1" id="ixv-4871">Yes</ix:nonNumeric>&#160;<span style="font-family:Wingdings">x</span> &#160;&#160;No&#160;<span style="font-family:Wingdings">o</span>&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt"> &#160;</kbd><kbd style="margin-left:18pt"></kbd>Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;<ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="Y25Q1" id="ixv-4872">Yes</ix:nonNumeric>&#160;<span style="font-family:Wingdings">x</span> &#160;&#160;No&#160;<span style="font-family:Wingdings">o</span>&#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:18pt"></kbd>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0">Large accelerated filer&#160;<span style="font-family:Wingdings">o</span></p>
</td><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0">Accelerated filer&#160;<span style="font-family:Wingdings">o</span></p>
</td></tr>
<tr><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="Y25Q1" format="ixt-sec:entityfilercategoryen" id="ixv-4873">Non-accelerated filer</ix:nonNumeric> <span style="font-family:Wingdings">x</span></p>
</td><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0">Smaller reporting company <ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="Y25Q1" format="ixt-sec:boolballotbox" id="ixv-4874">&#9746;</ix:nonNumeric></p>
</td></tr>
<tr><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="Y25Q1" format="ixt-sec:boolballotbox" id="ixv-4875">&#9744;</ix:nonNumeric></p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:18pt"></kbd>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<span style="font-family:Wingdings">o</span> &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:18pt"></kbd>Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &#160;Yes&#160;<ix:nonNumeric name="dei:EntityShellCompany" contextRef="Y25Q1" format="ixt-sec:boolballotbox" id="ixv-4876">&#9744;</ix:nonNumeric> &#160;&#160;No&#160;<span style="font-family:Wingdings">x</span>&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:18pt"></kbd>Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock as of May 12, 2025: <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="I250512" decimals="INF" unitRef="Shares" scale="0" format="ixt:num-dot-decimal" id="ixv-4877">3,248,210</ix:nonFraction>.&#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC.</span></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">INDEX TO FORM 10-Q</span></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:11.74%;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">PAGE</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0">PART I - FINANCIAL INFORMATION</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a1" style="text-decoration:none">Item 1. Financial Statements</a></span></p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">1</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-left:18pt;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a2" style="text-decoration:none">Consolidated Condensed Balance Sheets as of March 31, 2025 and December 31, 2024</a></span> </p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">1</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-left:18pt;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a3" style="text-decoration:none">Consolidated Condensed Statements of Income for the three months ended March 31, 2025 and March 31, 2024</a></span> </p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">2</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-left:18pt;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a4" style="text-decoration:none">Consolidated Condensed Statements of Cash Flows for the three months ended March 31, 2025 and March 31, 2024</a></span> </p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">3</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-left:18pt;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a5" style="text-decoration:none">Consolidated Condensed Statements of Stockholders&#8217; Equity for the three months ended March 31, 2025 and March 31, 2024</a></span> </p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">4</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-left:18pt;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a6" style="text-decoration:none">Notes to Consolidated Condensed Financial Statements</a></span></p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">5</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a7" style="text-decoration:none">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">7</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a8" style="text-decoration:none">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span> </p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">14</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a9" style="text-decoration:none">Item 4. Controls and Procedures</a></span> </p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">14</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">PART II &#8211;&#160;OTHER INFORMATION</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a10" style="text-decoration:none">Item 1. Legal Proceedings</a></span></p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">15</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a11" style="text-decoration:none">Item 1A. Risk Factors</a></span></p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">15</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a12" style="text-decoration:none">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">16</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a13" style="text-decoration:none">Item 6. Exhibits</a></span> </p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">17</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a14" style="text-decoration:none">SIGNATURES</a></span> </p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">18</p>
</td></tr>
</table>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</div>
<div style="margin-left:72pt"><a id="a1"></a><a id="a2"></a><table style="border-collapse:collapse;width:477pt"><tr style="height:7.2pt"><td colspan="7" valign="bottom" style="width:477pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">PART I &#160;- &#160;FINANCIAL INFORMATION</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:256.5pt"><p style="font:10pt Times New Roman;margin:0"><b>Item 1. &#160;Financial Statements</b></p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:90pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:103.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="7" valign="bottom" style="width:477pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</span></p>
</td></tr>
<tr style="height:7.2pt"><td colspan="7" valign="bottom" style="width:477pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">CONSOLIDATED CONDENSED BALANCE SHEETS AS OF</span></p>
</td></tr>
<tr style="height:7.2pt"><td colspan="7" valign="bottom" style="width:477pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">MARCH 31, 2025 AND DECEMBER 31, 2024</span></p>
</td></tr>
<tr style="height:7.2pt"><td colspan="7" valign="bottom" style="width:477pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(in thousands)</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:19.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:225pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:90pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(unaudited)</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:103.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(audited)</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:256.5pt"/><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:90pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">MARCH 31, 2025</span></p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:103.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">DECEMBER 31, 2024</span></p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:256.5pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">ASSETS</span></p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:90pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:103.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:256.5pt"><p style="font:10pt Times New Roman;margin:0">Current assets:</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:90pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:103.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:244.7pt"><p style="font:10pt Times New Roman;margin:0">Cash &amp; Investments</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:90pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="E25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4878">83,325</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:103.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:86pt"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4879">82,976</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="width:244.7pt"><p style="font:10pt Times New Roman;margin:0">Accounts &amp; other receivables, net</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:90pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="E25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4880">3,944</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:103.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:86pt"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4881">4,094</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:244.7pt"><p style="font:10pt Times New Roman;margin:0">Inventories</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:90pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="E25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4882">8,648</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:103.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:86pt"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4883">8,812</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="width:244.7pt"><p style="font:10pt Times New Roman;margin:0">Other current assets</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:90pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="E25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4884">482</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:103.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:86pt"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4885">448</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:19.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:225pt"><p style="font:10pt Times New Roman;margin:0">Total current assets</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:90pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="E25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4886">96,399</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:103.5pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:86pt"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4887">96,330</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:256.5pt"><p style="font:10pt Times New Roman;margin:0">Property and equipment, net</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:90pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="E25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4888">9,945</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:103.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:86pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4889">9,763</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:256.5pt"><p style="font:10pt Times New Roman;margin:0">Goodwill</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:90pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt"><ix:nonFraction name="us-gaap:Goodwill" contextRef="E25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4890">13,770</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:103.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:86pt"><ix:nonFraction name="us-gaap:Goodwill" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4891">13,580</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="width:244.7pt"><p style="font:10pt Times New Roman;margin:0">Other intangible assets</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:90pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="E25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4892">54,650</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:103.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:86pt"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4893">53,772</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:258.2pt"><p style="font:10pt Times New Roman;margin:0">Other intangible assets - accumulated amortization</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:90pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="E25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4894">52,245</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:103.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:86pt">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4895">50,907</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:256.5pt"><p style="font:10pt Times New Roman;margin:0">Other intangible assets, net</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:90pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="E25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4896">2,405</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:103.5pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:86pt"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4897">2,865</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:19.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:225pt"><p style="font:10pt Times New Roman;margin:0">Total assets</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:90pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt"><ix:nonFraction name="us-gaap:Assets" contextRef="E25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4898">122,519</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:103.5pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:86pt"><ix:nonFraction name="us-gaap:Assets" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4899">122,538</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:19.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:225pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:90pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:103.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:256.5pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">LIABILITIES AND STOCKHOLDERS' EQUITY</span></p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:90pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:103.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:256.5pt"><p style="font:10pt Times New Roman;margin:0">Current liabilities:</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:90pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:103.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:244.7pt"><p style="font:10pt Times New Roman;margin:0">Accounts payable</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:90pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="E25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4900">914</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:103.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:86pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4901">696</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="width:244.7pt"><p style="font:10pt Times New Roman;margin:0">Accrued expenses</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:90pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="E25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4902">3,410</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:103.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:86pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4903">3,061</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:19.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:225pt"><p style="font:10pt Times New Roman;margin:0">Total current liabilities</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:90pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="E25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4904">4,324</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:103.5pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:86pt"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4905">3,757</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:256.5pt"><p style="font:10pt Times New Roman;margin:0">Deferred tax liability - Femcare IIA</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:90pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="E25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4906">494</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:103.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:86pt"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4907">603</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:256.5pt"><p style="font:10pt Times New Roman;margin:0">Other long term liabilities</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:90pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt"><ix:nonFraction name="us-gaap:OtherLongTermDebtNoncurrent" contextRef="E25Q1" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4908">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:103.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:86pt"><ix:nonFraction name="us-gaap:OtherLongTermDebtNoncurrent" contextRef="E24" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4909">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:256.5pt"><p style="font:10pt Times New Roman;margin:0">Long-term lease liability</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:90pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt"><ix:nonFraction name="us-gaap:LongTermDebtAndCapitalLeaseObligations" contextRef="E25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4910">269</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:103.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:86pt"><ix:nonFraction name="us-gaap:LongTermDebtAndCapitalLeaseObligations" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4911">282</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:256.5pt"><p style="font:10pt Times New Roman;margin:0">Deferred income taxes</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:90pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="E25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4912">385</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:103.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:86pt"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4913">469</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:19.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:225pt"><p style="font:10pt Times New Roman;margin:0">Total liabilities</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:90pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt"><ix:nonFraction name="us-gaap:Liabilities" contextRef="E25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4914">5,472</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:103.5pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:86pt"><ix:nonFraction name="us-gaap:Liabilities" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4915">5,111</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:19.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:225pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:90pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:103.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:256.5pt"><p style="font:10pt Times New Roman;margin:0">Stockholders' equity:</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:90pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:103.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:244.7pt"><p style="font:10pt Times New Roman;margin:0;text-indent:-9.75pt;margin-left:9.75pt">Common stock - $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="E25Q1" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-4916"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="E24" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-4917">0.01</ix:nonFraction></ix:nonFraction> par value; authorized - <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="E25Q1" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-4918"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="E24" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-4919">50,000</ix:nonFraction></ix:nonFraction> shares; issued and outstanding - March 31, 2025, <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="E25Q1" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-4920"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="E25Q1" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-4921">3,281</ix:nonFraction></ix:nonFraction> shares and December 31, 2024, <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="E24" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-4922"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="E24" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-4923">3,335</ix:nonFraction></ix:nonFraction> shares</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:90pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="E25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4924">33</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:103.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:86pt"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4925">33</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="width:244.7pt"><p style="font:10pt Times New Roman;margin:0">Accumulated other comprehensive loss</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:90pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" contextRef="E25Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-4926">11,190</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:103.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:86pt">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" contextRef="E24" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-4927">11,908</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:244.7pt"><p style="font:10pt Times New Roman;margin:0">Additional paid-in capital</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:90pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="E25Q1" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4928">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:103.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:86pt"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="E24" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4929">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="width:244.7pt"><p style="font:10pt Times New Roman;margin:0">Retained earnings</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:90pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="E25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4930">128,204</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:103.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:86pt"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4931">129,302</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:19.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:225pt"><p style="font:10pt Times New Roman;margin:0">Total stockholders' equity</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:90pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="E25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4932">117,047</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:103.5pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:86pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4933">117,427</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:19.7pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:225pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:90pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:103.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:19.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:225pt"><p style="font:10pt Times New Roman;margin:0">Total liabilities and stockholders' equity</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:90pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="E25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4934">122,519</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:103.5pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:86pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4935">122,538</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:256.5pt"><p style="font:10pt Times New Roman;margin:0"><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:90pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:103.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">1</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</div>
<div style="margin-left:72pt"><a id="a3"></a><table style="border-collapse:collapse;width:469.85pt"><tr style="height:7.2pt"><td colspan="7" valign="bottom" style="width:469.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</span></p>
</td></tr>
<tr style="height:7.2pt"><td colspan="7" valign="bottom" style="width:469.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">CONSOLIDATED CONDENSED STATEMENTS OF INCOME</span></p>
</td></tr>
<tr style="height:7.2pt"><td colspan="7" valign="bottom" style="width:469.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">FOR THE THREE MONTHS ENDED MARCH 31, 2025 AND MARCH 31, 2024</span></p>
</td></tr>
<tr style="height:7.2pt"><td colspan="7" valign="bottom" style="width:469.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(in thousands, except per share amounts)</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="7" valign="bottom" style="width:469.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(unaudited)</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:228.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:204.35pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">THREE MONTHS ENDED</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:228.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:204.35pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">MARCH 31,&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:252pt"/><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:99pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">2025</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:91.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">2024</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:252pt"><p style="font:10pt Times New Roman;margin:0">Sales, net</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:99pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4936">9,710</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:91.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4937">11,340</ix:nonFraction> </p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:228.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:99pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:91.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:252pt"><p style="font:10pt Times New Roman;margin:0">Cost of goods sold</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:99pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4938">4,172</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:91.85pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4939">4,574</ix:nonFraction> </p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="width:240.2pt"><p style="font:10pt Times New Roman;margin:0">Gross profit</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:99pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4940">5,538</ix:nonFraction> </p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:91.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4941">6,766</ix:nonFraction> </p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:228.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:99pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:91.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:252pt"><p style="font:10pt Times New Roman;margin:0">Operating expense</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:99pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:91.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:240.2pt"><p style="font:10pt Times New Roman;margin:0">Selling, general and administrative</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:99pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4942">2,231</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:91.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4943">2,617</ix:nonFraction> </p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="width:240.2pt"><p style="font:10pt Times New Roman;margin:0">Research &amp; development</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:99pt;border-bottom:0.25pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4944">154</ix:nonFraction> </p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:91.85pt;border-bottom:0.25pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4945">266</ix:nonFraction> </p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:228.4pt"><p style="font:10pt Times New Roman;margin:0">Total operating expenses</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:99pt;border-top:0.25pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4946">2,385</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:91.85pt;border-top:0.25pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4947">2,883</ix:nonFraction> </p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="width:240.2pt"><p style="font:10pt Times New Roman;margin:0">Operating income</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:99pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4948">3,153</ix:nonFraction> </p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:91.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4949">3,883</ix:nonFraction> </p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:228.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:99pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:91.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:252pt"><p style="font:10pt Times New Roman;margin:0">Other income</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:99pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4950">705</ix:nonFraction> </p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:91.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4951">915</ix:nonFraction> </p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:240.2pt"><p style="font:10pt Times New Roman;margin:0">Income before provision for income taxes</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:99pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4952">3,858</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:91.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4953">4,798</ix:nonFraction> </p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:228.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:99pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:91.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:252pt"><p style="font:10pt Times New Roman;margin:0">Provision for income taxes</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:99pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4954">817</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:91.85pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4955">842</ix:nonFraction> </p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:228.4pt"><p style="font:10pt Times New Roman;margin:0">Net income</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:99pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4956">3,041</ix:nonFraction> </p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:91.85pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4957">3,956</ix:nonFraction> </p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:228.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:99pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:91.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:252pt"><p style="font:10pt Times New Roman;margin:0">Earnings per common share (basic)</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:99pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="Y25Q1" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-4958">0.92</ix:nonFraction> </p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:91.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="Y24Q1" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-4959">1.09</ix:nonFraction> </p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:252pt"><p style="font:10pt Times New Roman;margin:0">Earnings per common share (diluted)</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:99pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="Y25Q1" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-4960">0.92</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:91.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="Y24Q1" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-4961">1.09</ix:nonFraction> </p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:228.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:99pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:91.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:252pt"><p style="font:10pt Times New Roman;margin:0">Shares outstanding (basic)</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:99pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Y25Q1" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-4962">3,310</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:91.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Y24Q1" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-4963">3,618</ix:nonFraction> </p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:252pt"><p style="font:10pt Times New Roman;margin:0">Shares outstanding (diluted)</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:99pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Y25Q1" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-4964">3,310</ix:nonFraction> </p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:91.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Y24Q1" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-4965">3,618</ix:nonFraction> </p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:228.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:99pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:91.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:252pt"><p style="font:10pt Times New Roman;margin:0">Other comprehensive income (loss):</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:99pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:91.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:240.2pt"><p style="font:10pt Times New Roman;margin:0">Foreign currency translation net of taxes of <br/> &#160;&#160;$<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="Y25Q1" decimals="INF" unitRef="USD" scale="0" format="ixt:num-dot-decimal" id="ixv-4966"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="Y24Q1" decimals="INF" unitRef="USD" scale="0" format="ixt:num-dot-decimal" id="ixv-4967"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="Y25Q1" decimals="INF" unitRef="USD" scale="0" format="ixt:num-dot-decimal" id="ixv-4968"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="Y24Q1" decimals="INF" unitRef="USD" scale="0" format="ixt:num-dot-decimal" id="ixv-4969">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> in all periods</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:99pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4970">718</ix:nonFraction> </p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:91.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-4971">631</ix:nonFraction>)</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:228.4pt"><p style="font:10pt Times New Roman;margin:0">Total comprehensive income</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:99pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4972">3,759</ix:nonFraction> </p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:91.85pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4973">3,325</ix:nonFraction> </p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:228.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:99pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:91.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:252pt"><p style="font:8pt Times New Roman;margin:0"><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:99pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:91.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">2</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
</div>
<div style="margin-left:50.4pt;width:692.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"></p>
<a id="a5"></a><table style="border-collapse:collapse;width:100%"><tr style="height:7.2pt"><td colspan="12" valign="bottom" style="width:100%"><p style="font:8pt Times New Roman;margin:0;text-align:center">UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="12" valign="bottom" style="width:100%"><p style="font:8pt Times New Roman;margin:0;text-align:center">CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="12" valign="bottom" style="width:100%"><p style="font:8pt Times New Roman;margin:0;text-align:center">Three Months Ended March 31, 2025 and 2024</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="12" valign="bottom" style="width:100%"><p style="font:8pt Times New Roman;margin:0;text-align:center">(In thousands - unaudited)</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:25.64%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:8.94%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:8.44%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:10.4%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:14.3%"><p style="font:8pt Times New Roman;margin:0;text-align:center">Accumulated</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:9.42%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:12.36%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:25.64%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:8.94%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:8.44%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:10.4%"><p style="font:8pt Times New Roman;margin:0;text-align:center">Additional</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:14.3%"><p style="font:8pt Times New Roman;margin:0;text-align:center">Other</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:9.42%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:12.36%"><p style="font:8pt Times New Roman;margin:0;text-align:center">Total</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:25.64%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:19.48%;border-bottom:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0;text-align:center">Common Stock</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:10.4%"><p style="font:8pt Times New Roman;margin:0;text-align:center">Paid-in</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:14.3%"><p style="font:8pt Times New Roman;margin:0;text-align:center">Comprehensive</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:9.42%"><p style="font:8pt Times New Roman;margin:0;text-align:center">Retained</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:12.36%"><p style="font:8pt Times New Roman;margin:0;text-align:center">Stockholders'</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:25.64%"/><td valign="bottom" style="width:8.94%;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:8pt">Shares</span></p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:8.44%;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:8pt">Amount</span></p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:10.4%;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:8pt">Capital</span></p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:14.3%;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:8pt">Income</span></p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:9.42%;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:8pt">Earnings</span></p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:12.36%;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:8pt">Equity</span></p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:25.64%"><p style="font:10pt Times New Roman;margin:0"><span style="font-size:8pt">Balance at December 31, 2024</span></p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.94%"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:44pt"><span style="font-size:8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="E24_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-4974">3,335</ix:nonFraction>&#160;</span></kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.44%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:41pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24_StEqComps-CommonStock" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4975">33</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:10.4%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:54pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4976">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:14.3%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:81pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-4977">11,908</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:9.42%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:47pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4978">129,302</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:12.36%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:68pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4979">117,427</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:25.64%"><p style="font:8pt Times New Roman;margin:0">Shares issued upon exercise of employee <br/> &#160;stock options for cash</p>
</td><td valign="bottom" style="width:8.94%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:44pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="Y25Q1_StEqComps-CommonStock" decimals="-3" unitRef="Shares" format="ixt:fixed-zero" id="ixv-4980">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.44%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:41pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y25Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4981">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.4%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:54pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y25Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4982">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.3%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:81pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y25Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4983">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:9.42%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:47pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y25Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4984">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.36%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:68pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y25Q1" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4985">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:25.64%"><p style="font:10pt Times New Roman;margin:0"><span style="font-size:8pt">Shares received and retired upon exercise </span><br/><span style="font-size:8pt"> &#160;of stock options</span></p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.94%"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:44pt"><span style="font-size:8pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares" contextRef="Y25Q1_StEqComps-CommonStock" decimals="-3" unitRef="Shares" format="ixt:fixed-zero" id="ixv-4986">-</ix:nonFraction>&#160;</span></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.44%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:41pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions" contextRef="Y25Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4987">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.4%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:54pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions" contextRef="Y25Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4988">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:14.3%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:81pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions" contextRef="Y25Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4989">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:9.42%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:47pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions" contextRef="Y25Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4990">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12.36%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:68pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions" contextRef="Y25Q1" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4991">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:25.64%"><p style="font:8pt Times New Roman;margin:0">Tax benefit attributable to appreciation <br/> &#160;of stock options</p>
</td><td valign="bottom" style="width:8.94%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:44pt">-&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.44%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:41pt">-&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.4%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:54pt">-&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.3%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:81pt">-&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:9.42%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:47pt">-&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.36%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:68pt">-&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:25.64%"><p style="font:10pt Times New Roman;margin:0"><span style="font-size:8pt">Stock option compensation expense</span></p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.94%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:44pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y25Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4992">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.44%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:41pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y25Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4993">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.4%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:54pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y25Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4994">82</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:14.3%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:81pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y25Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4995">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:9.42%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:47pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y25Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4996">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12.36%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:68pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4997">82</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:25.64%"><p style="font:10pt Times New Roman;margin:0"><span style="font-size:8pt">Common stock purchased and retired</span></p>
</td><td valign="bottom" style="width:8.94%"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:44pt"><span style="font-size:8pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="Y25Q1_StEqComps-CommonStock" decimals="-3" unitRef="Shares" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-4998">54</ix:nonFraction>)</span></kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.44%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:41pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y25Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-4999">1</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.4%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:54pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y25Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5000">82</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.3%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:81pt"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y25Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5001">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:9.42%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:47pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y25Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5002">3,138</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.36%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:68pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y25Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5003">3,221</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:25.64%"><p style="font:10pt Times New Roman;margin:0"><span style="font-size:8pt">Foreign currency translation adjustment</span></p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.94%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:44pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y25Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5004">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.44%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:41pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y25Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5005">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.4%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:54pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y25Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5006">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:14.3%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:81pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y25Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5007">718</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:9.42%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:47pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y25Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5008">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12.36%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:68pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5009">718</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:25.64%"><p style="font:8pt Times New Roman;margin:0">Unrealized holding gain (loss) from investments,<br/>  available-for-sale, net of taxes</p>
</td><td valign="bottom" style="width:8.94%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:44pt">-&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.44%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:41pt">-&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.4%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:54pt">-&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.3%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:81pt">-&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:9.42%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:47pt">-&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.36%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:68pt">-&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:25.64%"><p style="font:10pt Times New Roman;margin:0"><span style="font-size:8pt">Common stock dividends</span></p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.94%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:44pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y25Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5010">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.44%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:41pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y25Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5011">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.4%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:54pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y25Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5012">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:14.3%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:81pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y25Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5013">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:9.42%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:47pt">(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y25Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5014">1,001</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12.36%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:68pt">(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5015">1,001</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:25.64%"><p style="font:10pt Times New Roman;margin:0"><span style="font-size:8pt">Net income</span></p>
</td><td valign="bottom" style="width:8.94%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:44pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5016">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.44%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:41pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5017">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.4%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:54pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5018">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.3%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:81pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5019">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:9.42%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:47pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5020">3,041</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.36%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:68pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5021">3,041</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:25.64%"><p style="font:8pt Times New Roman;margin:0">Balance at March 31, 2025</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.94%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:44pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="E25Q1_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-5022">3,281</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.1%;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.44%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:41pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E25Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5023">33</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.1%;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:10.4%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:54pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E25Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5024">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.1%;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:14.3%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:81pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E25Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5025">11,190</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.1%;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:9.42%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:47pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E25Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5026">128,204</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.1%;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:12.36%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:68pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5027">117,047</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="width:25.64%"><p style="font:10pt Times New Roman;margin:0"><span style="font-size:8pt">Balance at December 31, 2023</span></p>
</td><td valign="middle" style="width:8.94%"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:44pt"><span style="font-size:8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="E23_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-5028">3,630</ix:nonFraction>&#160;</span></kbd>&#160;</p>
</td><td valign="middle" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:8.44%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:41pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E23_StEqComps-CommonStock" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5029">36</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:10.4%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:54pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E23_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5030">593</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:14.3%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:81pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E23_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5031">10,658</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="middle" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:9.42%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:47pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E23_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5032">138,341</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:12.36%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:68pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5033">128,313</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:25.64%"><p style="font:8pt Times New Roman;margin:0">Shares issued upon exercise of employee <br/> &#160;stock options for cash</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.94%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:44pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-5034">2</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.44%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:41pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5035">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.4%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:54pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y24Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5036">96</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:14.3%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:81pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y24Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5037">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:9.42%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:47pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y24Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5038">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12.36%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:68pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5039">96</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:25.64%"><p style="font:10pt Times New Roman;margin:0"><span style="font-size:8pt">Shares received and retired upon exercise of stock</span><br/><span style="font-size:8pt"> &#160;options</span></p>
</td><td valign="bottom" style="width:8.94%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:44pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5040">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.44%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:41pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5041">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.4%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:54pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions" contextRef="Y24Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5042">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.3%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:81pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions" contextRef="Y24Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5043">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:9.42%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:47pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions" contextRef="Y24Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5044">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.36%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:68pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions" contextRef="Y24Q1" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5045">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:25.64%"><p style="font:8pt Times New Roman;margin:0">Tax benefit attributable to appreciation <br/> &#160;of stock options</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.94%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:44pt">-&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.44%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:41pt">-&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.4%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:54pt">-&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:14.3%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:81pt">-&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:9.42%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:47pt">-&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12.36%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:68pt">-&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:25.64%"><p style="font:10pt Times New Roman;margin:0"><span style="font-size:8pt">Stock option compensation expense</span></p>
</td><td valign="bottom" style="width:8.94%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:44pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5046">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.44%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:41pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5047">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.4%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:54pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5048">79</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.3%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:81pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5049">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:9.42%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:47pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5050">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.36%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:68pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5051">79</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:25.64%"><p style="font:10pt Times New Roman;margin:0"><span style="font-size:8pt">Common stock purchased and retired</span></p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.94%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:44pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="Shares" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5052">43</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.44%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:41pt"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5053">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.4%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:54pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5054">769</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:14.3%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:81pt"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5055">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:9.42%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:47pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5056">2,221</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12.36%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:68pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5057">2,990</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:25.64%"><p style="font:10pt Times New Roman;margin:0"><span style="font-size:8pt">Foreign currency translation adjustment</span></p>
</td><td valign="bottom" style="width:8.94%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:44pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5058">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.44%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:41pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5059">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.4%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:54pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5060">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.3%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:81pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5061">631</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:9.42%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:47pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5062">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.36%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:68pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5063">631</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:25.64%"><p style="font:8pt Times New Roman;margin:0">Unrealized holding gain (loss) from investments,<br/>  available-for-sale, net of taxes</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.94%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:44pt">-&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.44%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:41pt">-&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.4%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:54pt">-&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:14.3%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:81pt">-&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:9.42%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:47pt">-&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12.36%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:68pt">-&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:25.64%"><p style="font:10pt Times New Roman;margin:0"><span style="font-size:8pt">Common stock dividends</span></p>
</td><td valign="bottom" style="width:8.94%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:44pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5064">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.44%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:41pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5065">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.4%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:54pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5066">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.3%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:81pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5067">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:9.42%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:47pt">(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5068">1,081</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.36%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:68pt">(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5069">1,081</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:25.64%"><p style="font:10pt Times New Roman;margin:0"><span style="font-size:8pt">Net income</span></p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.94%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:44pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5070">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.44%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:41pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5071">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.4%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:54pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5072">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:14.3%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:81pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5073">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:9.42%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:47pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5074">3,956</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12.36%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:68pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5075">3,956</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="width:25.64%"><p style="font:10pt Times New Roman;margin:0"><span style="font-size:8pt">Balance at March 31, 2024</span></p>
</td><td valign="middle" style="width:8.94%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:44pt"><span style="font-size:8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="E24Q1_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-5076">3,588</ix:nonFraction>&#160;</span></kbd>&#160;</p>
</td><td valign="middle" style="width:2.1%;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:8.44%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:41pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5077">36</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="width:2.1%;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:10.4%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:54pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5078">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="width:2.1%;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:14.3%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:81pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5079">11,289</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="middle" style="width:2.1%;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:9.42%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:47pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5080">138,995</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="width:2.1%;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:12.36%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:68pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5081">127,742</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="width:25.64%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:8.94%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:8.44%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:10.4%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:14.3%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:9.42%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:12.36%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:25.64%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:8.94%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:8.44%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:10.4%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:14.3%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:9.42%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:2.1%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:12.36%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="12" valign="bottom" style="width:100%"><p style="font:8pt Times New Roman;margin:0"><i>see notes to consolidated condensed financial statements</i></p>
</td></tr>
</table>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"></p>
</div>
<div style="margin-left:72pt"><a id="a4"></a><table style="border-collapse:collapse;width:470.6pt"><tr style="height:7.2pt"><td colspan="8" valign="bottom" style="width:470.6pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</span></p>
</td></tr>
<tr style="height:7.2pt"><td colspan="8" valign="bottom" style="width:470.6pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS</span></p>
</td></tr>
<tr style="height:7.2pt"><td colspan="8" valign="bottom" style="width:470.6pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">FOR THE THREE MONTHS ENDED MARCH 31, 2025 AND MARCH 31, 2024</span></p>
</td></tr>
<tr style="height:7.2pt"><td colspan="8" valign="bottom" style="width:470.6pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(in thousands - unaudited)</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:253.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:169.5pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">MARCH 31,&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="width:289.3pt"/><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:81.4pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">2025</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:74.6pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">2024</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="width:289.3pt"><p style="font:10pt Times New Roman;margin:0">CASH FLOWS FROM OPERATING ACTIVITIES:</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:81.4pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:74.6pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="background-color:#D3F0FE;width:289.3pt"><p style="font:10pt Times New Roman;margin:0">Net income</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:81.4pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:64pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5082">3,041</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:74.6pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5083">3,956</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="width:289.3pt"><p style="font:10pt Times New Roman;margin:0">Adjustments to reconcile net income to net</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:81.4pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:74.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="background-color:#D3F0FE;width:289.3pt"><p style="font:10pt Times New Roman;margin:0"> &#160;cash provided by operating activities:</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:81.4pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:74.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:277.5pt"><p style="font:10pt Times New Roman;margin:0">Depreciation</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:81.4pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:64pt"><ix:nonFraction name="us-gaap:Depreciation" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5084">200</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:74.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:Depreciation" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5085">156</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:277.5pt"><p style="font:10pt Times New Roman;margin:0">Amortization</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:81.4pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:64pt"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5086">509</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:74.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5087">513</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:277.5pt"><p style="font:10pt Times New Roman;margin:0">Provision for losses on/(recovery of) accounts receivable</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:81.4pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:64pt">(<ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="Y25Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5088">9</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:74.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:57pt">(<ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="Y24Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5089">8</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:277.5pt"><p style="font:10pt Times New Roman;margin:0">Amortization of Right-of-Use Assets</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:81.4pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:64pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5090">12</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:74.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5091">14</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:277.5pt"><p style="font:10pt Times New Roman;margin:0">Deferred income taxes</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:81.4pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:64pt">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="Y25Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5092">209</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:74.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:57pt">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="Y24Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5093">192</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:277.5pt"><p style="font:10pt Times New Roman;margin:0">Stock-based compensation expense</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:81.4pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:64pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5094">82</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:74.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5095">79</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:277.5pt"><p style="font:10pt Times New Roman;margin:0">Tax benefit attributable to exercise of stock options</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:81.4pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:64pt"><ix:nonFraction name="us-gaap:DeferredTaxExpenseFromStockOptionsExercised" contextRef="Y25Q1" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5096">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:74.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:DeferredTaxExpenseFromStockOptionsExercised" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5097">9</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="background-color:#D3F0FE;width:289.3pt"><p style="font:10pt Times New Roman;margin:0">Changes in operating assets and liabilities:</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:81.4pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:74.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="width:265.7pt"><p style="font:10pt Times New Roman;margin:0">Accounts receivable and other receivables</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:81.4pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:64pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" contextRef="Y25Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5098">12</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:74.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:57pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5099">214</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:265.7pt"><p style="font:10pt Times New Roman;margin:0">Inventories</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:81.4pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:64pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="Y25Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5100">275</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:74.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="Y24Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5101">271</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="width:265.7pt"><p style="font:10pt Times New Roman;margin:0">Prepaid expenses and other current assets</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:81.4pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:64pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5102">26</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:74.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:57pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5103">87</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:265.7pt"><p style="font:10pt Times New Roman;margin:0">Accounts payable</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:81.4pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:64pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5104">217</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:74.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5105">230</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="width:265.7pt"><p style="font:10pt Times New Roman;margin:0">Accrued expenses</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:81.4pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:64pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5106">360</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:74.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5107">549</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:253.9pt"><p style="font:10pt Times New Roman;margin:0">Total adjustments</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:81.4pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:64pt"><ix:nonFraction name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5108">1,423</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:74.6pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5109">1,320</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:253.9pt"><p style="font:10pt Times New Roman;margin:0">Net cash provided by operating activities</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:81.4pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:64pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5110">4,464</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:74.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5111">5,276</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:253.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:81.4pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:74.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="width:289.3pt"><p style="font:10pt Times New Roman;margin:0">CASH FLOWS FROM INVESTING ACTIVITIES:</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:81.4pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:74.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="background-color:#D3F0FE;width:289.3pt"><p style="font:10pt Times New Roman;margin:0">Capital expenditures for:</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:81.4pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:74.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:277.5pt"><p style="font:10pt Times New Roman;margin:0">Property and equipment</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:81.4pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:64pt">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5112">184</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:74.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:57pt">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5113">22</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="background-color:#D3F0FE;width:289.3pt"><p style="font:10pt Times New Roman;margin:0">Proceeds from sale of equipment</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:81.4pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:64pt"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="Y25Q1" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5114">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:74.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5115">27</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:253.9pt"><p style="font:10pt Times New Roman;margin:0">Net cash provided by/(used in) investing activities</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:81.4pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:64pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="Y25Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5116">184</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:74.6pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5117">5</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:253.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:81.4pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:74.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="width:289.3pt"><p style="font:10pt Times New Roman;margin:0">CASH FLOWS FROM FINANCING ACTIVITIES:</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:81.4pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:74.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="background-color:#D3F0FE;width:289.3pt"><p style="font:10pt Times New Roman;margin:0">Proceeds from issuance of common stock - options</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:81.4pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:64pt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="Y25Q1" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5118">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:74.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5119">96</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="width:289.3pt"><p style="font:10pt Times New Roman;margin:0">Common stock purchased and retired</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:81.4pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:64pt">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5120">3,221</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:74.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:57pt">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5121">2,990</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="background-color:#D3F0FE;width:289.3pt"><p style="font:10pt Times New Roman;margin:0">Payment of dividends</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:81.4pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:64pt">(<ix:nonFraction name="us-gaap:PaymentsOfDividends" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5122">1,017</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:74.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:57pt">(<ix:nonFraction name="us-gaap:PaymentsOfDividends" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5123">1,089</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:253.9pt"><p style="font:10pt Times New Roman;margin:0">Net cash used in financing activities</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:81.4pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:64pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="Y25Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5124">4,238</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:74.6pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:57pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="Y24Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5125">3,983</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:253.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:81.4pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:74.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="width:289.3pt"><p style="font:10pt Times New Roman;margin:0">Effect of exchange rate changes on cash</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:81.4pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:64pt"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5126">307</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:74.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:57pt">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="Y24Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5127">358</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="background-color:#D3F0FE;width:289.3pt"><p style="font:10pt Times New Roman;margin:0">Net increase in cash and cash equivalents</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:81.4pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:64pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5128">349</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:74.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5129">940</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="width:289.3pt"><p style="font:10pt Times New Roman;margin:0">Cash at beginning of period</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:81.4pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:64pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5130">82,976</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:74.6pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5131">92,868</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="background-color:#D3F0FE;width:289.3pt"><p style="font:10pt Times New Roman;margin:0">Cash at end of period</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:81.4pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:64pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="E25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5132">83,325</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:74.6pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5133">93,808</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:253.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:81.4pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:74.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="5" valign="bottom" style="background-color:#D3F0FE;width:301.1pt"><p style="font:10pt Times New Roman;margin:0">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:81.4pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:74.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:277.5pt"><p style="font:10pt Times New Roman;margin:0">Cash paid during the period for income taxes</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:81.4pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:64pt"><ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5134">46</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:74.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5135">105</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:277.5pt"><p style="font:10pt Times New Roman;margin:0">Cash paid during the period for interest</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:81.4pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:64pt"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="Y25Q1" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5136">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:74.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="Y24Q1" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-5137">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:277.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:81.4pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:74.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="width:289.3pt"><p style="font:8pt Times New Roman;margin:0"><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:81.4pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:74.6pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<a id="a6"></a><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC.</span></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS</span></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">(unaudited)</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="Y25Q1" escape="true" id="ixv-2905"><p style="font:10pt Times New Roman;margin:0">(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. &#160;These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10-K for the year ended December 31, 2024. &#160;In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. &#160;Currency amounts are in thousands except per-share amounts and where noted.</p>
</ix:nonNumeric><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" contextRef="Y25Q1" escape="true" id="ixv-2908"><p style="font:10pt Times New Roman;margin:0">(2) Recent Accounting Standards. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">In December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. &#160;ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. &#160;The Company is currently evaluating the impact of adopting AUS 2023-09.</p>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;color:#000000">In November 2024, the FASB issued ASU 2024-03, <i>Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</i>, requiring public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. &#160;ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. &#160;The Company is currently evaluating the impact of adopting ASU 2024-03.</p>
</ix:nonNumeric><p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<ix:nonNumeric name="us-gaap:InventoryDisclosureTextBlock" contextRef="Y25Q1" escape="true" continuedAt="c1" id="ixv-2917"><p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:6pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">(3)</kbd><kbd style="margin-left:19.8pt"></kbd>Inventories at March 31, 2025 and December 31, 2024 consisted of the following:&#160;</p>
<ix:nonNumeric name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" contextRef="Y25Q1" escape="true" continuedAt="c2" id="ixv-2921"><p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:6pt">&#160;</p>
</ix:nonNumeric></ix:nonNumeric></div>
<div style="margin-left:72pt"><ix:continuation id="c1" continuedAt="c3"><ix:continuation id="c2" continuedAt="c4"><table style="border-collapse:collapse;margin-left:56.75pt"><tr style="height:7.2pt"><td valign="top" style="width:186.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:27pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:72pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">March 31,</p>
</td><td valign="top" style="width:73.35pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">December 31,</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="width:186.25pt"/><td valign="top" style="width:27pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:72pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">2025</span></p>
</td><td valign="top" style="width:73.35pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">2024</span></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE;width:186.25pt"><p style="font:10pt Times New Roman;margin:0">Finished goods</p>
</td><td valign="top" style="background-color:#D3F0FE;width:27pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:72pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;<ix:nonFraction name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="E25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5138">1,602</ix:nonFraction> </p>
</td><td valign="top" style="background-color:#D3F0FE;width:73.35pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;<ix:nonFraction name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5139">1,913</ix:nonFraction></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="width:186.25pt"><p style="font:10pt Times New Roman;margin:0">Work-in-process</p>
</td><td valign="top" style="width:27pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:72pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="E25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5140">1,544</ix:nonFraction></p>
</td><td valign="top" style="width:73.35pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5141">1,414</ix:nonFraction></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE;width:186.25pt"><p style="font:10pt Times New Roman;margin:0">Raw materials</p>
</td><td valign="top" style="background-color:#D3F0FE;width:27pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:72pt;border-bottom:0.25pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:InventoryRawMaterials" contextRef="E25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5142">5,502</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:73.35pt;border-bottom:0.25pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:InventoryRawMaterials" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5143">5,485</ix:nonFraction></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="width:186.25pt"><p style="font:10pt Times New Roman;margin:0">Total </p>
</td><td valign="top" style="width:27pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:72pt;border-top:0.25pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;<ix:nonFraction name="us-gaap:InventoryNet" contextRef="E25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5144">8,648</ix:nonFraction></p>
</td><td valign="top" style="width:73.35pt;border-top:0.25pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;<ix:nonFraction name="us-gaap:InventoryNet" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5145">8,812</ix:nonFraction></p>
</td></tr>
</table>
</ix:continuation></ix:continuation></div>
<div style="margin-left:72pt;width:468pt"><ix:continuation id="c3"><ix:continuation id="c4"></ix:continuation></ix:continuation><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="Y25Q1" escape="true" id="ixv-2984"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">(4)</kbd><kbd style="margin-left:18pt"></kbd>Stock-Based Compensation. At March 31, 2025, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. &#160;The Company accounts for stock compensation under FASB Accounting Standards Codification (&#8220;ASC&#8221;) 718, <i>Compensation - Stock Compensation</i>. &#160;This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. &#160;In the quarters ended March 31, 2025 and March 31, 2024, the Company recognized $<ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5148">82</ix:nonFraction> and $<ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5149">79</ix:nonFraction>, respectively, in stock-based compensation cost.&#160;</p>
</ix:nonNumeric><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:ProductWarrantyDisclosureTextBlock" contextRef="Y25Q1" escape="true" id="ixv-2990"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">(5) </kbd><kbd style="margin-left:18pt"></kbd>Warranty Reserve. &#160;The Company&#8217;s published warranty is: &#8220;UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. &#160;During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.&#8221; &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2024 or March 31, 2025. </p>
</ix:nonNumeric><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">5</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="Y25Q1" escape="true" continuedAt="c5" id="ixv-3001"><p style="font:10pt Times New Roman;margin:0">(6) 1Q 2025 global revenues (USD) by product category:</p>
<ix:nonNumeric name="fil:ScheduleofglobalrevenuesbyproductcategoryTextBlock" contextRef="Y25Q1" escape="true" continuedAt="c6" id="ixv-3003"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</ix:nonNumeric></ix:nonNumeric></div>
<div style="margin-left:72pt"><ix:continuation id="c5" continuedAt="c7"><ix:continuation id="c6" continuedAt="c8"><table style="border-collapse:collapse;border-bottom:0.5pt solid #000000"><tr><td valign="top" style="width:180pt"/><td valign="top" style="width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:58.3pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Domestic</p>
</td><td valign="top" style="width:18.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:62.6pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Outside US</p>
</td><td valign="top" style="width:19.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:54pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Total</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:180pt"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:58.3pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q1_ProductOrService-Obstetrics_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5150">832</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:18.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:62.6pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q1_ProductOrService-Obstetrics_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5151">193</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:19.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q1_ProductOrService-Obstetrics" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5152">1,025</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="width:180pt"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td valign="top" style="width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:58.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q1_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5153">2,329</ix:nonFraction></p>
</td><td valign="top" style="width:18.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:62.6pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q1_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5154">2,567</ix:nonFraction></p>
</td><td valign="top" style="width:19.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q1_ProductOrService-GynecologyElectrosurgeryUrology" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5155">4,896</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:180pt"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:58.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q1_ProductOrService-Neonatal_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5156">1,622</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:18.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:62.6pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q1_ProductOrService-Neonatal_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5157">360</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:19.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q1_ProductOrService-Neonatal" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5158">1,982</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="width:180pt"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td valign="top" style="width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:58.3pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q1_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5159">800</ix:nonFraction></p>
</td><td valign="top" style="width:18.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:62.6pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q1_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5160">1,007</ix:nonFraction></p>
</td><td valign="top" style="width:19.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q1_ProductOrService-BloodPressureMonitoringAndAccessories" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5161">1,807</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:180pt"><p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt">Total</p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:58.3pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q1_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5162">5,583</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:18.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:62.6pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q1_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5163">4,127</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:19.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5164">9,710</ix:nonFraction></p>
</td></tr>
</table>
</ix:continuation></ix:continuation></div>
<div style="margin-left:72pt;width:468pt"><ix:continuation id="c7"><ix:continuation id="c8"></ix:continuation></ix:continuation><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="Y25Q1" escape="true" continuedAt="c9" id="ixv-3136"><p style="font:10pt Times New Roman;margin:0">(7) Earnings Per Share. Basic earnings per share were calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during each applicable period. &#160;Diluted earnings per share were calculated by assuming the exercise of stock options at the closing price of stock at the end of first quarter 2025 and 2024, as applicable. The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:</p>
<ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="Y25Q1" escape="true" continuedAt="c10" id="ixv-3138"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</ix:nonNumeric></ix:nonNumeric></div>
<div style="margin-left:72pt"><ix:continuation id="c9" continuedAt="c11"><ix:continuation id="c10" continuedAt="c12"><table style="border-collapse:collapse"><tr style="height:7.3pt"><td valign="top" style="width:184.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" valign="top" style="width:179.55pt"><p style="font:10pt Times New Roman;margin:0;text-indent:3.75pt;margin-left:-13.5pt;text-align:center">Three months ended March 31</p>
</td></tr>
<tr style="height:7.3pt"><td valign="top" style="width:184.95pt"><p style="font:10pt Times New Roman;margin:0"><i> (in thousands)</i></p>
</td><td valign="middle" style="width:83.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2025</span></p>
</td><td valign="top" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:83.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2024</span></p>
</td></tr>
<tr style="height:7.3pt"><td valign="top" style="width:184.95pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000"><b>Numerator</b></span></p>
</td><td valign="top" style="width:83.85pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:83.9pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.3pt"><td valign="top" style="background-color:#D3F0FE;width:184.95pt"><p style="font:10pt Times New Roman;margin:0">Net income</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:83.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5167">3,041</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:83.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5168">3,956</ix:nonFraction></p>
</td></tr>
<tr style="height:7.3pt"><td valign="top" style="width:184.95pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000"><b>Denominator</b></span></p>
</td><td valign="top" style="width:83.85pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:83.9pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.3pt"><td valign="top" style="background-color:#D3F0FE;width:184.95pt"><p style="font:10pt Times New Roman;margin:0">Weighted average shares, basic</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:83.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Y25Q1" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-5169">3,310</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:83.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Y24Q1" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-5170">3,618</ix:nonFraction></p>
</td></tr>
<tr style="height:7.3pt"><td valign="top" style="width:184.95pt"><p style="font:10pt Times New Roman;margin:0">Dilutive effect of stock options</p>
</td><td valign="middle" style="width:83.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="Y25Q1" decimals="-3" unitRef="Shares" format="ixt:fixed-zero" id="ixv-5171">-</ix:nonFraction></p>
</td><td valign="top" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:83.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="Y24Q1" decimals="-3" unitRef="Shares" format="ixt:fixed-zero" id="ixv-5172">-</ix:nonFraction></p>
</td></tr>
<tr style="height:7.3pt"><td valign="top" style="background-color:#D3F0FE;width:184.95pt"><p style="font:10pt Times New Roman;margin:0">Diluted shares</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:83.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Y25Q1" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-5173">3,310</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:83.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Y24Q1" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-5174">3,618</ix:nonFraction></p>
</td></tr>
<tr style="height:6.75pt"><td valign="top" style="width:184.95pt"><p style="font:10pt Times New Roman;margin:0">Earnings per share, basic</p>
</td><td valign="middle" style="width:83.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="Y25Q1" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-5175">0.92</ix:nonFraction></p>
</td><td valign="top" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:83.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="Y24Q1" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-5176">1.09</ix:nonFraction></p>
</td></tr>
<tr style="height:7.3pt"><td valign="top" style="background-color:#D3F0FE;width:184.95pt"><p style="font:10pt Times New Roman;margin:0">Earnings per share, diluted</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:83.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="Y25Q1" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-5177">0.92</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:83.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="Y24Q1" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-5178">1.09</ix:nonFraction></p>
</td></tr>
</table>
</ix:continuation></ix:continuation></div>
<div style="margin-left:72pt;width:468pt"><ix:continuation id="c11"><ix:continuation id="c12"></ix:continuation></ix:continuation><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:SegmentReportingDisclosureTextBlock" contextRef="Y25Q1" escape="true" id="ixv-3239"><p style="font:10pt Times New Roman;margin:0">(8) Segment Information. &#160;The Company operates as one operating segment. &#160;The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) is its chief executive officer, who reviews financial information presented on a consolidated basis. &#160;The CODM uses consolidated gross profit margin, operating margin, and net income to assess financial performance and allocate resources. &#160;These financial metrics are used by the CODM to make key operating decisions such as the allocation of budget between cost of sales, sales and marketing, research and development, and general and administrative expenses.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The following table presents selected financial information with respect to the Company&#8217;s single operating segment for the quarters ended March 31, 2025 and March 31, 2024:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" contextRef="Y25Q1" escape="true" id="ixv-3244"><p style="font:12pt Times New Roman;margin:0"></p>
<table style="border-collapse:collapse;width:288.9pt"><tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" valign="top" style="width:129.35pt"><p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;text-align:center"><b>Quarter Ended March 31,</b></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"/><td valign="top" style="width:60.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000"><b> &#160;&#160;&#160;2025</b></span></p>
</td><td valign="top" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:57.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000"><b>2024</b></span></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0">Revenues</p>
</td><td valign="top" style="background-color:#D3F0FE;width:60.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q1_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5181">9,710</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:57.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q1_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5182">11,340</ix:nonFraction></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Less:</p>
</td><td valign="top" style="width:60.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:57.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0">Standard cost of sales</p>
</td><td valign="top" style="background-color:#D3F0FE;width:60.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="fil:StandardCostOfSales" contextRef="Y25Q1_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5183">3,656</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:57.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="fil:StandardCostOfSales" contextRef="Y24Q1_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5184">3,822</ix:nonFraction></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Other cost of sales</p>
</td><td valign="top" style="width:60.3pt;border-bottom:0.25pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="fil:OtherCostOfSales" contextRef="Y25Q1_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5185">516</ix:nonFraction></p>
</td><td valign="top" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:57.25pt;border-bottom:0.25pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="fil:OtherCostOfSales" contextRef="Y24Q1_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5186">753</ix:nonFraction></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0">Gross Profit</p>
</td><td valign="top" style="background-color:#D3F0FE;width:60.3pt;border-top:0.25pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="Y25Q1_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5187">5,538</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:57.25pt;border-top:0.25pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="Y24Q1_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5188">6,765</ix:nonFraction></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Gross Profit Margin</p>
</td><td valign="top" style="width:60.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="fil:GrossProfitMargin" contextRef="Y25Q1_StScenario-SingleOperatingSeg" decimals="INF" unitRef="Pure" scale="-2" format="ixt:num-dot-decimal" id="ixv-5189">57.0</ix:nonFraction>%</p>
</td><td valign="top" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:57.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="fil:GrossProfitMargin" contextRef="Y24Q1_StScenario-SingleOperatingSeg" decimals="INF" unitRef="Pure" scale="-2" format="ixt:num-dot-decimal" id="ixv-5190">59.7</ix:nonFraction>%</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0">Sales &amp; Marketing</p>
</td><td valign="top" style="background-color:#D3F0FE;width:60.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="Y25Q1_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5191">500</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:57.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="Y24Q1_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5192">411</ix:nonFraction></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Research &amp; Development</p>
</td><td valign="top" style="width:60.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="Y25Q1_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5193">154</ix:nonFraction></p>
</td><td valign="top" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:57.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="Y24Q1_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5194">266</ix:nonFraction></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0">Litigation Fees</p>
</td><td valign="top" style="background-color:#D3F0FE;width:60.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="fil:LitigationExpense" contextRef="Y25Q1_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5195">316</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:57.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="fil:LitigationExpense" contextRef="Y24Q1_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5196">751</ix:nonFraction></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Amortization</p>
</td><td valign="top" style="width:60.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="Y25Q1_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5197">509</ix:nonFraction></p>
</td><td valign="top" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:57.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="Y24Q1_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5198">513</ix:nonFraction></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0">Other General &amp; Administrative</p>
</td><td valign="top" style="background-color:#D3F0FE;width:60.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000"><ix:nonFraction name="us-gaap:OtherSellingGeneralAndAdministrativeExpense" contextRef="Y25Q1_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5199">906</ix:nonFraction></span></p>
</td><td valign="top" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:57.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000"><ix:nonFraction name="us-gaap:OtherSellingGeneralAndAdministrativeExpense" contextRef="Y24Q1_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5200">941</ix:nonFraction></span></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Operating Income</p>
</td><td valign="top" style="width:60.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="Y25Q1_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5201">3,153</ix:nonFraction></p>
</td><td valign="top" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:57.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="Y24Q1_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5202">3,883</ix:nonFraction></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0">Operating Income Margin</p>
</td><td valign="top" style="background-color:#D3F0FE;width:60.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="fil:OperatingIncomeMargin" contextRef="Y25Q1_StScenario-SingleOperatingSeg" decimals="INF" unitRef="Pure" scale="-2" format="ixt:num-dot-decimal" id="ixv-5203">32.5</ix:nonFraction>%</p>
</td><td valign="top" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:57.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="fil:OperatingIncomeMargin" contextRef="Y24Q1_StScenario-SingleOperatingSeg" decimals="INF" unitRef="Pure" scale="-2" format="ixt:num-dot-decimal" id="ixv-5204">34.2</ix:nonFraction>%</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Other Income</p>
</td><td valign="top" style="width:60.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:57.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0">Interest income</p>
</td><td valign="top" style="background-color:#D3F0FE;width:60.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherInterestAndDividendIncome" contextRef="Y25Q1_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5205">737</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:57.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherInterestAndDividendIncome" contextRef="Y24Q1_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5206">891</ix:nonFraction></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Other income (expense)</p>
</td><td valign="top" style="width:60.3pt;border-bottom:0.25pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="Y25Q1_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-5207">32</ix:nonFraction>)</p>
</td><td valign="top" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:57.25pt;border-bottom:0.25pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="Y24Q1_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5208">24</ix:nonFraction></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0">Income before income taxes</p>
</td><td valign="top" style="background-color:#D3F0FE;width:60.3pt;border-top:0.25pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="Y25Q1_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5209">3,858</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:57.25pt;border-top:0.25pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="Y24Q1_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5210">4,798</ix:nonFraction></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Provision for income taxes</p>
</td><td valign="top" style="width:60.3pt;border-bottom:0.25pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="Y25Q1_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5211">817</ix:nonFraction></p>
</td><td valign="top" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:57.25pt;border-bottom:0.25pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="Y24Q1_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5212">842</ix:nonFraction></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0">Net Income</p>
</td><td valign="top" style="background-color:#D3F0FE;width:60.3pt;border-top:0.25pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q1_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5213">3,041</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:57.25pt;border-top:0.25pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q1_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-5214">3,956</ix:nonFraction></p>
</td></tr>
</table>
</ix:nonNumeric></ix:nonNumeric><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">6</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="Y25Q1" escape="true" id="ixv-3442"><p style="font:10pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">(9)</kbd><kbd style="margin-left:18pt"></kbd> Subsequent Events.<b> &#160;</b>UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its March 31, 2025 financial statements. &#160;After March 31, 2025 through May 12, 2025, the Company made additional repurchases of 32,679 shares of its stock in the open market for $1,754, at an average price of $53.67 per share. &#160;</p>
</ix:nonNumeric><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a7"></a><p style="font:10pt Times New Roman;margin:0"><b>Item 2.</b> &#160;<b>Management's Discussion and Analysis of Financial Condition and Results of Operations</b></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">General</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Utah Medical Products, Inc. (UTMD) manufactures and markets a well-established range of specialty medical devices. &#160;The Company&#8217;s Form 10-K Annual Report for the year ended December 31, 2024 provided a detailed description of products, technologies, markets, regulatory issues, business initiatives, resources and business risks, among other details, and should be read in conjunction with this report. &#160;Because of the relatively short span of time, results for any given three-month period in comparison with a previous three-month period may not be indicative of comparative results for the year as a whole. &#160;Currency amounts in the report are in thousands, except per share amounts or where otherwise noted. &#160;Currencies in this report are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; &#163; or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and &#8364;&#160;or EUR = Euros. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Analysis of Results of Operations</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:10.8pt">a)</kbd><kbd style="margin-left:24.3pt"></kbd>Overview&#160;</p>
<p style="font:10pt Times New Roman;margin:0;margin-right:-6.5pt">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Income statement results in the first quarter (1Q) of 2025 compared to 1Q 2024 were as follows:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:322.95pt"><tr style="height:7.2pt"><td valign="bottom" style="width:148.8pt"><p style="font:12pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:60pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right"><span style="border-bottom:1px solid #000000">1Q 2025</span></p>
</td><td valign="middle" style="width:54.15pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right"><span style="border-bottom:1px solid #000000">1Q 2024</span></p>
</td><td valign="middle" style="width:60pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right"><span style="border-bottom:1px solid #000000">change</span></p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:148.8pt"><p style="font:10pt Times New Roman;margin:0;color:#000000">Net Sales</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:60pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">$ 9,710</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:54.15pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">$ 11,340</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:60pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">(14.4%)</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="width:148.8pt"><p style="font:10pt Times New Roman;margin:0;color:#000000">Gross Profit</p>
</td><td valign="middle" style="width:60pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">5,538</p>
</td><td valign="middle" style="width:54.15pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">6,766</p>
</td><td valign="middle" style="width:60pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">(18.1%)</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:148.8pt"><p style="font:10pt Times New Roman;margin:0;color:#000000">Operating Income</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:60pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">3,154</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:54.15pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">3,883</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:60pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">(18.8%)</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="width:148.8pt"><p style="font:10pt Times New Roman;margin:0;color:#000000">Income Before Tax</p>
</td><td valign="middle" style="width:60pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">3,859</p>
</td><td valign="middle" style="width:54.15pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">4,798</p>
</td><td valign="middle" style="width:60pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">(19.6%)</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:148.8pt"><p style="font:10pt Times New Roman;margin:0;color:#000000">Net Income</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:60pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">3,041</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:54.15pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">3,956</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:60pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">(23.1%)</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="width:148.8pt"><p style="font:10pt Times New Roman;margin:0;color:#000000">Earnings per Share (diluted)</p>
</td><td valign="middle" style="width:60pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">$ 0.919</p>
</td><td valign="middle" style="width:54.15pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">$ 1.093</p>
</td><td valign="middle" style="width:60pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">(16.0%)</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Profit margins in 1Q 2025 compared to 1Q 2024 follow:</p>
<table style="border-collapse:collapse;width:432.35pt"><tr style="height:7.2pt"><td valign="top" style="width:262.25pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.5pt">&#160;</p>
</td><td valign="top" style="width:85.05pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt;text-align:center">1Q 2025 </p>
<p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt;text-align:center"><span style="border-bottom:1px solid #000000">(JAN &#8211;&#160;MAR)</span></p>
</td><td valign="top" style="width:85.05pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt;text-align:center">1Q 2024 </p>
<p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt;text-align:center"><span style="border-bottom:1px solid #000000">(JAN &#8211;&#160;MAR)</span></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE;width:262.25pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt">Gross Profit Margin (Gross Profit/ sales):</p>
</td><td valign="top" style="background-color:#D3F0FE;width:85.05pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt;text-align:center">57.0%</p>
</td><td valign="top" style="background-color:#D3F0FE;width:85.05pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt;text-align:center">59.7%</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="width:262.25pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt">Operating Income Margin (Operating Income/ sales):</p>
</td><td valign="top" style="width:85.05pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt;text-align:center">32.5%</p>
</td><td valign="top" style="width:85.05pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt;text-align:center">34.2%</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE;width:262.25pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt">EBT Margin (Profits before Income Taxes/ sales):</p>
</td><td valign="top" style="background-color:#D3F0FE;width:85.05pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt;text-align:center">39.7%</p>
</td><td valign="top" style="background-color:#D3F0FE;width:85.05pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt;text-align:center">42.3%</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="width:262.25pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.25pt">Net Income Margin (Profit after Taxes/ sales):</p>
</td><td valign="top" style="width:85.05pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt;text-align:center">31.3% </p>
</td><td valign="top" style="width:85.05pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt;text-align:center">34.9% </p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Consolidated sales in 1Q 2025 were $1,630 lower than in 1Q 2024. &#160;OEM sales to PendoTECH were $1,476 lower, representing 91% of the decline. The decline in sales to PendoTECH in the first quarter represented 55% of the 2024-year total sales to PendoTECH. Excluding PendoTECH sales, domestic sales in 1Q 2025 were 9% higher, and sales outside the U.S. (OUS) were 14% lower in USD terms, compared to 1Q 2024. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Domestic sales in 1Q 2025 including PendoTECH were 10% lower and sales outside the U.S. (OUS) including PendoTECH were 20% lower, in USD terms, compared to 1Q 2024. &#160;Using the same foreign currency exchange (FX) rates for sales not invoiced in USD, i.e. in &#8220;constant currency&#8221; terms, OUS sales were 19% lower. Although 30% of consolidated USD sales were invoiced in foreign currencies, the change in FX rates for OUS sales had a minor impact on period-to-period relative financial results. FX rates for income statement purposes are transaction-weighted averages. The average FX rates from the applicable foreign currency to USD during 1Q 2025 and 1Q 2024 follow:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:269.3pt"><tr style="height:8.15pt"><td valign="bottom" style="width:96.6pt"><p style="font:12pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:55.05pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right"><span style="border-bottom:1px solid #000000">1Q 2025</span></p>
</td><td valign="middle" style="width:56.75pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right"><span style="border-bottom:1px solid #000000">1Q 2024</span></p>
</td><td valign="bottom" style="width:47.4pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right"><span style="border-bottom:1px solid #000000">Change</span></p>
</td></tr>
<tr style="height:8.15pt"><td valign="middle" style="background-color:#D3F0FE;width:96.6pt"><p style="font:10pt Times New Roman;margin:0;color:#000000">GBP</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:55.05pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">1.261</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:56.75pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">1.267</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:47.4pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">(0.6%)</p>
</td></tr>
<tr style="height:8.15pt"><td valign="middle" style="width:96.6pt"><p style="font:10pt Times New Roman;margin:0;color:#000000">EUR</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
</td><td valign="middle" style="width:55.05pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">1.073</p>
</td><td valign="middle" style="width:56.75pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">1.083</p>
</td><td valign="middle" style="width:47.4pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">(0.9%)</p>
</td></tr>
<tr style="height:8.15pt"><td valign="middle" style="background-color:#D3F0FE;width:96.6pt"><p style="font:10pt Times New Roman;margin:0;color:#000000">AUD</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:55.05pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">0.628</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:56.75pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">0.658</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:47.4pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">(4.5%)</p>
</td></tr>
<tr style="height:8.15pt"><td valign="middle" style="width:96.6pt"><p style="font:10pt Times New Roman;margin:0;color:#000000">CAD</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
</td><td valign="middle" style="width:55.05pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">0.697</p>
</td><td valign="middle" style="width:56.75pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">0.742</p>
</td><td valign="middle" style="width:47.4pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">(6.0%)</p>
</td></tr>
</table>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">7</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0">The weighted-average negative impact on foreign currency sales was 1.4%, decreasing reported USD sales $43 relative to the same foreign currency sales in 1Q 2024. &#160;In constant currency terms, total consolidated 1Q 2025 sales were $1,588 (14.0%) lower than in 1Q 2024.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD&#8217;s 1Q 2025 Gross Profit at $5,538 was $1,227 lower than 1Q 2024 Gross Profit of $6,766. &#160;The 18.1% lower Gross Profit was the result of 14.4% lower sales combined with a Gross Profit Margin (GPM), Gross Profit/ sales, almost three percentage points lower than in 1Q 2024. The lower GPM was due to manufacturing overhead costs which did not decline proportionally to the sales decline. &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Consolidated Operating Income, which is Gross Profit less Operating Expense (OE), in 1Q 2025 at $3,154 (32.5% of sales) was only $730 lower than 1Q 2024 OI of $3,883 (34.2% of sales), despite the $1,227 lower Gross Profit. OE in 1Q 2025 were $498 lower than in 1Q 2024 primarily due to $437 lower litigation expenses, which are included in General and Administrative (G&amp;A) portion of OE. &#160;The other components of OE, Product Development (R&amp;D) expenses and Sales &amp; Marketing (S&amp;M) expenses, were $112 lower and $88 higher than in 1Q 2024, respectively. The lower R&amp;D expense was related to independent certification of UTMD&#8217;s own biopharma manufacturing pressure sensors in 1Q 2024. &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Income Before Tax (EBT) had a higher percentage decline than Operating Income because net non-operating income in 1Q 2025 was $705 compared to $915 in 1Q 2024. The lower net non-operating income was due to lower interest earned on cash balances and an excise tax levied on share repurchases. Combining the $730 lower Operating Income with $210 lower net non-operating income yielded 1Q 2025 EBT $940 (19.6%) lower than in 1Q 2024. UTMD&#8217;s EBT Margin (EBT/ sales) was 39.7% in 1Q 2025 compared to 42.3% in 1Q 2024. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD&#8217;s consolidated income tax provision rate in 1Q 2025 was 21.2% compared to 17.6% in 1Q 2024. An EBT mix difference with a greater share of consolidated EBT generated in the U.S., and an income tax true-up related to repatriation tax payments, caused the provision rate difference. The basic corporate income tax rate for the U.S. (including Utah) is 25.45% and for Ireland on EBT from exports is 12.5%. The higher income tax provision rate on top of the 19.6% lower EBT resulted in 1Q 2025 Net Income that was 23.1% lower than in 1Q 2024. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">During the four calendar quarters following the end of 1Q 2024, UTMD repurchased 313,120 of its shares in the open market which resulted in 1Q 2025 EPS to only be 16.0% lower than 1Q 2024 despite 23.1% lower Net Income. There was no dilution from outstanding employee stock options for purposes of calculating diluted EPS in either 1Q 2025 or 1Q 2024. &#160;&#160;&#160;&#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD&#8217;s March 31, 2025 Balance Sheet, in the absence of debt, remained strong. &#160;Despite using $4.4 million in cash during 1Q 2025 to make share repurchases, pay stockholder dividends and purchase new equipment, UTMD&#8217;s March 31, 2025 cash equivalent balance of $83.3 million was slightly higher than the $83.0 million balance three months earlier at December 31, 2024. &#160;Stockholders&#8217; Equity also remained almost the same at $117 million at the end of 1Q 2025 from three months earlier despite the fact that dividends and share repurchases reduce Stockholders&#8217; Equity. FX rates for Balance Sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of 1Q 2025 and the end of 1Q 2024 follow:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:242.3pt"><tr style="height:7.2pt"><td valign="bottom" style="width:58.5pt"><p style="font:12pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:62.65pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right"><span style="border-bottom:1px solid #000000">3/31/2025</span></p>
</td><td valign="middle" style="width:62.65pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right"><span style="border-bottom:1px solid #000000">3/31/2024</span></p>
</td><td valign="bottom" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right"><span style="border-bottom:1px solid #000000">Change</span></p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0;color:#000000">GBP</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:62.65pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">1.289</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:62.65pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">1.263</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">2.1%</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;color:#000000">EUR</p>
</td><td valign="middle" style="width:62.65pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">1.079</p>
</td><td valign="middle" style="width:62.65pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">1.079</p>
</td><td valign="middle" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right"> &#160;&#160;&#160;&#160;-</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0;color:#000000">AUD</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:62.65pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">0.624</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:62.65pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">0.652</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">(4.4%)</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;color:#000000">CAD</p>
</td><td valign="middle" style="width:62.65pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">0.695</p>
</td><td valign="middle" style="width:62.65pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">0.739</p>
</td><td valign="middle" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">(5.8%)</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">b)</kbd><kbd style="margin-left:10.8pt"></kbd>Revenues&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Terms of sale are established in advance of UTMD&#8217;s acceptance of customer orders. &#160;In the U.S., Ireland, UK, Canada, Australia and New Zealand, UTMD generally accepted orders directly from and shipped directly to end user clinical facilities, as well as third party medical/surgical distributors, under UTMD&#8217;s Standard Terms and Conditions (T&amp;C) of Sale during both 1Q 2025 and 1Q 2024. &#160;UTMD may have separate discounted pricing agreements with a specific clinical facility or group of affiliated facilities based on volume of purchases. &#160;Pricing agreements which are documented arrangements with clinical facilities, or groups of affiliated facilities, if applicable, are established in advance of orders accepted or shipments made. For existing customers, past actual </p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">8</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0">shipment volumes typically determine the fixed price by part number for the next agreement period of one year. For new customers, the customer&#8217;s best estimate of volume is usually accepted by UTMD for determining the ensuing fixed prices for the agreement period. Prices are not adjusted after an order is accepted. For the sake of clarity, the separate pricing agreements with clinical facilities based on volume of purchases disclosure is not inconsistent with UTMD&#8217;s disclosure that the selling price is fixed prior to the acceptance of a specific customer order. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Total consolidated 1Q 2025 UTMD sales were $1,630 (14.4%) lower than in 1Q 2024. Constant currency sales were $1,588 (14.0%) lower. U.S. domestic sales were 9.8% lower and OUS sales were 19.8% lower. Because of the relatively short span of time, results for any given three-month period in comparison with a previous three-month period may not be indicative of comparative results for the year as a whole. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Domestic sales in 1Q 2025 were $5,583 compared to $6,192 in 1Q 2024. &#160;The components of domestic sales include 1) &#8220;direct sales&#8221; of UTMD&#8217;s medical devices to user facilities (and med/surg stocking distributors for hospitals), excluding Filshie device sales, 2) &#8220;OEM sales&#8221; of components and other products manufactured by UTMD for other medical device and non-medical device companies, and 3) &#8220;Filshie device sales&#8221;, manufactured by Femcare and distributed in the U.S. by UTMD. </p>
<p style="font:10pt Times New Roman;margin:0;margin-left:36pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">1)</kbd>Direct sales, representing 70% of total domestic sales, were $406 (+11.6%) higher in 1Q 2025 than in 1Q 2024. This was primarily due to recovery of NICU device sales that were harmed in 1Q 2024 from continuing supply chain disruption for raw material components. &#160;</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:36pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">2)</kbd>OEM sales, representing 11% of total domestic sales, were $993 (61.3%) lower. U.S. sales to UTMD&#8217;s largest OEM customer, PendoTECH, were $1,047 lower in 1Q 2025 compared to 1Q 2024. &#160;All other U.S. OEM sales were $54 (+10.8%) higher. &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:36pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">3)</kbd>Domestic Filshie device sales which were just $22 (2.0%) lower in 1Q 2025 compared to 1Q 2024 appear to have stabilized compared to recent previous period declines. &#160;&#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:36pt">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">OUS sales in 1Q 2025 were $4,127 compared to $5,149 in 1Q 2024. OUS OEM sales to PendoTECH were $429 lower, representing almost half of the decline. In 1Q 2024, UTMD had enjoyed a sporadic Africa distributor order for ES components that did not repeat in 1Q 2025, representing another 25% of the OUS sales decline. OUS sales invoiced in GBP, EUR, AUD and CAD currencies were decreased $43 as a result of changes in FX rates, resulting primarily from a 6.0% weaker CAD and 4.5% weaker AUD. &#160;In other words, constant currency OUS sales were $4,170, which was 11.7% lower than in 1Q 2024 excluding PendoTECH. &#160;OUS sales invoiced in foreign currencies in 1Q 2025 were $2,944, which was 71% of OUS sales and 30% of total 1Q 2025 consolidated sales. &#160;Foreign currency OUS sales in 1Q 2024 were $3,487, which was 68% of OUS sales and 31% of total 1Q 2024 consolidated sales. &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The following table provides USD consolidated sales amounts divided into general product categories for total worldwide sales and the subset of OUS sales. &#160;Sales to PendoTECH are included in the Blood Pressure Monitoring product category:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">WW revenues (USD) by product category:</p>
<table style="border-collapse:collapse;width:427.5pt;margin-left:23.4pt"><tr><td valign="top" style="width:252pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1Q 2025</span></p>
</td><td valign="top" style="width:31.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">%</span></p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1Q 2024</span></p>
</td><td valign="top" style="width:36pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">%</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:252pt"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 1,025</p>
</td><td valign="top" style="background-color:#D3F0FE;width:31.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">11</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 1,025</p>
</td><td valign="top" style="background-color:#D3F0FE;width:36pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"> &#160;9</p>
</td></tr>
<tr><td valign="top" style="width:252pt"><p style="font:10pt Times New Roman;margin:0">Gynecology/ Electrosurgery/ Urology</p>
</td><td valign="top" style="width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,896</p>
</td><td valign="top" style="width:31.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">50</p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,461</p>
</td><td valign="top" style="width:36pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">48</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:252pt"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,982</p>
</td><td valign="top" style="background-color:#D3F0FE;width:31.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">20</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,642</p>
</td><td valign="top" style="background-color:#D3F0FE;width:36pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">15</p>
</td></tr>
<tr><td valign="top" style="width:252pt"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories*</p>
</td><td valign="top" style="width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1,807</span></p>
</td><td valign="top" style="width:31.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">19</span></p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">3,212</span></p>
</td><td valign="top" style="width:36pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">28</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:252pt"><p style="font:10pt Times New Roman;margin:0">Total:</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 9,710</p>
</td><td valign="top" style="background-color:#D3F0FE;width:31.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">100</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 11,340</p>
</td><td valign="top" style="background-color:#D3F0FE;width:36pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">100</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">OUS revenues (USD) by product category:</p>
<table style="border-collapse:collapse;width:427.5pt;margin-left:23.4pt"><tr><td valign="top" style="width:252pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1Q 2025</span></p>
</td><td valign="top" style="width:31.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">%</span></p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1Q 2024</span></p>
</td><td valign="top" style="width:36pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">%</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:252pt"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;193</p>
</td><td valign="top" style="background-color:#D3F0FE;width:31.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"> &#160;5</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;222</p>
</td><td valign="top" style="background-color:#D3F0FE;width:36pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"> &#160;4</p>
</td></tr>
<tr><td valign="top" style="width:252pt"><p style="font:10pt Times New Roman;margin:0">Gynecology/ Electrosurgery/ Urology</p>
</td><td valign="top" style="width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,567</p>
</td><td valign="top" style="width:31.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">62</p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,108</p>
</td><td valign="top" style="width:36pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">60</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:252pt"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">360</p>
</td><td valign="top" style="background-color:#D3F0FE;width:31.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"> &#160;9 &#160;&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">395</p>
</td><td valign="top" style="background-color:#D3F0FE;width:36pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"> &#160;8</p>
</td></tr>
<tr><td valign="top" style="width:252pt"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories*</p>
</td><td valign="top" style="width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000"> &#160;&#160;&#160;&#160;&#160;1,007</span></p>
</td><td valign="top" style="width:31.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000"> 24</span></p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000"> &#160;&#160; &#160;1,424</span></p>
</td><td valign="top" style="width:36pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">28</span></p>
</td></tr>
<tr style="height:12.6pt"><td valign="top" style="background-color:#D3F0FE;width:252pt"><p style="font:10pt Times New Roman;margin:0">Total:</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 4,127</p>
</td><td valign="top" style="background-color:#D3F0FE;width:31.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">100</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 5,149</p>
</td><td valign="top" style="background-color:#D3F0FE;width:36pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">100</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:37.8pt"></kbd>*includes molded components sold to OEM customers.&#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">9</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-indent:13.7pt">c) Gross Profit &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Gross Profit results from subtracting the costs of manufacturing products, including direct labor, raw materials and manufacturing overhead expenses, from revenues. &#160;Manufacturing overhead expenses include supervision, engineering, quality assurance, outside services, depreciation of manufacturing equipment, purchasing and freight (including tariffs) for receiving raw materials from vendors. UTMD&#8217;s Gross Profit was $1,227 (18.1%) lower in 1Q 2025 than in 1Q 2024. &#160;Gross Profit declined more than revenues due to lower absorption of manufacturing overhead costs which, because of their more fixed nature, were only 5.0% lower when sales were 14.4% lower. &#160;Management expects revenues to be consistent with 1Q 2025 during the remainder of the year, so it has projected a similar percentage decline in its Gross Profit Margin for the year as a whole. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:9pt"></kbd> &#160;d) Operating Income &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Operating Income results from subtracting Operating Expenses (OE) from Gross Profit. OE are comprised of G&amp;A expenses, S&amp;M expenses and R&amp;D expenses. &#160;Consolidated OE were $2,385 in 1Q 2025 (24.6% of sales) compared to $2,882 in 1Q 2024 (25.4% of sales). &#160;Ignoring the portion of OE that were litigation expenses and non-cash Identifiable Intangible Asset (IIA) amortization expense, OE in 1Q 2025 were $1,570 (16.2% of consolidated sales) compared to $1,628 (14.4% of sales) in 1Q 2024. &#160;FX rate differences affecting OUS OE in USD terms in 1Q 2025 compared to 1Q 2024 were minor. All foreign currencies were slightly weaker which reduced 1Q 2025 OUS OE excluding the UK IIA expense just $7 in constant currency. A weaker GBP in 1Q 2025 compared to 1Q 2024 decreased IIA amortization expense also captured in the G&amp;A category in the UK by less than $3. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Consolidated G&amp;A expenses were $1,731 (17.8% of sales) in 1Q 2025 compared to $2,205 (19.4% of sales) in 1Q 2024. G&amp;A expenses include litigation costs which were $314 in 1Q 2025 compared to $751 in 1Q 2024. G&amp;A expenses in 1Q 2025 included $501 (5.2% of sales) of non-cash expense from the amortization of IIA resulting from the 2011 Femcare acquisition, which were $504 (4.4% of sales) in 1Q 2024. The decrease was the result of a weaker GBP as the Femcare GBP-denominated expense was the same in both periods. Excluding litigation costs and non-cash Filshie-related IIA amortization expenses, G&amp;A expenses were $916 (9.4% of sales) in 1Q 2025 compared to $950 (8.4% of sales) in 1Q 2024. The change in FX rates decreased 1Q 2025 OUS G&amp;A expenses by less than $8, comprised of decreasing IIA amortization expense by less than $3 and all other G&amp;A expenses by $5. &#160;UTMD&#8217;s Operating Income Margin  excluding IIA amortization and litigation expense was 40.9% in 1Q 2025 compared to 45.3% in 1Q 2024.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">S&amp;M expenses were $500 (5.1% of sales) in 1Q 2025 compared to $412 (3.6% of sales) in 1Q 2024. &#160;The change in FX rates decreased 1Q 2025 OUS S&amp;M expenses by less than $3. &#160;The $91 constant currency increase was due to increases in S&amp;M salaries and medical costs for employees on board in both periods, and the timing of trade shows.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">R&amp;D expenses in 1Q 2025 were $155 (1.6% of sales) compared to $266 (2.3% of sales) in 1Q 2024. &#160;There were no OUS R&amp;D expenses. The decrease was primarily due to one-time testing and certification of materials required for biopharma sensor manufacturing in 1Q 2024. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">In summary, Operating Income in 1Q 2025 was $3,154 (32.5% of sales) compared to $3,883 (34.2% of sales) in 1Q 2024. &#160;The 1Q 2025 Operating Income Margin did not decline as much as the GPM due primarily to lower litigation expenses. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">A summary comparison of (USD) consolidated Operating Expenses follows:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:248pt"><tr style="height:7.2pt"><td valign="middle" style="width:152pt"><p style="font:12pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:48pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right"><span style="border-bottom:1px solid #000000">1Q 2025</span></p>
</td><td valign="middle" style="width:48pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right"><span style="border-bottom:1px solid #000000">1Q 2024</span></p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:152pt"><p style="font:10pt Times New Roman;margin:0;color:#000000">S&amp;M Expenses</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:48pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">$500 </p>
</td><td valign="middle" style="background-color:#D3F0FE;width:48pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">$412 </p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="width:152pt"><p style="font:10pt Times New Roman;margin:0;color:#000000">R&amp;D Expenses</p>
</td><td valign="middle" style="width:48pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">155</p>
</td><td valign="middle" style="width:48pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">266</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:152pt"><p style="font:10pt Times New Roman;margin:0;color:#000000">G&amp;A Expenses:</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:48pt"><p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:48pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="width:152pt"><p style="font:10pt Times New Roman;margin:0;color:#000000"> &#160;&#160;&#160;Femcare IIA amortization</p>
</td><td valign="middle" style="width:48pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">501</p>
</td><td valign="middle" style="width:48pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">504</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:152pt"><p style="font:10pt Times New Roman;margin:0;color:#000000"> &#160;&#160;&#160;Litigation Expense</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:48pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">314</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:48pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">750</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="width:152pt"><p style="font:10pt Times New Roman;margin:0;color:#000000"> &#160;&#160;&#160;All Other G&amp;A Expenses</p>
</td><td valign="middle" style="width:48pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right"><span style="border-bottom:1px solid #000000">915</span></p>
</td><td valign="middle" style="width:48pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right"><span style="border-bottom:1px solid #000000">950</span></p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:152pt"><p style="font:10pt Times New Roman;margin:0;color:#000000">Total Operating Expenses:</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:48pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">$2,385 </p>
</td><td valign="middle" style="background-color:#D3F0FE;width:48pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">$2,882 </p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-indent:13.5pt">e) &#160;Non-operating expense/ Non-operating income</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Net Non-operating expense, or net Non-operating income, results from the combination of 1) expenses from loan interest and bank fees; 2) expenses or income from losses or gains from remeasuring the value of EUR cash bank </p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">10</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0">balances in the UK, and GBP cash balances in Ireland, in USD terms; and 3) income from rent of underutilized property, investment income, royalties received from licensing the Company&#8217;s technology and other miscellaneous income. &#160;Net Non-operating income in 1Q 2025 was $705 compared to $915 in 1Q 2024. &#160;The primary difference was $153 lower interest income due to lower average cash balances in 1Q 2025 compared to 1Q 2024 with lower interest rates. In addition, in 1Q 2025 compared to 1Q 2024, UTMD accrued $32 higher excise tax Non-operating expense for share repurchases and received $20 lower Non-operating income from renting underutilized warehouse space in Ireland. UTMD realized a $2 loss in 1Q 2025 compared to a $1 loss at the end of 1Q 2024 from remeasurement of foreign currency bank balances. &#160; </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:9pt">f)</kbd><kbd style="margin-left:22.5pt"></kbd>Income Before Income Taxes (EBT)&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">EBT results from adding net Non-operating income or subtracting net Non-operating expense to or from Operating Income, as applicable. Consolidated 1Q 2025 EBT was $3,859 (39.7% of sales) compared to $4,798 (42.3% of sales) in 1Q 2024. The almost $940 (19.6%) lower 1Q 2025 EBT compared to 1Q 2024 was the result of $730 lower Operating Income combined with $210 lower Non-operating income.  </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The EBT of Utah Medical Products, Inc. in the U.S. was $3,546 in 1Q 2025 compared to $2,806 in 1Q 2024. The EBT of Utah Medical Products, Ltd (Ireland) was EUR 1,393 in 1Q 2025 compared to EUR 1,640 in 1Q 2024. The EBT of Femcare Group Ltd (Femcare Ltd., UK and Femcare Australia Pty Ltd) was GBP (663) in 1Q 2025 compared to GBP (101) in 1Q 2024. The 1Q 2025 EBT of Utah Medical Products Canada, Inc. was CAD 107 compared to CAD 66 in 1Q 2024. &#160;The differences in the U.S. and UK EBT were accentuated by intercompany transfer of litigation expenses which did not affect consolidated results. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">EBITDA is a non-US GAAP metric that measures profitability performance without factoring in effects of financing, accounting decisions regarding non-cash expenses, capital expenditures or tax environments. Excluding the noncash effects of depreciation, amortization of intangible assets and stock option expense, 1Q 2025 consolidated EBT excluding the remeasured bank balance currency gain or loss and interest expense (&#8220;adjusted consolidated EBITDA&#8221;) were $4,652 compared to $5,547 in 1Q 2024, which supports a year 2025 target of $18 million. Management believes that the 1Q 2025 operating performance provides a start that is consistent with achieving its financial performance projections for the calendar year 2025, as previously provided in its Year 2024 SEC 10-K Report. UTMD&#8217;s trailing twelve-month EBITDA as of March 31, 2025 was $18,957. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD&#8217;s non-US GAAP adjusted consolidated EBITDA is the sum of the elements in the following table, each element of which is a US GAAP number: &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse;margin-left:5.4pt"><tr><td valign="top" style="width:207pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:76.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1Q 2025</span></p>
</td><td valign="top" style="width:81pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1Q 2024</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:207pt"><p style="font:10pt Times New Roman;margin:0">EBT</p>
</td><td valign="top" style="background-color:#D3F0FE;width:76.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$3,859</p>
</td><td valign="top" style="background-color:#D3F0FE;width:81pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$4,798</p>
</td></tr>
<tr><td valign="top" style="width:207pt"><p style="font:10pt Times New Roman;margin:0">Depreciation Expense</p>
</td><td valign="top" style="width:76.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">200</p>
</td><td valign="top" style="width:81pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">156</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:207pt"><p style="font:10pt Times New Roman;margin:0">Femcare IIA Amortization Expense</p>
</td><td valign="top" style="background-color:#D3F0FE;width:76.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">501</p>
</td><td valign="top" style="background-color:#D3F0FE;width:81pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">504</p>
</td></tr>
<tr><td valign="top" style="width:207pt"><p style="font:10pt Times New Roman;margin:0">Other Non-Cash Amortization Expense</p>
</td><td valign="top" style="width:76.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">8</p>
</td><td valign="top" style="width:81pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">10</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:207pt"><p style="font:10pt Times New Roman;margin:0">Stock Option Compensation Expense</p>
</td><td valign="top" style="background-color:#D3F0FE;width:76.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">82</p>
</td><td valign="top" style="background-color:#D3F0FE;width:81pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">78</p>
</td></tr>
<tr><td valign="top" style="width:207pt"><p style="font:10pt Times New Roman;margin:0">Interest Expense</p>
</td><td valign="top" style="width:76.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td valign="top" style="width:81pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:207pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">Remeasured Foreign Currency Balances</p>
</td><td valign="top" style="background-color:#D3F0FE;width:76.5pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">2</p>
</td><td valign="top" style="background-color:#D3F0FE;width:81pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">1</p>
</td></tr>
<tr><td valign="top" style="width:207pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">UTMD non-US GAAP EBITDA:</p>
</td><td valign="top" style="width:76.5pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$4,652</p>
</td><td valign="top" style="width:81pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$5,547</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:9pt">g)</kbd><kbd style="margin-left:22.5pt"></kbd>Net Income&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Net Income is EBT less a provision for income taxes worldwide. &#160;Net Income in 1Q 2025 of $3,041 was 23.1% lower than the Net Income of $3,956 in 1Q 2024. UTMD&#8217;s Net Income Margin, Net Income divided by consolidated sales, was 31.3% in 1Q 2025 and 34.9% in 1Q 2024. The greater Net Income decline compared to 19.6% lower EBT was due to average consolidated income tax provision rates (as a % of EBT) in 1Q 2025 of 21.2% and 17.6% in 1Q 2024. &#160;Although basic corporate income tax rates did not change, the consolidated income tax provision can vary from period-to-period depending on the portion of EBT in sovereignties with differing rates, and a periodic true-up when actual tax returns are filed. &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:9pt"></kbd>h) &#160;Earnings Per Share (EPS)&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">EPS are consolidated Net Income divided by the weighted average number of shares of stock outstanding (diluted to take into consideration stock option awards which are &#8220;in the money,&#8221; i.e., have exercise prices below the applicable period&#8217;s weighted average market value). &#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">11</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0">EPS in 1Q 2025 at $0.919 were 16.0% lower than the $1.093 in 1Q 2024. &#160;UTMD&#8217;s smaller decline in EPS relative to Net Income was a result of 307,920 fewer diluted shares used to calculate EPS in 1Q 2025 compared to 1Q 2024. Diluted shares were 3,310,248 in 1Q 2025 compared to 3,618,168 in 1Q 2024. &#160;Outstanding shares were 3,280,889 at the end of 1Q 2025. The number of shares used for calculating EPS was higher than ending shares because of a time-weighted calculation of average outstanding shares for shares which were repurchased during the quarter. There was no dilution from unexercised employee options in either 1Q 2025 or 1Q 2024 as the average option exercise prices were above the period-ending closing stock prices. The total number of outstanding unexercised employee and outside director options at March 31, 2025 was 97,779 at an average exercise price of $73.77, including shares awarded but not yet vested. This compares to 97,985 unexercised option shares at the end of 2024 at an average exercise price of $73.77/ share, including shares awarded but not vested. &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Outstanding shares at the end of 1Q 2025 were 3,280,889 compared to 3,335,156 at the end of calendar year 2024 and 3,588,336 at the end of 1Q 2024. The difference in outstanding shares at the end of 1Q 2025 compared to the end of 2024 resulted from 54,267 shares repurchased in the open market, with no employee options exercised, during 1Q 2025.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">As previously stated, UTMD repurchased 54,267 of its shares at an average price of $59.35 during 1Q 2025. Because of a time-weighted calculation, the full antidilution impact of the 1Q 2025 repurchases won&#8217;t be felt until 2Q 2025. There were 43,108 share repurchases in 1Q 2024 at an average price of $69.37. No options were awarded in 1Q 2025 or 1Q 2024. During the rest of 2024 after 1Q 2024, 14,600 option shares were awarded to 47 employees at an exercise price of $64.09. The Company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders. UTMD&#8217;s closing share price at the end of 1Q 2025 was $56.04, down 9% from the $61.47 closing price at the end of 2024. The closing share price at the end of 1Q 2024 was $71.11. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD paid $1,017 ($0.305/share) in cash dividends to stockholders in 1Q 2025. UTMD paid $1,089 ($0.300/share) in cash dividends to stockholders in 1Q 2024. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:9pt">i) </kbd><kbd style="margin-left:22.5pt"></kbd>Return on Equity (ROE)&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">ROE is the portion of Net Income retained by UTMD to internally finance its growth, divided by the average accumulated Stockholders&#8217; Equity for the applicable time period. Annualized ROE (before stockholder dividends) in 1Q 2025 was 10% and in 1Q 2024 was 12%. &#160;The lower ROE in 1Q 2025 was due to 23% lower Net Income divided by 8% lower average Stockholders&#8217; Equity. Targeting a high ROE of 20% remains a key financial target for UTMD management. &#160;ROE can be increased by increasing Net Income, and/or by reducing Stockholders&#8217; Equity by paying cash dividends to stockholders or by repurchasing shares. &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Liquidity and Capital Resources</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:9pt">j)</kbd><kbd style="margin-left:22.5pt"></kbd>Cash flows&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Net cash provided by operating activities, including adjustments for depreciation and amortization and other non-cash expenses along with changes in working capital, totaled $4,464 in 1Q 2025 compared to $5,276 in 1Q 2024. Net Income provided $915 less to cash in 1Q 2025 than in 1Q 2024. &#160;Other differences in cash provided during the two periods were a $277 higher source of cash from reduction in accounts receivable along with $61 lower decrease in prepaid expenses and $44 higher depreciation, offset by a $189 higher use of cash for accrued expenses and $51 for interest and other receivables. &#160; &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Capital expenditures for property and equipment (PP&amp;E) netting proceeds from disposal were $184 in 1Q 2025 compared to $(5) in 1Q 2024. &#160;Depreciation of PP&amp;E was $200 in 1Q 2025 compared to $156 in 1Q 2024 as improvements from previous capital expenditures were put into service. &#160;&#160;&#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Cash dividends paid to stockholders in 1Q 2025 were $1,017 compared to $1,089 in 1Q 2024, despite a $.005/ share higher dividend. &#160;UTMD spent $3,221 in 1Q 2025 to repurchase 54,267 of its shares. &#160;In 1Q 2024, UTMD spent $2,990 to repurchase 43,108 of its shares. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">In 1Q 2025, there were no exercises of employee stock options. &#160;In comparison, in 1Q 2024 UTMD received $96 and issued 1,919 shares of its stock upon the exercise of employee stock options. Option exercises in 1Q 2024 were at an average price of $50.15 per share. &#160;&#160;&#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">12</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0">Management believes that current cash balances, income from operations and effective management of working capital will provide the liquidity needed to meet the challenges of the current economic environment in achieving operating objectives, to maintain the capability to make opportunistic investments that will provide for growth in future profits and to continue to allocate capital in a way that will maximize stockholder value over time. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">During the remainder of 2024 the Company may utilize cash not needed to support normal operations in one or a combination of the following: 1) in general, to continue to invest at an opportune time in ways that will enhance future profitability; 2) to make additional investments in new technology and/or processes; and/or 3) to acquire a product line or company that will augment revenue and EPS growth and better utilize UTMD&#8217;s existing infrastructure. &#160;If there are no better strategic uses for UTMD&#8217;s cash, the Company will continue to return cash to stockholders in the form of dividends and share repurchases when the stock appears undervalued. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:9pt">k)</kbd><kbd style="margin-left:22.5pt"></kbd>Assets and Liabilities&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD&#8217;s March 31, 2025 Balance Sheet, in the absence of debt, continued to be strong. &#160;At March 31, 2025 Cash and liquid Investments represented 68% of total consolidated assets, and Stockholders&#8217; Equity represented 96% of Total Liabilities and Stockholders&#8217; Equity which equals total consolidated assets. &#160;At March 31, 2025 compared to three months earlier at the end of 2024, UTMD&#8217;s cash and investments balance increased $349 to $83.3 million from $83.0 million despite using $4,238 in cash for share repurchases and stockholder dividends. Compared to a year earlier at March 31, 2024, cash and investments declined just $10.5 million while the Company used $24.4 million in cash for share repurchases and stockholder dividends. Inventories declined $165 from the end of 2024, and $0.6 million from a year earlier. Working capital at the end of 1Q 2025 declined $499 from the end of 2024, and was $9.6 million lower than at March 31, 2024, primarily as a result of the decrease in cash. UTMD&#8217;s strong current ratio improved to 22.3 at March 31, 2025 from 19.6 at March 31, 2024. &#160;The current ratio at the end of 2024 was 25.6. As a result of lower revenues, consolidated Accounts Receivable (net of allowances) decreased $151 at March 31, 2025 from the end of 2024, but increased $0.4 million compared to March 31, 2024. &#160;On a rolling sales quarter basis, the aging of receivables was a healthy 36.6 days at the end of 1Q 2025 compared to 40.3 days at the end of 2024, and 28.5 days at the end of March 2024.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Net fixed assets at March 31, 2025 compared to December 31, 2024 increased $183 from $184 in capital expenditures offset by $200 in depreciation, and the impact of the period-to-period foreign currency exchange (FX) rates for assets OUS. &#160;FX rates for Balance Sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of 1Q 2025 and the end of 2024 follow:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:262.35pt"><tr style="height:7.2pt"><td valign="bottom" style="width:61.8pt"><p style="font:12pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:66.15pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right"><span style="border-bottom:1px solid #000000">3/31/2025</span></p>
</td><td valign="middle" style="width:72.6pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right"><span style="border-bottom:1px solid #000000">12/31/2024</span></p>
</td><td valign="bottom" style="width:61.8pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right"><span style="border-bottom:1px solid #000000">Change</span></p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:61.8pt"><p style="font:10pt Times New Roman;margin:0;color:#000000">GBP</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:66.15pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">1.289</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:72.6pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">1.252</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:61.8pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">3.0%</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="width:61.8pt"><p style="font:10pt Times New Roman;margin:0;color:#000000">EUR</p>
</td><td valign="middle" style="width:66.15pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">1.079</p>
</td><td valign="middle" style="width:72.6pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">1.035</p>
</td><td valign="middle" style="width:61.8pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">4.3%</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:61.8pt"><p style="font:10pt Times New Roman;margin:0;color:#000000">AUD</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:66.15pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">0.624</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:72.6pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">0.618</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:61.8pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">0.8%</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="width:61.8pt"><p style="font:10pt Times New Roman;margin:0;color:#000000">CAD</p>
</td><td valign="middle" style="width:66.15pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">0.695</p>
</td><td valign="middle" style="width:72.6pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">0.694</p>
</td><td valign="middle" style="width:61.8pt"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">0.2%</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">At March 31, 2025, net Intangible Assets declined $270 to 13.2% of total consolidated assets from 13.4% on December 31, 2024, as a result of $509 in amortization offset by the FX rate impact of stronger ending currencies OUS. &#160;The decline in net Intangible Assets in USD terms from a year earlier was $1.9 million. &#160; &#160; &#160;</p>
<p style="font:10pt Times New Roman;margin:0">A $567 increase in current liabilities at March 31, 2025 compared to December 31, 2024 was a result of a $349 increase in accrued liabilities and a $218 increase in accounts payable. But current liabilities at March 31, 2025 were $1.2 million lower from a year earlier. The current liability changes resulted from business activity fluctuations. Long-term liabilities at March 31, 2025 compared to December 31, 2024 declined $206 primarily as a result of a $110 reduction in the deferred tax liability for the Femcare Ltd GBP IIA to $494 from $604 at the end of 2024. The Femcare deferred tax liability was $986 a year earlier at March 31, 2024, and $9,084 on the date of the 2011 acquisition.  This long-term liability will be fully amortized in March 2026. &#160;Reduction of the deferred tax liability occurs as the book/tax difference of IIA amortization is eliminated over the remaining useful life of the Femcare Ltd IIA. There was also a 1Q 2025 $76 decline in deferred income taxes in the U.S. and Ireland. UTMD&#8217;s total debt ratio (total liabilities/total assets) as of March 31, 2025 was 4.5% compared to 4.2% as of December 31, 2024, and 5.7% on March 31, 2024. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">As of March 31, 2025, Stockholders&#8217; Equity (SE) declined $10.7 million compared to a year earlier at March 31, 2024 as a result of the $24.4 million combination of share repurchases and stockholder cash dividends paid during the last twelve months which reduce SE, offset by Net Income of $13.0 million. During 1Q 2025, SE remained about the same from the end of 2024 (only $380 lower) because of $3,041 1Q 2025 Net Income which increased SE, while the company paid $1,017 in dividends and repurchased $3,221 in stock, which reduce SE.</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">13</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"> &#160;&#160; l) &#160;Management's Outlook</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The first quarter of 2025 results were consistent with management projections for 2025 as described in UTMD&#8217;s 2024 Form SEC 10-K filed in March. The major projected change in 2025 financial results compared to 2024 primarily had to do with continuing to lose UTMD&#8217;s largest biopharma pressure sensor OEM customer, PendoTECH. In 1Q 2025 WW sales to this customer were $1.5 million lower than in 1Q 2024, accounting for 91% of the period-to-period quarterly revenue decline. The $1.5 million decline also represents 55% of total 2024 sales to PendoTECH. Given PendoTECH orders recently received, most of the projected PendoTECH decline for 2025 has already been realized.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Not included in the Company&#8217;s prior outlook, however, is a possible 2025 negative impact of geopolitical tariffs. &#160;Although UTMD does import some components subject to U.S. tariffs which would dilute gross profit margins, the  greater exposure is the impact of uncertain reciprocal tariffs imposed by the sovereignties of UTMD&#8217;s OUS customers. &#160;For example, UTMD has two major distributors of its finished devices in China which have expressed an interest in postponing shipment of existing orders during 2Q 2025 totaling $0.8 million in sales. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Objectives for 2025 remain to</p>
<p style="font:10pt Times New Roman;margin-top:2pt;margin-bottom:0pt;margin-left:9pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-1.5pt">1)</kbd><kbd style="margin-left:18pt"></kbd>exploit UTMD&#8217;s pre-qualified status to market a line of high-pressure process control transducer configurations directly to biopharmaceutical manufacturers;&#160;</p>
<p style="font:10pt Times New Roman;margin-top:2pt;margin-bottom:0pt;margin-left:9pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">2)</kbd><kbd style="margin-left:18pt"></kbd>continue to leverage OUS distribution and manufacturing synergies by further integrating capabilities and resources in multinational operations; &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin-top:2pt;margin-bottom:0pt;margin-left:25.5pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">3)</kbd>focus on defending the proven safety and effectiveness of the Filshie Clip System in the U.S.;&#160;</p>
<p style="font:10pt Times New Roman;margin-top:2pt;margin-bottom:0pt;margin-left:25.5pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">4)</kbd>introduce additional products helpful to clinicians through product development; &#160;</p>
<p style="font:10pt Times New Roman;margin-top:2pt;margin-bottom:0pt;margin-left:25.5pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">5)</kbd>continue to achieve excellent overall financial operating performance despite a contraction in revenues; &#160;</p>
<p style="font:10pt Times New Roman;margin-top:2pt;margin-bottom:0pt;margin-left:25.5pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">6)</kbd>utilize positive cash generation to continue providing cash dividends to stockholders and make open market share repurchases if/ when the UTMD share price seems undervalued; and&#160;</p>
<p style="font:10pt Times New Roman;margin-top:2pt;margin-bottom:0pt;margin-left:25.5pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">7)</kbd>remain vigilant for affordable accretive acquisition opportunities which may be brought about by difficult economic conditions on small, innovative companies. &#160;</p>
<p style="font:10pt Times New Roman;margin-top:2pt;margin-bottom:0pt">&#160;</p>
<p style="font:10pt Times New Roman;margin-top:2pt;margin-bottom:0pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7.2pt">m)</kbd><kbd style="margin-left:27pt"></kbd>Accounting Policy Changes&#160;</p>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;color:#000000">None.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><b>Forward-Looking Information</b>. &#160;&#160;This report contains certain forward-looking statements and information relating to the Company that are based on the beliefs of management as well as assumptions made by management based on information currently available. &#160;When used in this document, the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend&#8221;, &#8220;should&#8221; and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. &#160;Such statements reflect the current view of the Company respecting future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties stated throughout the document. &#160;Although the Company has attempted to identify important factors that could cause the actual results to differ materially, there may be other factors that cause the forward statement not to come true as anticipated, believed, projected, expected, or intended. &#160;Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those described herein as anticipated, believed, projected, estimated, expected or intended. &#160;Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results, and the Company assumes no obligation to update or disclose revisions to those estimates.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a8"></a><p style="font:10pt Times New Roman;margin:0"><b>Item 3.</b> <b>Quantitative and Qualitative Disclosures about Market Risk</b></p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">UTMD has manufacturing and trading operations, including related assets, in the U.S. denominated in the U.S. Dollar (USD), in Ireland denominated in the Euro (EUR), in England denominated in the British Pound (GBP), in Australia denominated in the Australia Dollar (AUD), and in Canada denominated in the Canadian Dollar (CAD). &#160;The currencies are subject to exchange rate fluctuations that are beyond the control of UTMD. &#160;The exchange rates were .9264, .9661 and .9267 EUR per USD as of March 31, 2025, December 31, 2024 and March 31, 2024, respectively. &#160;Exchange rates were .7756, .7987, and .7915 GBP per USD as of March 31, 2025, December 31, 2024 and March 31, 2024, respectively. &#160;Exchange rates were 1.6038, 1.6172 and 1.5332 AUD per USD on March 31, 2025, December 31, 2024 and March 31, 2024, respectively. &#160;Exchange rates were 1.4379, 1.4403, and 1.3539 CAD </p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">14</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">per USD on March 31, 2025, December 31, 2024, and March 31, 2024 respectively. UTMD manages its foreign currency risk without separate hedging transactions by invoicing customers in the local currency where costs of production were incurred, by converting currencies as transactions occur and by optimizing global account structures through liquidity management accounts.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a9"></a><p style="font:10pt Times New Roman;margin:0"><b>Item 4. Controls and Procedures</b></p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">The Company&#8217;s management, under the supervision and with the participation of the Chief Executive Officer and the Principal Financial Officer, evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) as of March 31, 2025. Based on this evaluation, the Chief Executive Officer and Principal Financial Officer concluded that, as of March 31, 2025, the Company&#8217;s disclosure controls and procedures were effective. </p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">There were no changes in the Company&#8217;s internal controls over financial reporting that occurred during the quarter ended March 31, 2025, that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal controls over financial reporting. </p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">PART II - OTHER INFORMATION</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a10"></a><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt"><b>Item 1.</b></kbd><kbd style="margin-left:45pt"></kbd><b>Legal Proceedings</b>&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD is a party from time to time in litigation incidental to its business. Presently, except for Filshie clip product liability lawsuits, there is no litigation or threatened litigation. The Company does not expect the outcome of the Filshie clip litigation will be material to consolidated financial results.  </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a11"></a><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt"><b>Item 1A.</b></kbd><kbd style="margin-left:46.8pt"></kbd><b>Risk Factors</b>&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><span style="color:#333333">In addition to the other information set forth in this report, investors should carefully consider the factors discussed in Part I, &#8220;Item 1A. Risk Factors&#8221; in UTMD&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024, which could materially affect its business, financial condition or future results. &#160;The risks described in the Annual Report on Form 10-K are not the only risks facing the Company. &#160;Additional risks and uncertainties not currently known to UTMD or currently deemed to be immaterial also may materially adversely affect the Company&#8217;s business, financial condition and/or operating results.</span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">15</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<a id="a12"></a><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt"><b>Item 2.</b></kbd><kbd style="margin-left:37.8pt"></kbd><b>Unregistered Sales of Equity Securities and Use of Proceeds</b>&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The following table details purchases by UTMD of its own securities during 1Q 2025.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><b>ISSUER PURCHASES OF EQUITY SECURITIES</b></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse;width:481.05pt;border:0.5pt solid #000000"><tr style="height:107.7pt"><td valign="top" style="width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Period</p>
</td><td valign="top" style="width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">(a)</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">Total number of shares purchased (1)</p>
</td><td valign="top" style="width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">(b)</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">Average price paid per share (1)</p>
</td><td valign="top" style="width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">(c)</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">Total number of shares purchased as part of publicly announced plans or programs (1)</p>
</td><td valign="top" style="width:96.25pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">(d)</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">Maximum number (or approximate dollar value) of shares that may yet be purchased under the plans or programs (1)</p>
</td></tr>
<tr style="height:12.8pt"><td valign="top" style="background-color:#D3F0FE;width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">01/01/25 - 01/31/25</p>
</td><td valign="top" style="background-color:#D3F0FE;width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">13,840</p>
</td><td valign="top" style="background-color:#D3F0FE;width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">60.75</p>
</td><td valign="top" style="background-color:#D3F0FE;width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td><td valign="top" style="background-color:#D3F0FE;width:96.25pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td></tr>
<tr style="height:13.55pt"><td valign="top" style="width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">02/01/25 &#8211;&#160;02/28/25</p>
</td><td valign="top" style="width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">13,885</p>
</td><td valign="top" style="width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">60.01</p>
</td><td valign="top" style="width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td><td valign="top" style="width:96.25pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td></tr>
<tr style="height:13.55pt"><td valign="top" style="background-color:#D3F0FE;width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">03/01/25 &#8211;&#160;03/31/25</p>
</td><td valign="top" style="background-color:#D3F0FE;width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">25,615</p>
</td><td valign="top" style="background-color:#D3F0FE;width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">58.36</p>
</td><td valign="top" style="background-color:#D3F0FE;width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td><td valign="top" style="background-color:#D3F0FE;width:96.25pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td></tr>
<tr style="height:12.8pt"><td valign="top" style="width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">Total</p>
</td><td valign="top" style="width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">53,340</p>
</td><td valign="top" style="width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">59.41</p>
</td><td valign="top" style="width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td><td valign="top" style="width:96.25pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:8pt Times New Roman;margin:0;margin-left:36pt"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:-18pt">1)</kbd>None of the shares were purchased as part of a publicly announced plan and all were purchased on the open market.&#160;</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:36pt">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The frequency of UTMD&#8217;s open market share repurchases depends on the availability of sellers and the price of the stock. &#160;The board of directors has not established an expiration date or a maximum dollar or share limit for UTMD&#8217;s continuing and long-term pattern of open market share repurchases since 1992. &#160;</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">The purpose of UTMD&#8217;s ongoing share repurchases is to maximize the value of the Company for its continuing stockholders, and maximize its return on stockholder equity by employing excess cash generated by effectively managing its business<span style="color:#FF0000">. </span>UTMD does not intend to repurchase shares that would result in terminating its Nasdaq Global Market listing.</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">Please see item 9) Subsequent Events in the Notes to Financial Statements for shares repurchased in April 2025.</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:36pt"> &#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">16</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a13"></a><p style="font:10pt Times New Roman;margin:0"><b>Item 6. &#160;Exhibits </b></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse"><tr style="height:14.4pt"><td valign="bottom" style="width:50.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Exhibit #</span></p>
</td><td valign="bottom" style="width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">SEC <span style="border-bottom:1px solid #000000">Reference #</span></p>
</td><td valign="bottom" style="width:358.2pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">Title of Document</span></p>
</td></tr>
<tr style="height:3.6pt"><td valign="top" style="width:50.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:358.2pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:50.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">31.1</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">31</p>
</td><td valign="top" style="background-color:#D3F0FE;width:358.2pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="utmd_ex31z1.htm" style="text-decoration:none">Certification of CEO pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr><td valign="top" style="width:50.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">31.2</p>
</td><td valign="top" style="width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">31</p>
</td><td valign="top" style="width:358.2pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="utmd_ex31z2.htm" style="text-decoration:none">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:50.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">32.1</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">32</p>
</td><td valign="top" style="background-color:#D3F0FE;width:358.2pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="utmd_ex32z1.htm" style="text-decoration:none">Certification of CEO pursuant to 18 U.S.C. &#167;1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr><td valign="top" style="width:50.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">32.2</p>
</td><td valign="top" style="width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">32</p>
</td><td valign="top" style="width:358.2pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="utmd_ex32z2.htm" style="text-decoration:none">Certification of Principal Financial Officer pursuant to 18 U.S.C. &#167;1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:50.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101.ins</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101 ins</p>
</td><td valign="top" style="background-color:#D3F0FE;width:358.2pt"><p style="font:10pt Times New Roman;margin:0">XBRL Instance</p>
</td></tr>
<tr><td valign="top" style="width:50.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101.sch</p>
</td><td valign="top" style="width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101.sch</p>
</td><td valign="top" style="width:358.2pt"><p style="font:10pt Times New Roman;margin:0">XBRL Schema</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:50.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101.cal</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101.cal</p>
</td><td valign="top" style="background-color:#D3F0FE;width:358.2pt"><p style="font:10pt Times New Roman;margin:0">XBRL Calculation</p>
</td></tr>
<tr><td valign="top" style="width:50.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101.def</p>
</td><td valign="top" style="width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101.def</p>
</td><td valign="top" style="width:358.2pt"><p style="font:10pt Times New Roman;margin:0">XBRL Definition</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:50.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101.lab</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101.lab</p>
</td><td valign="top" style="background-color:#D3F0FE;width:358.2pt"><p style="font:10pt Times New Roman;margin:0">XBRL Label</p>
</td></tr>
<tr><td valign="top" style="width:50.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101.pre</p>
</td><td valign="top" style="width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101.pre</p>
</td><td valign="top" style="width:358.2pt"><p style="font:10pt Times New Roman;margin:0">XBRL Presentation</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">17</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<a id="a14"></a><p style="font:10pt Times New Roman;margin:0;text-align:center">SIGNATURES</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:28.8pt"></kbd>Pursuant to the requirements of the Securities Exchanges Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:204.2pt"></kbd><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC.</span>&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:204.2pt"></kbd>REGISTRANT&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">Date: <span style="border-bottom:1px solid #000000"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;5/13/25 &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></kbd><kbd style="margin-left:204.2pt"></kbd>By: <span style="border-bottom:1px solid #000000"> &#160;&#160;&#160;&#160;&#160;&#160;/s/ Kevin L. Cornwell &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:55.4pt"> &#160;&#160;&#160;&#160;</kbd><kbd style="margin-left:219.1pt"></kbd>Kevin L. Cornwell&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:55.4pt"> &#160;&#160;&#160;&#160;</kbd><kbd style="margin-left:219.1pt"></kbd>CEO&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">Date: <span style="border-bottom:1px solid #000000"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;5/13/25 &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></kbd><kbd style="margin-left:204.2pt"></kbd>By: <span style="border-bottom:1px solid #000000"> &#160;&#160;&#160;&#160;&#160;&#160;/s/ Brian L. Koopman &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:55.4pt"> &#160;&#160;&#160;&#160;</kbd><kbd style="margin-left:219.1pt"></kbd>Brian L. Koopman&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:219.1pt"></kbd>Principal Financial Officer&#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">18</p>
</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>utmd_ex31z1.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VAAJHZFF]. www.edgarsuite.com -->
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><P align=right style='font:10pt Times New Roman;margin:0'><B>Exhibit 31.1</B></P>
<P align=center style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><B>CERTIFICATION OF CEO </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>I, Kevin L. Cornwell, certify that:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0.05pt'>1.</KBD><KBD style=margin-left:18pt></KBD>I have reviewed this quarterly report on Form 10-Q of Utah Medical Products, Inc.; &nbsp;&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0.05pt'>2.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0.05pt'>3.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0.05pt'>4.</KBD><KBD style=margin-left:18pt></KBD>The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(a)</KBD>designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(c)</KBD>evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(d)</KBD>disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0.05pt'>5.</KBD><KBD style=margin-left:18pt></KBD>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions):&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(a)</KBD>all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Date: May 13, 2025</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;/s/ Kevin L. Cornwell &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Kevin L. Cornwell</P>
<P style='font:10pt Times New Roman;margin:0'>Chief Executive Officer</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'></DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>utmd_ex31z2.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VAAJHZFF]. www.edgarsuite.com -->
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><P align=right style='font:10pt Times New Roman;margin:0'><B>Exhibit 31.2</B></P>
<P align=center style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>I, Brian L. Koopman, certify that:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0.05pt'>1.</KBD><KBD style=margin-left:18pt></KBD>I have reviewed this quarterly report on Form 10-Q of Utah Medical Products, Inc.; &nbsp;&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0.05pt'>2.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0.05pt'>3.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0.05pt'>4.</KBD><KBD style=margin-left:18pt></KBD>The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(a)</KBD>designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(c)</KBD>evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(d)</KBD>disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0.05pt'>5.</KBD><KBD style=margin-left:18pt></KBD>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions):&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(a)</KBD>all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Date: May 13, 2025</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Brian L. Koopman</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Brian L. Koopman</P>
<P style='font:10pt Times New Roman;margin:0'>Principal Financial Officer</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'></DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>utmd_ex32z1.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VAAJHZFF]. www.edgarsuite.com -->
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><P align=right style='font:10pt Times New Roman;margin:0'><B>Exhibit 32.1</B></P>
<P align=center style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><B>CERTIFICATION PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>18 U.S.C. SECTION 1350,</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>AS ADOPTED PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>In connection with the Quarterly Report of Utah Medical Products, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending March 31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Kevin L. Cornwell, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:36pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-34.2pt'>(1)</KBD>the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:36pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-34.2pt'>(2)</KBD>the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;/s/ Kevin L. Cornwell &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Kevin L. Cornwell</P>
<P style='font:10pt Times New Roman;margin:0'>Chief Executive Officer</P>
<P style='font:10pt Times New Roman;margin:0'>May 13, 2025</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><I>A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. &nbsp;</I></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'></DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>utmd_ex32z2.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VAAJHZFF]. www.edgarsuite.com -->
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><P style='font:10pt Times New Roman;margin:0'><KBD style=margin-left:374.4pt></KBD><B>Exhibit 32.2</B>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><B>CERTIFICATION PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>18 U.S.C. SECTION 1350,</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>AS ADOPTED PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>In connection with the Quarterly Report of Utah Medical Products, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending March 31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Brian L. Koopman, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:36pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-34.2pt'>(1)</KBD>the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:36pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-34.2pt'>(2)</KBD>the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;/s/ Brian L. Koopman</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Brian L. Koopman</P>
<P style='font:10pt Times New Roman;margin:0'>Principal Financial Officer</P>
<P style='font:10pt Times New Roman;margin:0'>May 13, 2025</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><I>A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. &nbsp;</I></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'></DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>utmd-20250331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK5GW761L0VEWPD92X]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20250331"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent' xlink:label='us-gaap_OtherAssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OtherAssetsCurrent' xlink:to='us-gaap_CashAndCashEquivalentsAtCarryingValue' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent' xlink:label='us-gaap_AccountsReceivableNetCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OtherAssetsCurrent' xlink:to='us-gaap_AccountsReceivableNetCurrent' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OtherAssetsCurrent' xlink:to='us-gaap_InventoryNet' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_OtherAssetsCurrent' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_AssetsCurrent' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_PropertyPlantAndEquipmentNet' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill' xlink:label='us-gaap_Goodwill'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_Goodwill' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_IntangibleAssetsNetExcludingGoodwill' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross' xlink:label='us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:to='us-gaap_FiniteLivedIntangibleAssetsGross' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:to='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent' xlink:label='us-gaap_AccountsPayableCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='us-gaap_AccountsPayableCurrent' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='us-gaap_AccruedLiabilitiesCurrent' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_LiabilitiesCurrent' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:label='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermDebtNoncurrent' xlink:label='us-gaap_OtherLongTermDebtNoncurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_OtherLongTermDebtNoncurrent' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations' xlink:label='us-gaap_LongTermDebtAndCapitalLeaseObligations'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_LongTermDebtAndCapitalLeaseObligations' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:label='us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_DeferredIncomeTaxLiabilitiesNet' use='optional' order='5.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='us-gaap_Liabilities' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='us-gaap_StockholdersEquity' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_CommonStockValue' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock' xlink:label='us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_AdditionalPaidInCapitalCommonStock' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_RetainedEarningsAccumulatedDeficit' use='optional' order='4.0' weight='1.0'/>
	</link:calculationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_GrossProfit' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold' xlink:label='us-gaap_CostOfGoodsAndServicesSold'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_GrossProfit' xlink:to='us-gaap_CostOfGoodsAndServicesSold' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='us-gaap_GrossProfit' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='us-gaap_OperatingExpenses' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingExpenses' xlink:to='us-gaap_SellingGeneralAndAdministrativeExpense' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingExpenses' xlink:to='us-gaap_ResearchAndDevelopmentExpense' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:to='us-gaap_OperatingIncomeLoss' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense' xlink:label='us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:to='us-gaap_OtherNonoperatingIncomeExpense' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ProfitLoss' xlink:to='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ProfitLoss' xlink:to='us-gaap_IncomeTaxExpenseBenefit' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ComprehensiveIncomeNetOfTax' xlink:to='us-gaap_ProfitLoss' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ComprehensiveIncomeNetOfTax' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='2.0' weight='1.0'/>
	</link:calculationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_ProfitLoss' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation' xlink:label='us-gaap_Depreciation'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_Depreciation' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets' xlink:label='us-gaap_AmortizationOfIntangibleAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_AmortizationOfIntangibleAssets' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_ProvisionForDoubtfulAccounts' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:label='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_DeferredIncomeTaxExpenseBenefit' use='optional' order='5.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation' xlink:label='us-gaap_ShareBasedCompensation'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_ShareBasedCompensation' use='optional' order='6.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:label='us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_DeferredTaxExpenseFromStockOptionsExercised' use='optional' order='7.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets' xlink:label='us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets' use='optional' order='8.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInInventories' use='optional' order='9.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' use='optional' order='10.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInAccountsPayable' use='optional' order='11.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInAccruedLiabilities' use='optional' order='12.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivities' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivities' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivities' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' use='optional' order='1.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment' xlink:label='us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:label='us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='us-gaap_ProceedsFromIssuanceOfCommonStock' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:label='us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='us-gaap_PaymentsForRepurchaseOfCommonStock' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividends' xlink:label='us-gaap_PaymentsOfDividends'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='us-gaap_PaymentsOfDividends' use='optional' order='3.0' weight='-1.0'/>
	</link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>utmd-20250331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK5GW761L0VEWPD92X]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20250331"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementEquityComponentsAxis' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_CommonStockMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_AdditionalPaidInCapitalMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeMember' xlink:label='us-gaap_ComprehensiveIncomeMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_ComprehensiveIncomeMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_RetainedEarningsMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:closed='true' xbrldt:contextElement='segment' use='optional'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:label='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionPlanExpense' xlink:label='us-gaap_StockOptionPlanExpense'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockOptionPlanExpense' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStockCash' xlink:label='us-gaap_DividendsCommonStockCash'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_DividendsCommonStockCash' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ProfitLoss' use='optional' order='12.0'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure1BasisOfPresentation" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure1BasisOfPresentation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure1BasisOfPresentation"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure2RecentAccountingStandards" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure2RecentAccountingStandards"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure2RecentAccountingStandards"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure3Inventories" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure3Inventories"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure3Inventories"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure4StockBasedCompensation" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure4StockBasedCompensation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure4StockBasedCompensation"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure5WarrantyReserve" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure5WarrantyReserve"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure5WarrantyReserve"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognition" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure6RevenueRecognition"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognition"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure7EarningsPerShare" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure7EarningsPerShare"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure7EarningsPerShare"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformation" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure8SegmentInformation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformation"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure9SubsequentEvents" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure9SubsequentEvents"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure9SubsequentEvents"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure4StockBasedCompensationDetails" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure4StockBasedCompensationDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure4StockBasedCompensationDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis' xlink:label='srt_StatementGeographicalAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='srt_StatementGeographicalAxis' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='srt_StatementGeographicalAxis' xlink:to='srt_SegmentGeographicalDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='srt_StatementGeographicalAxis' xlink:to='srt_SegmentGeographicalDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_DomesticUsMember' xlink:label='fil_DomesticUsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_SegmentGeographicalDomain' xlink:to='fil_DomesticUsMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_OutsideUsMember' xlink:label='fil_OutsideUsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_SegmentGeographicalDomain' xlink:to='fil_OutsideUsMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis' xlink:label='srt_ProductOrServiceAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='srt_ProductOrServiceAxis' use='optional' order='2.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='srt_ProductOrServiceAxis' xlink:to='srt_ProductsAndServicesDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='srt_ProductOrServiceAxis' xlink:to='srt_ProductsAndServicesDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_ObstetricsMember' xlink:label='fil_ObstetricsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_ObstetricsMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_GynecologyElectrosurgeryUrologyMember' xlink:label='fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_GynecologyElectrosurgeryUrologyMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_NeonatalMember' xlink:label='fil_NeonatalMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_NeonatalMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_BloodPressureMonitoringAndAccessoriesMember' xlink:label='fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_BloodPressureMonitoringAndAccessoriesMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:closed='true' xbrldt:contextElement='segment' use='optional'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis' xlink:label='srt_StatementScenarioAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='srt_StatementScenarioAxis' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain' xlink:label='srt_ScenarioUnspecifiedDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='srt_StatementScenarioAxis' xlink:to='srt_ScenarioUnspecifiedDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain' xlink:label='srt_ScenarioUnspecifiedDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='srt_StatementScenarioAxis' xlink:to='srt_ScenarioUnspecifiedDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_SingleOperatingSegmentMember' xlink:label='fil_SingleOperatingSegmentMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ScenarioUnspecifiedDomain' xlink:to='fil_SingleOperatingSegmentMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:closed='true' xbrldt:contextElement='segment' use='optional'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_StandardCostOfSales' xlink:label='fil_StandardCostOfSales'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_StandardCostOfSales' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_OtherCostOfSales' xlink:label='fil_OtherCostOfSales'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OtherCostOfSales' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_GrossProfit' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_GrossProfitMargin' xlink:label='fil_GrossProfitMargin'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_GrossProfitMargin' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense' xlink:label='us-gaap_SellingAndMarketingExpense'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SellingAndMarketingExpense' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ResearchAndDevelopmentExpense' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_LitigationExpense' xlink:label='fil_LitigationExpense'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_LitigationExpense' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets' xlink:label='us-gaap_AmortizationOfIntangibleAssets'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_AmortizationOfIntangibleAssets' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_OtherSellingGeneralAndAdministrativeExpense'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherSellingGeneralAndAdministrativeExpense' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OperatingIncomeLoss' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_OperatingIncomeMargin' xlink:label='fil_OperatingIncomeMargin'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OperatingIncomeMargin' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInterestAndDividendIncome' xlink:label='us-gaap_OtherInterestAndDividendIncome'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherInterestAndDividendIncome' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet' xlink:label='us-gaap_OtherOperatingIncomeExpenseNet'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherOperatingIncomeExpenseNet' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_IncomeTaxExpenseBenefit' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ProfitLoss' use='optional' order='17.0'/>
	</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>utmd-20250331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK5GW761L0VEWPD92X]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20250331"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
	<link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInterestAndDividendIncome' xlink:label='us-gaap_OtherInterestAndDividendIncome'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherInterestAndDividendIncome' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other Interest and Dividend Income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherInterestAndDividendIncome' xlink:to='lab_us-gaap_OtherInterestAndDividendIncome'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_ProductsAndServicesDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Product and Service</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_ProductsAndServicesDomain' xlink:to='lab_srt_ProductsAndServicesDomain'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:label='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet' xlink:label='us-gaap_InterestPaidNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InterestPaidNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash paid during the period for interest</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InterestPaidNet' xlink:to='lab_us-gaap_InterestPaidNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract' xlink:label='us-gaap_SupplementalCashFlowInformationAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SupplementalCashFlowInformationAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SupplementalCashFlowInformationAbstract' xlink:to='lab_us-gaap_SupplementalCashFlowInformationAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net cash used in financing activities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net cash used in financing activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermDebtNoncurrent' xlink:label='us-gaap_OtherLongTermDebtNoncurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherLongTermDebtNoncurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other long term liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherLongTermDebtNoncurrent' xlink:to='lab_us-gaap_OtherLongTermDebtNoncurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:label='us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>LIABILITIES AND STOCKHOLDERS&apos; EQUITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis' xlink:label='srt_StatementScenarioAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_StatementScenarioAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Scenario [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_StatementScenarioAxis' xlink:to='lab_srt_StatementScenarioAxis'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Prepaid expenses and other current assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Prepaid expenses and other current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:to='lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:label='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amortization of Right-of-Use Assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:to='lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Foreign currency translation adjustment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Foreign currency translation net of taxes of $0 in all periods</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:to='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock' xlink:label='us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdditionalPaidInCapitalCommonStock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Additional paid-in capital</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdditionalPaidInCapitalCommonStock' xlink:to='lab_us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross' xlink:label='us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsGross' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other intangible assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FiniteLivedIntangibleAssetsGross' xlink:to='lab_us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and equipment, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentNet' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntitySmallBusiness' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Small Business</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntitySmallBusiness' xlink:to='lab_dei_EntitySmallBusiness'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentPeriodEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Period End Date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentPeriodEndDate' xlink:to='lab_dei_DocumentPeriodEndDate'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_OperatingIncomeMargin' xlink:label='fil_OperatingIncomeMargin'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OperatingIncomeMargin' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating Income Margin</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OperatingIncomeMargin' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the percentage value of Operating Income Margin, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OperatingIncomeMargin' xlink:to='lab_fil_OperatingIncomeMargin'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock' xlink:label='us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Segment Reporting Information, by Segment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock' xlink:to='lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock' xlink:label='us-gaap_SubsequentEventsTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SubsequentEventsTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(9) Subsequent Events</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SubsequentEventsTextBlock' xlink:to='lab_us-gaap_SubsequentEventsTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash at beginning of period</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Cash at beginning of period</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Cash at end of period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:to='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementLineItems' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Statement [Line Items]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementLineItems' xlink:to='lab_us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Shares outstanding (diluted)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:to='lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:label='us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:to='lab_us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total current liabilities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total current liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='lab_us-gaap_LiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentFlag' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Flag</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentFlag' xlink:to='lab_dei_AmendmentFlag'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityIncorporationStateCountryCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Incorporation, State or Country Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityIncorporationStateCountryCode' xlink:to='lab_dei_EntityIncorporationStateCountryCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityWellKnownSeasonedIssuer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Well-known Seasoned Issuer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityWellKnownSeasonedIssuer' xlink:to='lab_dei_EntityWellKnownSeasonedIssuer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_TradingSymbol' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Symbol</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_TradingSymbol' xlink:to='lab_dei_TradingSymbol'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_SingleOperatingSegmentMember' xlink:label='fil_SingleOperatingSegmentMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_SingleOperatingSegmentMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Single Operating Segment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_SingleOperatingSegmentMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Single Operating Segment, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_SingleOperatingSegmentMember' xlink:to='lab_fil_SingleOperatingSegmentMember'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_OutsideUsMember' xlink:label='fil_OutsideUsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OutsideUsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>OutsideUsMember</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OutsideUsMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the OutsideUsMember, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OutsideUsMember' xlink:to='lab_fil_OutsideUsMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock' xlink:label='us-gaap_SegmentReportingDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SegmentReportingDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(8) Segment Information</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SegmentReportingDisclosureTextBlock' xlink:to='lab_us-gaap_SegmentReportingDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock' xlink:label='us-gaap_EarningsPerShareTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(7) Earnings Per Share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareTextBlock' xlink:to='lab_us-gaap_EarningsPerShareTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyDisclosureTextBlock' xlink:label='us-gaap_ProductWarrantyDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProductWarrantyDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(5) Warranty Reserve</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProductWarrantyDisclosureTextBlock' xlink:to='lab_us-gaap_ProductWarrantyDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill' xlink:label='us-gaap_Goodwill'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Goodwill' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Goodwill</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Goodwill' xlink:to='lab_us-gaap_Goodwill'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCentralIndexKey' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Central Index Key</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCentralIndexKey' xlink:to='lab_dei_EntityCentralIndexKey'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_GynecologyElectrosurgeryUrologyMember' xlink:label='fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_GynecologyElectrosurgeryUrologyMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Gynecology/Electrosurgery/Urology</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_GynecologyElectrosurgeryUrologyMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Gynecology/Electrosurgery/Urology, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_GynecologyElectrosurgeryUrologyMember' xlink:to='lab_fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryRawMaterials' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory, Raw Materials, Gross</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryRawMaterials' xlink:to='lab_us-gaap_InventoryRawMaterials'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(2) Recent Accounting Standards</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:to='lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net cash provided by operating activities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net cash provided by operating activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockMember' xlink:to='lab_us-gaap_CommonStockMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpenses' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total operating expenses</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpenses' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total operating expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingExpenses' xlink:to='lab_us-gaap_OperatingExpenses'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract' xlink:label='us-gaap_IncomeStatementAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeStatementAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeStatementAbstract' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - Parenthetical</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='lab_us-gaap_IncomeStatementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total current assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsCurrent' xlink:to='lab_us-gaap_AssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle' xlink:label='dei_Security12bTitle'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_Security12bTitle' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Title of 12(b) Security</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_Security12bTitle' xlink:to='lab_dei_Security12bTitle'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityExTransitionPeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Ex Transition Period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityExTransitionPeriod' xlink:to='lab_dei_EntityExTransitionPeriod'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense' xlink:label='us-gaap_SellingAndMarketingExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SellingAndMarketingExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Selling and Marketing Expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SellingAndMarketingExpense' xlink:to='lab_us-gaap_SellingAndMarketingExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsPayable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts payable {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsPayable' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Accounts payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccountsPayable' xlink:to='lab_us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStockCash' xlink:label='us-gaap_DividendsCommonStockCash'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DividendsCommonStockCash' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock dividends</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DividendsCommonStockCash' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Common stock dividends</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DividendsCommonStockCash' xlink:to='lab_us-gaap_DividendsCommonStockCash'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Shares outstanding (basic)</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Weighted average shares, basic</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:to='lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Provision for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxExpenseBenefit' xlink:to='lab_us-gaap_IncomeTaxExpenseBenefit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Income before provision for income taxes</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Income before provision for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:to='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Sales, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:to='lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SecurityExchangeName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Security Exchange Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SecurityExchangeName' xlink:to='lab_dei_SecurityExchangeName'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_StandardCostOfSales' xlink:label='fil_StandardCostOfSales'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_StandardCostOfSales' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Standard cost of sales</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_StandardCostOfSales' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the monetary amount of Standard cost of sales, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_StandardCostOfSales' xlink:to='lab_fil_StandardCostOfSales'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain' xlink:label='srt_ScenarioUnspecifiedDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_ScenarioUnspecifiedDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Scenario</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_ScenarioUnspecifiedDomain' xlink:to='lab_srt_ScenarioUnspecifiedDomain'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_ObstetricsMember' xlink:label='fil_ObstetricsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ObstetricsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Obstetrics</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ObstetricsMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Obstetrics, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ObstetricsMember' xlink:to='lab_fil_ObstetricsMember'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_DomesticUsMember' xlink:label='fil_DomesticUsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DomesticUsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>DomesticUsMember</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DomesticUsMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the DomesticUsMember, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DomesticUsMember' xlink:to='lab_fil_DomesticUsMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:label='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(4) Stock-Based Compensation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:to='lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation' xlink:label='us-gaap_ShareBasedCompensation'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ShareBasedCompensation' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stock-based compensation expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ShareBasedCompensation' xlink:to='lab_us-gaap_ShareBasedCompensation'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProvisionForDoubtfulAccounts' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Provision for losses on/(recovery of) accounts receivable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProvisionForDoubtfulAccounts' xlink:to='lab_us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionPlanExpense' xlink:label='us-gaap_StockOptionPlanExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockOptionPlanExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stock option compensation expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockOptionPlanExpense' xlink:to='lab_us-gaap_StockOptionPlanExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock issued upon exercise of employee stock options, shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:to='lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock issued upon exercise of employee stock options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:to='lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeMember' xlink:label='us-gaap_ComprehensiveIncomeMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ComprehensiveIncomeMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Comprehensive Income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ComprehensiveIncomeMember' xlink:to='lab_us-gaap_ComprehensiveIncomeMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementTable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Statement</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementTable' xlink:to='lab_us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense' xlink:label='us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherNonoperatingIncomeExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherNonoperatingIncomeExpense' xlink:to='lab_us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GrossProfit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Gross profit</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GrossProfit' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Gross profit</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_GrossProfit' xlink:to='lab_us-gaap_GrossProfit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations' xlink:label='us-gaap_LongTermDebtAndCapitalLeaseObligations'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LongTermDebtAndCapitalLeaseObligations' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Long-term lease liability</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LongTermDebtAndCapitalLeaseObligations' xlink:to='lab_us-gaap_LongTermDebtAndCapitalLeaseObligations'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent' xlink:label='us-gaap_AccountsReceivableNetCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccountsReceivableNetCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts &amp; other receivables, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccountsReceivableNetCurrent' xlink:to='lab_us-gaap_AccountsReceivableNetCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressCityOrTown' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, City or Town</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressCityOrTown' xlink:to='lab_dei_EntityAddressCityOrTown'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFilerCategory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Filer Category</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFilerCategory' xlink:to='lab_dei_EntityFilerCategory'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TextBlockAbstract' xlink:to='lab_us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_LitigationExpense' xlink:label='fil_LitigationExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_LitigationExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Litigation Expense</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_LitigationExpense' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the monetary amount of Litigation Expense, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_LitigationExpense' xlink:to='lab_fil_LitigationExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TableTextBlockSupplementAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tables/Schedules</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='lab_us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:label='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(1) Basis of Presentation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:to='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred income taxes {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Deferred income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:to='lab_us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation' xlink:label='us-gaap_Depreciation'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Depreciation' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Depreciation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Depreciation' xlink:to='lab_us-gaap_Depreciation'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:to='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ComprehensiveIncomeNetOfTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total comprehensive income</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ComprehensiveIncomeNetOfTax' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total comprehensive income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ComprehensiveIncomeNetOfTax' xlink:to='lab_us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total stockholders&apos; equity</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total stockholders&apos; equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquity' xlink:to='lab_us-gaap_StockholdersEquity'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Liabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total liabilities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Liabilities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Liabilities' xlink:to='lab_us-gaap_Liabilities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:label='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred tax liability - Femcare IIA</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:to='lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccruedLiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accrued expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccruedLiabilitiesCurrent' xlink:to='lab_us-gaap_AccruedLiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent' xlink:label='us-gaap_OtherAssetsCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherAssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other current assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherAssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Other current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherAssetsCurrent' xlink:to='lab_us-gaap_OtherAssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CityAreaCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>City Area Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CityAreaCode' xlink:to='lab_dei_CityAreaCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:label='us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Inventory, Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net cash provided by/(used in) investing activities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net cash provided by/(used in) investing activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInInventories' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventories {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInInventories' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Inventories</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInInventories' xlink:to='lab_us-gaap_IncreaseDecreaseInInventories'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets' xlink:label='us-gaap_AmortizationOfIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AmortizationOfIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amortization {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AmortizationOfIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Amortization</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AmortizationOfIntangibleAssets' xlink:to='lab_us-gaap_AmortizationOfIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock received and retired upon exercise of stock options</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the monetary amount of Common stock received and retired upon exercise of stock options, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:to='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized' xlink:label='us-gaap_CommonStockSharesAuthorized'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Shares Authorized</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesAuthorized' xlink:to='lab_us-gaap_CommonStockSharesAuthorized'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent' xlink:label='us-gaap_AccountsPayableCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccountsPayableCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccountsPayableCurrent' xlink:to='lab_us-gaap_AccountsPayableCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Assets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Assets' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Assets' xlink:to='lab_us-gaap_Assets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus' xlink:label='dei_DocumentFiscalYearFocus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentFiscalYearFocus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Fiscal Year Focus</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentFiscalYearFocus' xlink:to='lab_dei_DocumentFiscalYearFocus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityInteractiveDataCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Interactive Data Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityInteractiveDataCurrent' xlink:to='lab_dei_EntityInteractiveDataCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressStateOrProvince' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, State or Province</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressStateOrProvince' xlink:to='lab_dei_EntityAddressStateOrProvince'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityVoluntaryFilers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Voluntary filer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityVoluntaryFilers' xlink:to='lab_dei_EntityVoluntaryFilers'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_GrossProfitMargin' xlink:label='fil_GrossProfitMargin'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_GrossProfitMargin' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Gross Profit Margin</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_GrossProfitMargin' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the percentage value of Gross Profit Margin, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_GrossProfitMargin' xlink:to='lab_fil_GrossProfitMargin'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:label='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Dilutive effect of stock options</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Dilutive effect of stock options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:to='lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_SegmentGeographicalDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Geographical</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_SegmentGeographicalDomain' xlink:to='lab_srt_SegmentGeographicalDomain'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock' xlink:label='fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule Of Global Revenues By Product Category</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Schedule of Global Revenues by Product Category.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock' xlink:to='lab_fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RevenueRecognitionPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(6) Revenue Recognition</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RevenueRecognitionPolicyTextBlock' xlink:to='lab_us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Effect of exchange rate changes on cash</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:to='lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and equipment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Property and equipment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:to='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract' xlink:label='us-gaap_StatementOfCashFlowsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfCashFlowsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='lab_us-gaap_StatementOfCashFlowsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock purchased and retired</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:to='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareBasic' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Earnings per common share (basic)</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareBasic' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Earnings per common share (basic)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareBasic' xlink:to='lab_us-gaap_EarningsPerShareBasic'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total liabilities and stockholders&apos; equity</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total liabilities and stockholders&apos; equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='lab_us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock - $.01 par value; authorized - 50,000 shares; issued and outstanding - March 31, 2025, 3,281 shares and December 31, 2024, 3,335 shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockValue' xlink:to='lab_us-gaap_CommonStockValue'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:label='us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tax benefit attributable to exercise of stock options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:to='lab_us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock received and retired upon exercise of stock options, shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Common stock received and retired upon exercise of stock options, shares (number of shares), during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:to='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EquityComponentDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Component</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EquityComponentDomain' xlink:to='lab_us-gaap_EquityComponentDomain'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdditionalPaidInCapitalMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Additional Paid-in Capital</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdditionalPaidInCapitalMember' xlink:to='lab_us-gaap_AdditionalPaidInCapitalMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract' xlink:label='us-gaap_StatementOfStockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfStockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementOfStockholdersEquityAbstract' xlink:to='lab_us-gaap_StatementOfStockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating income</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Operating income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='lab_us-gaap_OperatingIncomeLoss'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ResearchAndDevelopmentExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Research &amp; development</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ResearchAndDevelopmentExpense' xlink:to='lab_us-gaap_ResearchAndDevelopmentExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other intangible assets, net</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Other intangible assets, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:to='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract' xlink:label='us-gaap_StatementOfFinancialPositionAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfFinancialPositionAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfFinancialPositionAbstract' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS - Parenthetical</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='lab_us-gaap_StatementOfFinancialPositionAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CurrentFiscalYearEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current Fiscal Year End Date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CurrentFiscalYearEndDate' xlink:to='lab_dei_CurrentFiscalYearEndDate'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_OtherCostOfSales' xlink:label='fil_OtherCostOfSales'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OtherCostOfSales' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other cost of sales</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OtherCostOfSales' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the monetary amount of Other cost of sales, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OtherCostOfSales' xlink:to='lab_fil_OtherCostOfSales'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_NeonatalMember' xlink:label='fil_NeonatalMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NeonatalMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Neonatal</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NeonatalMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Neonatal, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NeonatalMember' xlink:to='lab_fil_NeonatalMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis' xlink:label='srt_ProductOrServiceAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_ProductOrServiceAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Product and Service [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_ProductOrServiceAxis' xlink:to='lab_srt_ProductOrServiceAxis'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess' xlink:label='us-gaap_InventoryWorkInProcess'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryWorkInProcess' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory, Work in Process, Gross</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryWorkInProcess' xlink:to='lab_us-gaap_InventoryWorkInProcess'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:label='us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Proceeds from issuance of common stock - options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:to='lab_us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets' xlink:label='us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts receivable and other receivables</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Accounts receivable and other receivables</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets' xlink:to='lab_us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:label='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Balance, value</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Equity Balance, value</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Equity Balance, value</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:to='lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract' xlink:label='us-gaap_OperatingExpensesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpensesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='lab_us-gaap_OperatingExpensesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold' xlink:label='us-gaap_CostOfGoodsAndServicesSold'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CostOfGoodsAndServicesSold' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cost of goods sold</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CostOfGoodsAndServicesSold' xlink:to='lab_us-gaap_CostOfGoodsAndServicesSold'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding' xlink:label='us-gaap_CommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Shares, Outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesOutstanding' xlink:to='lab_us-gaap_CommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other intangible assets - accumulated amortization</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Other intangible assets - accumulated amortization</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:to='lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport' xlink:label='dei_DocumentQuarterlyReport'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentQuarterlyReport' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Quarterly Report</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentQuarterlyReport' xlink:to='lab_dei_DocumentQuarterlyReport'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCurrentReportingStatus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Current Reporting Status</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCurrentReportingStatus' xlink:to='lab_dei_EntityCurrentReportingStatus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_OtherSellingGeneralAndAdministrativeExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherSellingGeneralAndAdministrativeExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other Selling, General and Administrative Expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherSellingGeneralAndAdministrativeExpense' xlink:to='lab_us-gaap_OtherSellingGeneralAndAdministrativeExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis' xlink:label='srt_StatementGeographicalAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_StatementGeographicalAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Geographical [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_StatementGeographicalAxis' xlink:to='lab_srt_StatementGeographicalAxis'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividends' xlink:label='us-gaap_PaymentsOfDividends'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsOfDividends' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Payment of dividends</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsOfDividends' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Payment of dividends</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsOfDividends' xlink:to='lab_us-gaap_PaymentsOfDividends'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:label='us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock purchased and retired {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Common stock purchased and retired</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:to='lab_us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Balance, shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Equity Balance, shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Equity Balance, shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SharesOutstanding' xlink:to='lab_us-gaap_SharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressPostalZipCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Postal Zip Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressPostalZipCode' xlink:to='lab_dei_EntityAddressPostalZipCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentDescription' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Description</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentDescription' xlink:to='lab_dei_AmendmentDescription'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet' xlink:label='us-gaap_OtherOperatingIncomeExpenseNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherOperatingIncomeExpenseNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other Operating Income (Expense), Net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherOperatingIncomeExpenseNet' xlink:to='lab_us-gaap_OtherOperatingIncomeExpenseNet'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_BloodPressureMonitoringAndAccessoriesMember' xlink:label='fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BloodPressureMonitoringAndAccessoriesMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Blood Pressure Monitoring and Accessories</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BloodPressureMonitoringAndAccessoriesMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Blood Pressure Monitoring and Accessories, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BloodPressureMonitoringAndAccessoriesMember' xlink:to='lab_fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare' xlink:label='us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockParOrStatedValuePerShare' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Par or Stated Value Per Share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockParOrStatedValuePerShare' xlink:to='lab_us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus' xlink:label='dei_DocumentFiscalPeriodFocus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentFiscalPeriodFocus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Fiscal Period Focus</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentFiscalPeriodFocus' xlink:to='lab_dei_DocumentFiscalPeriodFocus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFileNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Securities Act File Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFileNumber' xlink:to='lab_dei_EntityFileNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityShellCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Shell Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityShellCompany' xlink:to='lab_dei_EntityShellCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Common Stock, Shares Outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCommonStockSharesOutstanding' xlink:to='lab_dei_EntityCommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:label='us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory, Finished Goods, Net of Reserves</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:to='lab_us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DisclosureTextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Notes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='lab_us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net increase in cash and cash equivalents</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net increase in cash and cash equivalents</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment' xlink:label='us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Proceeds from sale of equipment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment' xlink:to='lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accrued expenses {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Accrued expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:to='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract' xlink:label='us-gaap_AssetsCurrentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='lab_us-gaap_AssetsCurrentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressAddressLine1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Address Line One</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressAddressLine1' xlink:to='lab_dei_EntityAddressAddressLine1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentType' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Type</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentType' xlink:to='lab_dei_DocumentType'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock' xlink:label='us-gaap_InventoryDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(3) Inventories</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryDisclosureTextBlock' xlink:to='lab_us-gaap_InventoryDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid' xlink:label='us-gaap_IncomeTaxesPaid'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxesPaid' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash paid during the period for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxesPaid' xlink:to='lab_us-gaap_IncomeTaxesPaid'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total adjustments</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total adjustments</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementEquityComponentsAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Components [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='lab_us-gaap_StatementEquityComponentsAxis'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProfitLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net income</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProfitLoss' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProfitLoss' xlink:to='lab_us-gaap_ProfitLoss'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RetainedEarningsAccumulatedDeficit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Retained earnings</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RetainedEarningsAccumulatedDeficit' xlink:to='lab_us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract' xlink:label='us-gaap_StockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stockholders&apos; equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='lab_us-gaap_StockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract' xlink:label='us-gaap_LiabilitiesCurrentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='lab_us-gaap_LiabilitiesCurrentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventories</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryNet' xlink:to='lab_us-gaap_InventoryNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash &amp; Investments</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:to='lab_us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityEmergingGrowthCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Emerging Growth Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityEmergingGrowthCompany' xlink:to='lab_dei_EntityEmergingGrowthCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityTaxIdentificationNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Tax Identification Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityTaxIdentificationNumber' xlink:to='lab_dei_EntityTaxIdentificationNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock purchased and retired, shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:to='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RetainedEarningsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Retained Earnings</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RetainedEarningsMember' xlink:to='lab_us-gaap_RetainedEarningsMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareDiluted' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Earnings per common share (diluted)</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareDiluted' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Earnings per common share (diluted)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareDiluted' xlink:to='lab_us-gaap_EarningsPerShareDiluted'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SellingGeneralAndAdministrativeExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Selling, general and administrative</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SellingGeneralAndAdministrativeExpense' xlink:to='lab_us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued' xlink:label='us-gaap_CommonStockSharesIssued'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesIssued' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Shares, Issued</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesIssued' xlink:to='lab_us-gaap_CommonStockSharesIssued'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accumulated other comprehensive loss</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:to='lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract' xlink:label='us-gaap_AssetsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>ASSETS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsAbstract' xlink:to='lab_us-gaap_AssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_LocalPhoneNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Local Phone Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_LocalPhoneNumber' xlink:to='lab_dei_LocalPhoneNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport' xlink:label='dei_DocumentTransitionReport'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentTransitionReport' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Transition Report</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentTransitionReport' xlink:to='lab_dei_DocumentTransitionReport'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityPublicFloat' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Public Float</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityPublicFloat' xlink:to='lab_dei_EntityPublicFloat'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityRegistrantName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Registrant Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityRegistrantName' xlink:to='lab_dei_EntityRegistrantName'/>
	</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>utmd-20250331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK5GW761L0VEWPD92X]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20250331"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityRegistrantName' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCentralIndexKey' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentType' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentPeriodEndDate' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CurrentFiscalYearEndDate' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_TradingSymbol' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityTaxIdentificationNumber' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCommonStockSharesOutstanding' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityPublicFloat' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFilerCategory' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCurrentReportingStatus' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityVoluntaryFilers' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityWellKnownSeasonedIssuer' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityShellCompany' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntitySmallBusiness' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityEmergingGrowthCompany' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityExTransitionPeriod' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentDescription' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport' xlink:label='dei_DocumentQuarterlyReport'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentQuarterlyReport' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport' xlink:label='dei_DocumentTransitionReport'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentTransitionReport' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFileNumber' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityIncorporationStateCountryCode' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressAddressLine1' use='optional' order='23.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressCityOrTown' use='optional' order='24.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressStateOrProvince' use='optional' order='25.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressPostalZipCode' use='optional' order='26.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CityAreaCode' use='optional' order='27.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_LocalPhoneNumber' use='optional' order='28.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle' xlink:label='dei_Security12bTitle'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_Security12bTitle' use='optional' order='29.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SecurityExchangeName' use='optional' order='30.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityInteractiveDataCurrent' use='optional' order='31.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentFlag' use='optional' order='32.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus' xlink:label='dei_DocumentFiscalYearFocus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentFiscalYearFocus' use='optional' order='33.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus' xlink:label='dei_DocumentFiscalPeriodFocus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentFiscalPeriodFocus' use='optional' order='34.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract' xlink:label='us-gaap_StatementOfFinancialPositionAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract' xlink:label='us-gaap_AssetsAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_AssetsAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract' xlink:label='us-gaap_AssetsCurrentAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsAbstract' xlink:to='us-gaap_AssetsCurrentAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_CashAndCashEquivalentsAtCarryingValue' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent' xlink:label='us-gaap_AccountsReceivableNetCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_AccountsReceivableNetCurrent' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_InventoryNet' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent' xlink:label='us-gaap_OtherAssetsCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_OtherAssetsCurrent' use='optional' order='4.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherAssetsCurrent' xlink:to='us-gaap_AssetsCurrent' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsAbstract' xlink:to='us-gaap_PropertyPlantAndEquipmentNet' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill' xlink:label='us-gaap_Goodwill'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsAbstract' xlink:to='us-gaap_Goodwill' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross' xlink:label='us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsAbstract' xlink:to='us-gaap_FiniteLivedIntangibleAssetsGross' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsAbstract' xlink:to='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' use='optional' order='5.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsAbstract' xlink:to='us-gaap_IntangibleAssetsNetExcludingGoodwill' use='optional' order='6.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsAbstract' xlink:to='us-gaap_Assets' use='optional' order='7.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:label='us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_LiabilitiesAndStockholdersEquityAbstract' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract' xlink:label='us-gaap_LiabilitiesCurrentAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='us-gaap_LiabilitiesCurrentAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent' xlink:label='us-gaap_AccountsPayableCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_AccountsPayableCurrent' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_AccruedLiabilitiesCurrent' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_LiabilitiesCurrent' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:label='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermDebtNoncurrent' xlink:label='us-gaap_OtherLongTermDebtNoncurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='us-gaap_OtherLongTermDebtNoncurrent' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations' xlink:label='us-gaap_LongTermDebtAndCapitalLeaseObligations'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='us-gaap_LongTermDebtAndCapitalLeaseObligations' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:label='us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='us-gaap_DeferredIncomeTaxLiabilitiesNet' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_Liabilities' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract' xlink:label='us-gaap_StockholdersEquityAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_StockholdersEquityAbstract' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockValue' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock' xlink:label='us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_AdditionalPaidInCapitalCommonStock' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_RetainedEarningsAccumulatedDeficit' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_StockholdersEquity' use='optional' order='9.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_LiabilitiesAndStockholdersEquity' use='optional' order='10.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract' xlink:label='us-gaap_StatementOfFinancialPositionAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare' xlink:label='us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockParOrStatedValuePerShare' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized' xlink:label='us-gaap_CommonStockSharesAuthorized'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockSharesAuthorized' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued' xlink:label='us-gaap_CommonStockSharesIssued'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockSharesIssued' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding' xlink:label='us-gaap_CommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockSharesOutstanding' use='optional' order='4.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract' xlink:label='us-gaap_IncomeStatementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold' xlink:label='us-gaap_CostOfGoodsAndServicesSold'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_CostOfGoodsAndServicesSold' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_GrossProfit' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract' xlink:label='us-gaap_OperatingExpensesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OperatingExpensesAbstract' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_SellingGeneralAndAdministrativeExpense' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_ResearchAndDevelopmentExpense' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OperatingExpenses' use='optional' order='7.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OperatingIncomeLoss' use='optional' order='8.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense' xlink:label='us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OtherNonoperatingIncomeExpense' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' use='optional' order='10.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_IncomeTaxExpenseBenefit' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_ProfitLoss' use='optional' order='12.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_EarningsPerShareBasic' use='optional' order='13.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_EarningsPerShareDiluted' use='optional' order='14.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='17.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_ComprehensiveIncomeNetOfTax' use='optional' order='18.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract' xlink:label='us-gaap_IncomeStatementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract' xlink:label='us-gaap_StatementOfStockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfStockholdersEquityAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementEquityComponentsAxis' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_CommonStockMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_AdditionalPaidInCapitalMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeMember' xlink:label='us-gaap_ComprehensiveIncomeMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_ComprehensiveIncomeMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_RetainedEarningsMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:label='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionPlanExpense' xlink:label='us-gaap_StockOptionPlanExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockOptionPlanExpense' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStockCash' xlink:label='us-gaap_DividendsCommonStockCash'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_DividendsCommonStockCash' use='optional' order='11.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ProfitLoss' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:label='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1' use='optional' order='13.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding_1' use='optional' order='14.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract' xlink:label='us-gaap_StatementOfCashFlowsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_ProfitLoss' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation' xlink:label='us-gaap_Depreciation'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_Depreciation' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets' xlink:label='us-gaap_AmortizationOfIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_AmortizationOfIntangibleAssets' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_ProvisionForDoubtfulAccounts' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:label='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_DeferredIncomeTaxExpenseBenefit' use='optional' order='5.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation' xlink:label='us-gaap_ShareBasedCompensation'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_ShareBasedCompensation' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:label='us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_DeferredTaxExpenseFromStockOptionsExercised' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets' xlink:label='us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets' use='optional' order='8.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_IncreaseDecreaseInInventories' use='optional' order='9.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' use='optional' order='10.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccountsPayable' use='optional' order='11.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccruedLiabilities' use='optional' order='12.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' use='optional' order='13.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivities' use='optional' order='14.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment' xlink:label='us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivities' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:label='us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='us-gaap_ProceedsFromIssuanceOfCommonStock' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:label='us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='us-gaap_PaymentsForRepurchaseOfCommonStock' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividends' xlink:label='us-gaap_PaymentsOfDividends'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='us-gaap_PaymentsOfDividends' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivities' use='optional' order='4.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' use='optional' order='7.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' use='optional' order='8.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1' use='optional' order='9.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract' xlink:label='us-gaap_SupplementalCashFlowInformationAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_SupplementalCashFlowInformationAbstract' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid' xlink:label='us-gaap_IncomeTaxesPaid'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_SupplementalCashFlowInformationAbstract' xlink:to='us-gaap_IncomeTaxesPaid' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet' xlink:label='us-gaap_InterestPaidNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_SupplementalCashFlowInformationAbstract' xlink:to='us-gaap_InterestPaidNet' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure1BasisOfPresentation" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure1BasisOfPresentation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure1BasisOfPresentation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:label='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure2RecentAccountingStandards" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure2RecentAccountingStandards"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure2RecentAccountingStandards">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure3Inventories" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure3Inventories"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure3Inventories">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock' xlink:label='us-gaap_InventoryDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_InventoryDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure4StockBasedCompensation" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure4StockBasedCompensation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure4StockBasedCompensation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:label='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure5WarrantyReserve" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure5WarrantyReserve"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure5WarrantyReserve">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyDisclosureTextBlock' xlink:label='us-gaap_ProductWarrantyDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_ProductWarrantyDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognition" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure6RevenueRecognition"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognition">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_RevenueRecognitionPolicyTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure7EarningsPerShare" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure7EarningsPerShare"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure7EarningsPerShare">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock' xlink:label='us-gaap_EarningsPerShareTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_EarningsPerShareTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformation" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure8SegmentInformation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock' xlink:label='us-gaap_SegmentReportingDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_SegmentReportingDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure9SubsequentEvents" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure9SubsequentEvents"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure9SubsequentEvents">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock' xlink:label='us-gaap_SubsequentEventsTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_SubsequentEventsTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:label='us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='us-gaap_ScheduleOfInventoryCurrentTableTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock' xlink:label='fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:label='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock' xlink:label='us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:label='us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryFinishedGoodsNetOfReserves' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess' xlink:label='us-gaap_InventoryWorkInProcess'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryWorkInProcess' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryRawMaterials' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryNet' use='optional' order='4.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure4StockBasedCompensationDetails" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure4StockBasedCompensationDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure4StockBasedCompensationDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionPlanExpense' xlink:label='us-gaap_StockOptionPlanExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_StockOptionPlanExpense' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis' xlink:label='srt_StatementGeographicalAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='srt_StatementGeographicalAxis' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_DomesticUsMember' xlink:label='fil_DomesticUsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementGeographicalAxis' xlink:to='fil_DomesticUsMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_OutsideUsMember' xlink:label='fil_OutsideUsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementGeographicalAxis' xlink:to='fil_OutsideUsMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementGeographicalAxis' xlink:to='srt_SegmentGeographicalDomain' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis' xlink:label='srt_ProductOrServiceAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='srt_ProductOrServiceAxis' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_ObstetricsMember' xlink:label='fil_ObstetricsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_ObstetricsMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_GynecologyElectrosurgeryUrologyMember' xlink:label='fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_GynecologyElectrosurgeryUrologyMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_NeonatalMember' xlink:label='fil_NeonatalMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_NeonatalMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_BloodPressureMonitoringAndAccessoriesMember' xlink:label='fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_BloodPressureMonitoringAndAccessoriesMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='srt_ProductsAndServicesDomain' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_ProfitLoss' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:label='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_EarningsPerShareBasic' use='optional' order='5.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_EarningsPerShareDiluted' use='optional' order='6.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" xlink:type="simple" xlink:href="utmd-20250331.xsd#idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis' xlink:label='srt_StatementScenarioAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='srt_StatementScenarioAxis' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain' xlink:label='srt_ScenarioUnspecifiedDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementScenarioAxis' xlink:to='srt_ScenarioUnspecifiedDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_SingleOperatingSegmentMember' xlink:label='fil_SingleOperatingSegmentMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementScenarioAxis' xlink:to='fil_SingleOperatingSegmentMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_StandardCostOfSales' xlink:label='fil_StandardCostOfSales'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_StandardCostOfSales' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_OtherCostOfSales' xlink:label='fil_OtherCostOfSales'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OtherCostOfSales' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_GrossProfit' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_GrossProfitMargin' xlink:label='fil_GrossProfitMargin'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_GrossProfitMargin' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense' xlink:label='us-gaap_SellingAndMarketingExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SellingAndMarketingExpense' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ResearchAndDevelopmentExpense' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_LitigationExpense' xlink:label='fil_LitigationExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_LitigationExpense' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets' xlink:label='us-gaap_AmortizationOfIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_AmortizationOfIntangibleAssets' use='optional' order='9.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_OtherSellingGeneralAndAdministrativeExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherSellingGeneralAndAdministrativeExpense' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OperatingIncomeLoss' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250331.xsd#fil_OperatingIncomeMargin' xlink:label='fil_OperatingIncomeMargin'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OperatingIncomeMargin' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInterestAndDividendIncome' xlink:label='us-gaap_OtherInterestAndDividendIncome'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherInterestAndDividendIncome' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet' xlink:label='us-gaap_OtherOperatingIncomeExpenseNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherOperatingIncomeExpenseNet' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_IncomeTaxExpenseBenefit' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ProfitLoss' use='optional' order='17.0'/>
	</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>utmd-20250331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK5GW761L0VEWPD92X]. www.edgarsuite.com -->
<schema attributeFormDefault='unqualified' elementFormDefault='qualified' targetNamespace='http://www.utahmed.com/20250331' xmlns='http://www.w3.org/2001/XMLSchema' xmlns:xbrli='http://www.xbrl.org/2003/instance' xmlns:fil='http://www.utahmed.com/20250331' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns:xbrldi='http://xbrl.org/2006/xbrldi' xmlns:xbrldt='http://xbrl.org/2005/xbrldt' xmlns:srt='http://fasb.org/srt/2024' xmlns:us-gaap='http://fasb.org/us-gaap/2024' xmlns:dei='http://xbrl.sec.gov/dei/2024' xmlns:dtr-types='http://www.xbrl.org/dtr/type/2022-03-31'>
	<annotation>
		<appinfo>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20250331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20250331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20250331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20250331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:roleType roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails" id="idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails">
				<link:definition>000240 - Disclosure - (7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow" id="idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow">
				<link:definition>000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure4StockBasedCompensationDetails" id="idr_Disclosure4StockBasedCompensationDetails">
				<link:definition>000220 - Disclosure - (4) Stock-Based Compensation (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure4StockBasedCompensation" id="idr_Disclosure4StockBasedCompensation">
				<link:definition>000110 - Disclosure - (4) Stock-Based Compensation</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables" id="idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables">
				<link:definition>000170 - Disclosure - (3) Inventories: Schedule of Inventory, Current (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure7EarningsPerShare" id="idr_Disclosure7EarningsPerShare">
				<link:definition>000140 - Disclosure - (7) Earnings Per Share</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" id="idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails">
				<link:definition>000250 - Disclosure - (8) Segment Information: Schedule of Segment Reporting Information, by Segment (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformation" id="idr_Disclosure8SegmentInformation">
				<link:definition>000150 - Disclosure - (8) Segment Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure9SubsequentEvents" id="idr_Disclosure9SubsequentEvents">
				<link:definition>000160 - Disclosure - (9) Subsequent Events</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognition" id="idr_Disclosure6RevenueRecognition">
				<link:definition>000130 - Disclosure - (6) Revenue Recognition</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical" id="idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical">
				<link:definition>000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - Parenthetical</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure3Inventories" id="idr_Disclosure3Inventories">
				<link:definition>000100 - Disclosure - (3) Inventories</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical" id="idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical">
				<link:definition>000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS - Parenthetical</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables" id="idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables">
				<link:definition>000200 - Disclosure - (8) Segment Information: Schedule of Segment Reporting Information, by Segment (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure2RecentAccountingStandards" id="idr_Disclosure2RecentAccountingStandards">
				<link:definition>000090 - Disclosure - (2) Recent Accounting Standards</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome" id="idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome">
				<link:definition>000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables" id="idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables">
				<link:definition>000180 - Disclosure - (6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets" id="idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets">
				<link:definition>000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity" id="idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity">
				<link:definition>000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure1BasisOfPresentation" id="idr_Disclosure1BasisOfPresentation">
				<link:definition>000080 - Disclosure - (1) Basis of Presentation</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation" id="idr_DocumentDocumentAndEntityInformation">
				<link:definition>000010 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables" id="idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables">
				<link:definition>000190 - Disclosure - (7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails" id="idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails">
				<link:definition>000230 - Disclosure - (6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails" id="idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails">
				<link:definition>000210 - Disclosure - (3) Inventories: Schedule of Inventory, Current (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250331/role/idr_Disclosure5WarrantyReserve" id="idr_Disclosure5WarrantyReserve">
				<link:definition>000120 - Disclosure - (5) Warranty Reserve</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
		</appinfo>
	</annotation>
	<import schemaLocation='https://www.xbrl.org/dtr/type/2022-03-31/types.xsd' namespace='http://www.xbrl.org/dtr/type/2022-03-31'/>
	<import schemaLocation='http://www.xbrl.org/2005/xbrldt-2005.xsd' namespace='http://xbrl.org/2005/xbrldt'/>
	<import schemaLocation='http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd' namespace='http://www.xbrl.org/2003/instance'/>
	<import schemaLocation='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd' namespace='http://fasb.org/srt/2024'/>
	<import schemaLocation='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd' namespace='http://fasb.org/us-gaap/2024'/>
	<import schemaLocation='https://xbrl.sec.gov/dei/2024/dei-2024.xsd' namespace='http://xbrl.sec.gov/dei/2024'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DomesticUsMember' name='DomesticUsMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_OutsideUsMember' name='OutsideUsMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ObstetricsMember' name='ObstetricsMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_NeonatalMember' name='NeonatalMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_GynecologyElectrosurgeryUrologyMember' name='GynecologyElectrosurgeryUrologyMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_BloodPressureMonitoringAndAccessoriesMember' name='BloodPressureMonitoringAndAccessoriesMember'/>
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_StandardCostOfSales' name='StandardCostOfSales'/>
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_OtherCostOfSales' name='OtherCostOfSales'/>
	<element nillable='true' type='dtr-types:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_GrossProfitMargin' name='GrossProfitMargin'/>
	<element nillable='true' type='dtr-types:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_OperatingIncomeMargin' name='OperatingIncomeMargin'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_SingleOperatingSegmentMember' name='SingleOperatingSegmentMember'/>
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_LitigationExpense' name='LitigationExpense'/>
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' name='CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
	<element nillable='true' type='xbrli:sharesItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' name='CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
	<element nillable='true' type='dtr-types:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock' name='ScheduleofglobalrevenuesbyproductcategoryTextBlock'/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>37
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( !AXKUI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( !AXKUK]%*]&[P   "L"   1
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M@2";_-;;I/;=X Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F
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MY_<T*-A*$0S>-!MD%-_3C,J>#@^=BO:K$\+O\G88<RMFT*UFC?ZN\;,67&O
MIEPEL"NU%E"4] P'L-4TZ!8U18^7JA+)D]K8B)[O8:J5'T"CDUA07@1["+:J
M!G]%UEY;.:9L!3XR,FFB_%'8URM:<8-N=9N1!Z)8+H'$3PW19]7Q/I$\Q9R
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M4A)1K@S@_IHQ^7ZB'G#Z3C/X!U!+ P04    "  8>*]:'#-0IIT"  !(!@
M&    'AL+W=O<FMS:&5E=',O<VAE970U+GAM;+U576_:,!3]*U?9-+42(R'0
M;NH@$H1412H?XJ-[=I,+R9K8S#;0_OM>.X'1BJ(]3'O!OO8]Q^?>V(?V3L@G
ME2)J>"YRKCI.JO7ZQG55G&+!5%VLD=/.4LB":0KERE5KB2RQH")W?<^[=@N6
M<2=HV[6)#-IBH_.,XT2"VA0%DR\]S,6NXS2<_<(T6Z7:++A!>\U6.$.]6$\D
M1>Z!)<D*Y"H3'"0N.TZW<1.V3+Y->,APIX[F8"IY%.+)!(.DXWA&$.88:\/
M:-ABB'ENB$C&[XK3.1QI@,?S/?NMK9UJ>60*0Y'_S!*==ISO#B2X9)M<3\7N
M#JMZK@Q?+')E?V%7Y7H.Q!NE15&!24&1\7)DSU4?C@#$<QK@5P#_/:#U :!9
M 9JVT%*9+:O/- O:4NQ FFQB,Q/;&XNF:C)NON),2]K-"*>#Q;Q[!\.H/PB[
M]S"9CON+<#ZKP6 4UB$<CV;C^T&_.X_Z,)O3,(Q&<QC?FNWQ,(+NJ$])P\DT
MNHM&L\%#M-_X"A,FD>L4=1:SG.+%K \7GR_;KB;1YF@WK@3V2H'^!P*;,!1$
MI"#B"29O\2X5>ZC8WU?<\\\2#IFL0[-1 ]_SKT[H"?\>WCHCIWGX $W+U_R?
M'^!4FTL9K=,RC%G<J#6+L>.0&RB46W2"+Y\:U]Z/4SWZ1V1O.M8Z=*QUCCT8
MT[62$(J"N%/C)UN$ 8]%@7!Q+Y2ZK &]<'J_',*-I&L8O\!<,JYR9IVCF_RB
M=T5.I&LP9\^G>E4*N+8"C ]N Z_M;H\;<"ZCK,H]>I0%RI7U*@6QV'!=WM;#
M:FF'/;)#:QOOULDFN]8=W#\TI<?275QE7$&.2Z+TZM_(9&3I6V6@Q=H^_4>A
MR4CL-"6K1VD2:'\IA-X'YH##GT?P"E!+ P04    "  8>*]:;LS?")P&  "*
M*0  &    'AL+W=O<FMS:&5E=',O<VAE970V+GAM;+5::W/B-A3]*QJZT\=,
M"):,P6P),XD?LYGN)FD@[?2CUE:"NWZPMB')OZ]L'(PE(<%&_1(P.??H^MPK
MVT?R]#G+OQ5+0DKPDL1I<=%;EN7JXV!0!$N2X.(\6Y&4_N<QRQ-<TL/\:5"L
M<H+#.BB)!\@P1H,$1VEO-JU_N\MGTVQ=QE%*[G)0K),$YZ]7),Z>+WJP]_;#
M??2T+*L?!K/I"C^1.2D?5G<Y/1KL6,(H(6D192G(R>-%[Q)^])%=!=2(OR+R
M7.Q]!]6I?,VR;]7!=7C1,ZJ,2$R"LJ+ ]&-#'!+'%1/-XWM#VMN-607N?W]C
M]^N3IR?S%1?$R>*_H[!<7O3L'@C)(U['Y7WV_(DT)V15?$$6%_5?\-Q@C1X(
MUD69)4TPS2")TNTG?FF$V N YH$ U 0@)@"-#P2838#)!L # <,F8,BF9!\(
ML)H Z]AS&#4!HUK[K5BUTBXN\6R:9\\@K]"4K?I2EZN.I@)':=59\S*G_XUH
M7#E[6%Q^ E\\]]JY_ SN[F_=!V<Q/P/7-\XY<&YOYK>?K]W+A>>"^8)^?/%N
M%G-PZ].C6^>/3[>?7>]^_@OP_GRX7OP#^N!A[H)?/_P&BB7.20&B%"R6V;K
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M+W=O<FMS:&5E=',O<VAE970W+GAM;+59;6_B.!#^*Q:W.NU*2TGL\-9KD;)
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M)%#U<ZWD .I;#@I:0"%P0S.QYF"<+?'R='Y+&EA8"5^L_ :="F]B=@:0_Q5
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M^-PQES4S<*7$ Z]L/:<S2BK8L)VP*]5]A2&?S/&52AC_)5T?&TTI*7?&JF8
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M--Z [K>:NJ#?> ?CY,_^ %!+ P04    "  8>*]:"T_UU*4"  "5!0  &0
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M_BN$6Q0M<#N_7=(DNSN@UV38/C0(FJW]K+/ILQ!9<B4YE_S[D?)+O34)UL&
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M7R\5LM(IM4T_B:)!OV5<!+.)V[M7LXE<F88+O%>@5VW+U.LE-G(]#>)@L_'
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M@_-'MA1H/DT"2[0<>)#O*<Q:"O$[%!*X4]*N#=S( HN_\P.2TVF*#YIF\4G
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M\\Z_ZERB[;WM1/':MJ][KG0SM,-2?ZY F *]ON5</4],1^P_@-D_4$L#!!0
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M$Z@+DMZ<&(RLW0GL50NZ9>N/@A<KU9TX,ZEK4:BO&]THB2V91+U@(;=@O=1
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M<F]P<R]A<' N>&UL4$L! A0#%     @ &'BO6OT4KT;O    *P(  !$
M         ( !PP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ &'BO
M6IE<G",0!@  G"<  !,              ( !X0$  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    "  8>*]:95GL3]8%  #5'@  &
M@($B"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ &'BO
M6J-;O\3'!0  11<  !@              ("!+@X  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( !AXKUH7$Y'YH0(  &8'   8
M      " @2L4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M"  8>*]:XG@OB\X$  "S$0  &               @($"%P  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ &'BO6APS4*:= @  2 8  !@
M             ("!!AP  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( !AXKUINS-\(G 8  (HI   8              " @=D>  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  8>*]:^/2A)>,&  !]
M'   &               @(&K)0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ &'BO6@UB[ZQR P  BP<  !@              ("!Q"P
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( !AXKUK!6Z'@
MB0(  .(%   8              " @6PP  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    "  8>*]:WOWG$$0"    !0  &0
M@($K,P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( !AX
MKUHV.S%7_@$  + $   9              " @:8U  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ &'BO6H0T["NT @  !08  !D
M         ("!VS<  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    "  8>*]:"T_UU*4"  "5!0  &0              @('&.@  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( !AXKUKP5NU$40,  *D'
M   9              " @:(]  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ &'BO6HXA@8=<!   PPD  !D              ("!*D$
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  8>*]: %O)
M@?0!  "6!   &0              @(&]10  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( !AXKUK(CT.:90(  %4%   9
M  " @>A'  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
M&'BO6GN6D)6O @  T04  !D              ("!A$H  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    "  8>*]:V/<Z1<("  "%!@  &0
M            @(%J30  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( !AXKUJ@A&?_0P,  #0'   9              " @6-0  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ &'BO6I5 :BJ/ @
M# <  !D              ("!W5,  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    "  8>*]:^B.ELD\"  ">!0  &0              @(&C
M5@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( !AXKUK>
M(<%6K@0  '@=   9              " @2E9  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ &'BO6GYIW<<] P  =0D  !D
M     ("!#EX  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M"  8>*]:Q&8#AAX%  !?%0  &0              @(&"80  >&PO=V]R:W-H
M965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( !AXKUH<Q0^@'@,  $@1   -
M              "  ==F  !X;"]S='EL97,N>&UL4$L! A0#%     @ &'BO
M6I>*NQS     $P(   L              ( !(&H  %]R96QS+RYR96QS4$L!
M A0#%     @ &'BO6BE]N3GB @  C1$   \              ( !"6L  'AL
M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( !AXKUI^V5 B/ $  +(/   :
M          "  1AN  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( !AXKUHKT'*.<@$  )\0   3              "  8QO  !;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     A "$ W@@  "]Q      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>44
<FILENAME>0001096906-25-000816-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001096906-25-000816-xbrl.zip
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M8P(@VK[IOOS6<<SB(=MX"!Y4%7+->@T,3TFLH6Q:I[ 'X=B1[/N"89" P#)
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M_>TA6XN"ZG9BM.U0XD9'W7Q/-6":#ZW>;6M#Z/!XYO.7'P/%O7YJ</_YM3P
MG6]FT\^[GL##[B6,M'N^<'C@PE/]5PH\*,^NZ>@*^A$H3L,:CNGP!X$K?\"9
MILPW@O+;G'L2+X1+,I8MG$(%DE_6-/@2XR>H$/QGIJ(Z %K @#H7P#,]C:",
MGA0>R7#T I\ZX2(1=07\&B,91)EA A.[=&K2(67,3Q )"Y59Y *>!P8>L6;
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M7V/H;Y16>QV%[R>:^3(\OJHHC,!D#4QC52FH.AGR-)MST#Y2PW]WG#X/"8^
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MT8W2#ZG4: 7;075"7E*?:&5=CZEN<1E,W_#G0'5"H;R;J4R[X*K:HR:##L?
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M11N: J+Z,$4R:3$44T)343.G1@CF=(SL]V?=I/#0OZA"L(<4G"'R B>*7&@
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M!I!<-2H)GARA11^G_;#.@G(2/9,KI3)@H-*(S%66(*E%'D'^N(9Z.5DSO2R
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M!6GDFN(:E_\9>;]2MZ ]^/LN#2T<X^_HKU2W#5/=D[6?I0*6"F'@PT1R[%[
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M&7C3JGVFOBE9[%QVD9K;HA0Q+9=+.)TZWPC:G295JFCJR21V+KE,)N6HR40
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MEZT2IT@[H<#X2["D.K;%676&X,XB67+T!4%2(]>LK?8^PX@I!CPQZJB]YS'
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M=X35#/FSP['XSEGS3?]DRCRA;T,*E#P?BNO>"._YR=@^@_=/'(,+BZ3*TIL
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MYG^>\<HO_U:FMN1]2T+IYJOW=M%2+;7Y9GC6CX8+_',\FX2__#]02P,$%
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MJ?,8Z=*^)T% 52&,Z(O7\'6F3#Q0F(4X3$O5\%T'Z8+-ID(*ZQ(>P.PK#DF
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M?</?KUP1Z1>_3N,[&DY\]H:F43SPG9%[[SI,=/:&#M8T8\8[^>,SQ8?.<YV
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M!T 53PW&2$Z6I'2-&_RJ3I>'7ZCI[J+UU*/_%1_2$+G7\0V +'ZOXB* @?<
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MJO53<ZB4/*"_)H_.0V*>^E?6)HB^Y]$:L2FW#]2U4%]7Y7@GO9P#6\WK)GD
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MKMA?/WV1?</^;V%%]*<O_A=02P,$%     @ &'BO6E[LZ(AJ&0  39<! !4
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MD5S3R$'H+5.10G"#-BV53S10Z@8AMDPQF,@&%<N61#EF<^ 86P*KI;5,)XC
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MTDQEH!>KO-PM@5R$PABN9R22\0\"=I=T&MR+X Q,IH[=8(,$0JG#,H,8*-O
MDPB%.TUDF#!3TI^;]5.A1:6$-I!)DPH>R7S,IM(FV* I1.@<)+T%7%,1MCG!
M,M<LEL+P8R=\[]L3+E@L<X24LG,3P@#9AC@>ZZ7G,H]1+JX]XGN8EA%T(DU+
M\0J08DDE5B#*!! "3IK>(* *OOG,-$ 6N5 $)%&F$$#:%7+CN['S)^0F87&J
MIF:."2W&TEC-88C33>\WO R64FOFSMSR]L?.[M.-LSM<"<434V6N(GT"OHIC
MB4L7GC[#].,2@<#*42HH8$P@^Z-4FH3$22Q#T5/ATW4D39@J4V(=T8%6J<](
MH17F)]PV; L)B 0RZJ/<^Q0F/!\+UD&E798I)%Q_WM\2VVYI<S_R5_Y24B/.
M/1)(/Z-R7 *(3QCYLK&A>,50#$.TS\]A PGJ%:T'AL)*1O?VZGL/A0[LQ2O#
MH..S'PF#60;1<#SX]50%1-$A+\WF2X@K1X(M+'GV525&IQ)%-I'&E2ZD1.[T
MT)QQ4_3+Q*%%RET>*_J]R450D0H]E"  ^(+(R(A;Y^C(R$AR+6D#TC<)1V4Y
M:2H-$;>#O7$L[PI=&0&'+.),BPJT?QF6*2=^PK:<$S<- "M\.UGN@O@V$B0(
M"L%Z$3TT97P'G(S6XF3C@KL%E\U+=6/4 &D3&1$8N%$Y)T[B!D"B7D\(X3J:
M9POXD7PD4VEGU 76F27LNL2ZG'G8K8@NS0J.^CY5&RI*C7 CI-2UPE#IR#G@
MIH:QR-&,4D '3T1!F"013$0>'L"N+, ^/R% P@H@8L+3TE4;14_$,1JUG&#?
M9DW#??SHQ6[S^8'9A#W\Y?H>[/" A:A\XSO]2)7VRQYLPF]\(2UHC(F_/N>Q
MT7Q <A"O(@%_#ISRGR^GT;SH?;ANAYW&^:ISNB=K<WN'4B?"5V%8:@KN$KNN
MT9HI8W&?#M_09>BT59W-V-87EL1 "8KP,^G*<<R%PIU$Z)"2EPN_MKU7"3>+
M5D3EZU E(L=K+AX5Y\QPWO@@TNI8\IE\\,TA<DCZH0?._7L.G(M8?&7L=&?R
M!2"#FYHC"E@&Q4WY45KOT*ENS10+USCF"JNT630'=P,J,YQ5K7#X6;-LI-!Z
MZ%DDX9M3L 78@$L,<14^:;*98UU\+"5<=[@N\]"=7+9_XLF23F[4NR6R2,,R
MC=VA% A[1>J+"6\J^ =B:=\['4^[KN_>!LQ/<7=*9C6,^:/*F@KE$18:L2C0
M+R:^FA6P!!E$2P]\JS#H$Z;,$ #YCW";J8AQ[7GW_RC>[SCZ$=G'&I /$%;A
MJA2)<2]'J@P&GBME/E'I1!!AYGQ<O>/156&+K$C53.#I-%&^FOD*/I#/!^DF
M]7N_;KSWPB[BT&)O^ RGQX#1&_[O:?W^KU=/!N?#^8(1T"WT'&'-XA-SYR?V
MJ.'^/3E<>8GI_^Z8G=OOB]?(K;[^)*OW>:M]R](]=!PG4L0X]HNPI-F0#7R/
M\9I.+U>#T6H<)(+>(N*+_P&E,5?5? HS#?J/,.YT^V_IUYCJ9Y@=_S/2OU!+
M P04    "  8>*]:.]W.V1 '  !:&@  #P   '5T;61?97@S,7HR+FAT;=59
M;6\;-Q+^WE\Q18'&!O1JQTD@JP9D2ZK5.)9.5G+M'?J!VN5*1':7VR57BOKK
M^PRYDN58N<B.+T@2P-(NA\/AS#//#*GVY>3-U=D/[1^K51KE.BP"&=)T1;WN
MKYVQ*9259'1DER*7%>J$"Y&RP(5.LL+*G 9IJA?"*IV:"AZ"6@5CV2I7L[FE
M@XM#.FHT7E6/&D<G]-_1Z/?7)[_^^^6+YE7C7:?SV^5_^OT_:[1<+FLRG(G<
MK58+=$+5*BRZ['6Z^)@,)E>]LW;=?_[0KI?OSX?=/_#1';PC8U>Q_"41^4RE
MU5A&MO7R*+.G2Q7:>>OYBU>9/6N/2,1JEO[B+?,SGD4ZM:UF([,T48DT="V7
M--:)2$^]LE;CV5G[_*SW8:ZFRM)QLW;4KI_#F!%67FL,9,J>V%-EU>JL]0+6
ME8]3;:U.6IC@EKKHC2>#_N"B,QD,KVG8I]%X<'TQ&'6NJ#^X[N KO@W[D.B-
MZ4MM*;<W>CN^>=NYGM!D2..W5SUJ'HMJ\_F!.*3.#76ZP]&DUZ5MJ2=:^*9W
MX;9YW#CBK4XN>W33&9]WKGLWU>'O5[T_J',QX1& Z.C.H@]8Y^=T:K+31TP<
M5.@\5R*EJQJ]UCK#:(4"F5L5K<C.A6U]36O:K\^[:_E,&\4IUQ)3HV/DX>EG
M4>>RHE%KG##.FK5V'>JV=6Z+-5W".(D!S<5"4BX72BZ1]W:N#/U5B!S!CE=X
MG^G<DDZIK_.$FHWJOTA']-:*.;V1H0I$7)**+>GAE+P''N6'_YD[3^B?H[W]
M<RX,O(+])RMZG^IE#"(#3SHWE<X)-=9+M:4 -@B5DDA75*0V+\"L5EB9('78
M:X(2/ %Q,44BP*N<= +6L=K+W1-(92"-$?F*11+Q7F+=+9T&[T(8@R5C1WI8
M@P4"E0=% C$PN8$E(?)V.5?!G$S!?V[G+V4N2R6\@4296(I0I3-:*CO'!DTF
M V<@Z\U@F@ZQS06FN1JRY89O.^#'7QYP29%*X5*.SJT+*X@VQ#&<;XVK-$*Z
MN*J)[T%<A-"),&WYJX(0*TZQ#%YF@#!PXO@6 :7SS4=+ V2A<T6%)8H8 @B[
M1FQ\D7;V!,+,*8KUTJPQD<N9,C876$CP2V\WK*QLA=:LC;EG[;<=W>=[1W=R
MQQ7/3!FYDO09^#J*%!Z=>P:$IL@% HY5TUBRPT@B^M-8F3F+LUB"I.?$Y^=0
MF2#6IL \IH-<QSXB6:[15N&UH0,$()2(J/=R[T,P%^E,4@>9-BYB2+CR?'(@
M#]W4YDGHG_RCXCJ<>B2P?N)TW *(#QC;LO="T9V%(BS$^_P8-I#@6M%Z8BC<
MB>CQ<>WXJ="!O7AEZ'-\]$-IT,K &XX'/Q^J"E-T( JS_Q3FRJFDS4J>?76!
MSJE DBV4<:D+*9DZ/=QGW";]-G'D,A8NCB7]WL:B4I(*#RH0 &R!9U0HK#-T
M:E2H1*YX \H7"4=E*6LJ#!.W@[UQ+.\271L)@RS\S),RE'\5%+%@?L*VG!&W
M!0 S?#G9KH+X-I4L" K!?!D^-65\!9Q,=^)D[X2[!Y?]4W5OU !I"Q4R&(31
MJ6!.$@9 XEK/"!%YN(X6\*/$5,7*KK@*[%J6L>L"ZV+F87='=*M7<-3WH=Q0
M5N1P-US*52L(=!XZ US7,),IBE$,Z&!$9HQ)%D%'Y.$![*H,[/,= B0H 2(7
M(BY<MK'W9!2A4*L%]FUV%-R??WIUU'QY:O9A#_^XNP8[/& B,M_X2C_5A?VT
M!?OPF]A(2VYCHL_W>31=-T@.XJ4G8,^I4_[]Q31<)[UWUWVW<SM?5DXWLC.V
M#TAU)GP=!$7.SMUBUQU:$VTLWO/9&[H,G[;*LQD=?&)*!)0@"3^2+@U'7RC=
M280/*6FQL>O06S479E.*.'T=JF3H>,WYH^2<%<X;[V5<'DL^DJ]\L8L<DK[I
MAO/DD0WGQA>?:3O=F7P#R,IMSC$%;(/B-OTXK ^H5/=ZBHUI GV%U;G9% ?W
M BH3G%6M=/C9,6VJ47IX+%2PS2DX &S )8:Y"I_<V:RQ+O\J%$QWN"[2P)U<
M#K_CSI)/;ER[%:+(S3*WW8&2<'M)ZIL.;RG%>V9I7SL=3[NJ[VX#UJ>X!P6S
M;,;\465'AHH0$XW<).@G U_V"IB""**D5WRI,*@3IDC@ /6W=)LIB7'G>??_
MD;Q?L?5CLH]R0+X"MTJ7I0B,NQPI(UCQ7*G2A8X7D@DS%;/RCB<O$ULF6:Q7
M$J/+N?;9+.[@ _%\DFI2>_1UXZ,G=N&'%KT1*YP>*\07_U]S]<=?K_:'UY/U
MA"G0+?,UPIK9!W+G)_JIX?X].[MSB?FIOW53OW>!W*[S.H^YQKZOZ<$J1KZW
M!D#Z&Z@,?6'QVB['=SW0:IS.)5\=XHO_,:6Q5M=\CJ4:_!^^JW<'[_B7F?(G
MF;K_2>D?4$L#!!0    ( !AXKUI2TQ(^:P0  "0,   /    =71M9%]E>#,R
M>C$N:'1MU5=K;]LV%/W>7W&' DT"2+)D)VEJNP846VZ\/.S:3M=NV =:HBQB
M$JE1E!W_^UU24N(V"-IFW88E@67Q<>Z#]YS+]"^6UU>#%_V?;!MF4D1E2"-8
M[2 8O?/G1<D4A4+$:DLDM<"/-H3K!4.1Y:6B$B:<BPU13/#"PI?0L7 NWTFV
M3A0<#H^@[;IG=MMMG\!OL]G'RY-WO[P^]:[<#[[_\\6OX_'O#FRW6X=&:R*-
M-2<4&=@V>G01^"-\+"?+JV#0;U7/%_U6/7X^'7W"QVCR 0JU2^G;C,@UXW9*
M8]5]W<Y5;\LBE72/3\]R->C/@*1LS=]6GE4[#F+!5==S<P5+EM$";N@6YB(C
MO%>!==V#0?]\$-PE;,44=-J.UV^=HS,SM-P@AI3K3'PCI*U$WCU%[^K7E5!*
M9%W<8$P-@_ER,IX,_>5D>@.SV_GBUK]9PG+Z=^W6H7AG<.LLG*$#BV!H;'B=
M$]?Z0>C^ OS1=+8,1O^ ZXW#;]Q3F(YA>1' PI^?^S?!PIY^O H^@3]<ZADL
MN?:/L/F*KXJ\UZ!\Q\8)AU!P3D/-"]@RE8!**+POB407TAW,:2ZD A'#K2()
M7-.(A22M^:=J)L&AWO3JY5F[[?8TX0C?F3>O=P2(.Q8R \^UWT,LI#&04\E$
M!)1'C*_AFL@P@8YG@::?!:2 F*5(WGN'%C0L)5,,PR \@N N3 A?4\WNC!6%
M=A[_],J(H XD5%)T>=^M*I#&*_3;@DNZ81RN'$21?$O3%!4A831&>#2GV(;"
M-(Y9B&>!8!JKCLT"'%,LQB]YB6) N (E8*]BZX2:BM7AD$CD"@/:7]XLTE52
MXR^(7!%."WMZE](=^*')O*X2"^>)LO0^O7!%"S.5[> /+K:8*TR&SLR*IAA!
M]SM+X6FJ]_:UJG-JN']Y/FJ <U$P'427K J1HL[VOFK*(-F=8Z>MP0Z]HWX+
M 0<ZJKK8XC+%RD-US5-]X/=%(.F?)9,T0WH4.OB'+!\2K#,)WLEA='2?RX>2
MN2^7.J'>F\YQSZ3K6<3Y#[/5WLL6X\BFS'0T36)%&,<*8Q4-FE02IEF<2UKH
MK%EZFJ0IX#9D(!(9)W)JB*QWQ8QCU]3C"!@97TV:<%69FM0)9&[51+_@A/-L
M#?KW-_;'4Y3[>L-*R(C*YA"]_ YO$2F+X*5K?@X&=9$\_FP5K<<:\N3JQEMM
M>_ ,IQ]9>@;&$_+V#*1KLD/>58+]_SCSR<"' MLK<D3@U0HK/:U*F*'$H% H
MRA$/>:'UI=$:<\'<$VI+RXS LI<0B; T2TF)[UQA7U38S%#NPT:2S6NS8<L*
M6O4!W?(T<[0W1)62&FT'DN<4KY:&P;L<36MZ&_6K.4U3=$0*SD+84%DUO2<#
M2+#KK"@.Y5)L6(1P=>NH^6IXO658L"NMK+5Z8+1?KHE+R5F1/ !\2R^6P%"C
MT9LXAC+'$9U/[%G.O>).:@Y<S#\G8M?M)53??/%+=2UVFU/TCO&$7?V+Q]G"
MZ[2^8]>7ZU;US\%?4$L#!!0    ( !AXKUK\3S0>= 0   H,   /    =71M
M9%]E>#,R>C(N:'1MU5=K<]HX%/W>7W%W.M,D,\;8D%>!,F/ -&P>4"#==G?V
M@[!EK%DC:64YA'^_5[(AI*]MLJ_9)#.V+.F^=,ZY2N=B?GW5?='YH5:#B1)Q
M$=$8%AL(!V^#:5XP32$7B5X311T(XCO"S8*^6,E"4P4CSL4=T4SPW,%!Y#HX
M)S>*+5,-A_TC:'C>>:WA-4[@E\GDP^7)VY_.3OTK[WT0_'CQ\W#XJPOK]=JE
M\9(HZ\V-Q IJ-8SH(@P&^)B/YE=AMU,OGR\Z]>I[;SSXB(_!Z#WD>I/1-RNB
MEHS7,IKHUEE#ZO::Q3IM'9^>2]WM3*I5!XG@NN5[4L.<K6@.-W0-4[$BO%T:
M:'D'W<YE;_ %J\VS8_?8&*OC?+?3ZX;W*5LP#<V&V^C4>]U7?)'+=J<^P< F
M0#*VY&\BRDVAOM-[30O9.L7@J^%":"U6+=QP8!SVP^E\-!SU@_EH? .3V^GL
M-KB9PWQLO/\5OS;K7M<_AUMWYO9=F(5]Z\-OGGC.WV0]F$$P&$_FX> ?"'T;
M\&OO%,9#F%^$, NFO> FG-7&'Z["CQ#TYV8&$=G8]_D$-X_/]PD;1QPBP3F-
M#%-@S70*.J7PKB *,\TV,*52* TB@5M-4KBF,8M(5C%25]R"0[/IU<OS1L-K
M&PH2OK$COWT$:'<HU I\K_8.$J&L TD5$S%0'C.^A&NBHA2:O@.&D Z0'!*6
M(9UW <UH5"BF&:9!> SA?902OJ2&[RN6YR9X_#,K8X+*D%)%,>3]L,I$ME%A
MW [T%",<KERX%$)B71Q,B_&(24QPR#@J"L.W<9*P"$\=[1ES57H.X#?-$GR1
M!2H$X1JT@#V<5C6U.#49D5A(C3GM+]\N,MBH[,^(6A!.\]KX/J,;"");?(,-
M!^>)=LP^LW!!<SNUVL!O7*RQ7%@/4YP%S1A-6D]$P]<)WGXD-:>6\0\Z="!%
MSDP2+;+(18;BV_Y35]92K7GL-HRQ0_^H%"Z3586WI,@0?"BY,C-GOL.!HK\7
M3-$5$C$WR3]4^9 @U!3X)X?QT:Z6#ZC9(:8JJ/^Z>=RVY7H6=_[#:C7VJL4X
M$FIEVYSAL2:,(\)8R81M*0DS1):*YJ9JCIDF60:X#4F( ,<)22V7S:YD!WPT
M&-M8;9EP59'9T@DD;]E9/^&$^VP9^O<W=H9C%/EJPT*HF*KM(?KR'J\6&8OA
MI6=_#KH52.IY_3/1Z-2-I>>(]N>6GFSB&WKU#&O79(-$*D7X_W&(HVX .79F
M!+W JQW6("LQR5 SD/F:<K2'0#>"L14/>XW<4U['Z(9 '"N(1538I:3 ,=?8
MZS0V*-3O:*NQ=KC=L&8Y+87=M#%#!1,-T86B5JR!2$GQ FDIN9'HVO#5REE%
M4IIA($IP%L$=564C^VH"*;:1!<5/4HD[%J.YJA=4!+1$73,D]\)(924'F.VG
M:Y)"<9:G#P:^I[\J8"BZ&$V20"'QBZDG-B%W)Z&CB@87T\?,:GGME)J;-[Z4
MEU]O>XH^WEO!,[]XG'6\-)N;='6%KI?_ OP!4$L! A0#%     @ &'BO6AG?
MB-4ID0  5U,& !$              ( !     '5T;60M,C R-3 S,S$N:'1M
M4$L! A0#%     @ &'BO6K5<?:O*"   "48  !$              ( !6)$
M '5T;60M,C R-3 S,S$N>'-D4$L! A0#%     @ &'BO6DP%NEI""0  H74
M !4              ( !49H  '5T;60M,C R-3 S,S%?8V%L+GAM;%!+ 0(4
M Q0    ( !AXKUJ/=5CV\@H  ,&(   5              "  <:C  !U=&UD
M+3(P,C4P,S,Q7V1E9BYX;6Q02P$"% ,4    "  8>*]:X!8WEZ(H  !:\ $
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M   /              "  6$$ 0!U=&UD7V5X,S)Z,BYH=&U02P4&      H
,"@!^ @   @D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>utmd-20250331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:fil="http://www.utahmed.com/20250331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="utmd-20250331.xsd" xlink:type="simple"/>
    <context id="Y25Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="E25Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="I250512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2025-05-12</instant>
        </period>
    </context>
    <context id="E24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Y24Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Y25Q1_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Y25Q1_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Y25Q1_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Y25Q1_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="E24_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="E24_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="E24_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="E24_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="E25Q1_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="E25Q1_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="E25Q1_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="E25Q1_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="E23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="E23_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="E23_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="E23_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="E23_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Y24Q1_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Y24Q1_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Y24Q1_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Y24Q1_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="E24Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="E24Q1_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="E24Q1_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="E24Q1_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="E24Q1_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="Y25Q1_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Y25Q1_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Y25Q1_ProductOrService-Obstetrics">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Y25Q1_ProductOrService-Obstetrics_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Y25Q1_ProductOrService-Obstetrics_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Y25Q1_ProductOrService-GynecologyElectrosurgeryUrology">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Y25Q1_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Y25Q1_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Y25Q1_ProductOrService-Neonatal">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Y25Q1_ProductOrService-Neonatal_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Y25Q1_ProductOrService-Neonatal_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Y25Q1_ProductOrService-BloodPressureMonitoringAndAccessories">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Y25Q1_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Y25Q1_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Y25Q1_StScenario-SingleOperatingSeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">fil:SingleOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Y24Q1_StScenario-SingleOperatingSeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">fil:SingleOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="UsdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="Y25Q1" id="fact1">0000706698</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="Y25Q1" id="fact2">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag contextRef="Y25Q1" id="fact3">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="Y25Q1" id="fact4">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="Y25Q1" id="fact5">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType contextRef="Y25Q1" id="ixv-4854">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="Y25Q1" id="ixv-4855">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="Y25Q1" id="ixv-4856">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="Y25Q1" id="ixv-4857">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="Y25Q1" id="ixv-4858">001-12575</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="Y25Q1" id="ixv-4859">UTAH MEDICAL PRODUCTS INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="Y25Q1" id="ixv-4860">UT</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="Y25Q1" id="ixv-4861">87-0342734</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="Y25Q1" id="ixv-4862">7043 South 300 West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="Y25Q1" id="ixv-4863">Midvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="Y25Q1" id="ixv-4864">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="Y25Q1" id="ixv-4865">84047</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="Y25Q1" id="ixv-4866">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="Y25Q1" id="ixv-4867">566-1200</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="Y25Q1" id="ixv-4868">Common stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="Y25Q1" id="ixv-4869">UTMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="Y25Q1" id="ixv-4870">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="Y25Q1" id="ixv-4871">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="Y25Q1" id="ixv-4872">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="Y25Q1" id="ixv-4873">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="Y25Q1" id="ixv-4874">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="Y25Q1" id="ixv-4875">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="Y25Q1" id="ixv-4876">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I250512"
      decimals="INF"
      id="ixv-4877"
      unitRef="Shares">3248210</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-4878"
      unitRef="USD">83325000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="E24" decimals="-3" id="ixv-4879" unitRef="USD">82976000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-4880"
      unitRef="USD">3944000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="E24" decimals="-3" id="ixv-4881" unitRef="USD">4094000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-4882"
      unitRef="USD">8648000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="E24" decimals="-3" id="ixv-4883" unitRef="USD">8812000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-4884"
      unitRef="USD">482000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="E24" decimals="-3" id="ixv-4885" unitRef="USD">448000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-4886"
      unitRef="USD">96399000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="E24" decimals="-3" id="ixv-4887" unitRef="USD">96330000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-4888"
      unitRef="USD">9945000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="E24" decimals="-3" id="ixv-4889" unitRef="USD">9763000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-4890"
      unitRef="USD">13770000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="E24" decimals="-3" id="ixv-4891" unitRef="USD">13580000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-4892"
      unitRef="USD">54650000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="E24" decimals="-3" id="ixv-4893" unitRef="USD">53772000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-4894"
      unitRef="USD">52245000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="E24" decimals="-3" id="ixv-4895" unitRef="USD">50907000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-4896"
      unitRef="USD">2405000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="E24" decimals="-3" id="ixv-4897" unitRef="USD">2865000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Assets
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-4898"
      unitRef="USD">122519000</us-gaap:Assets>
    <us-gaap:Assets contextRef="E24" decimals="-3" id="ixv-4899" unitRef="USD">122538000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-4900"
      unitRef="USD">914000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="E24" decimals="-3" id="ixv-4901" unitRef="USD">696000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-4902"
      unitRef="USD">3410000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="E24" decimals="-3" id="ixv-4903" unitRef="USD">3061000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-4904"
      unitRef="USD">4324000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="E24" decimals="-3" id="ixv-4905" unitRef="USD">3757000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-4906"
      unitRef="USD">494000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="E24" decimals="-3" id="ixv-4907" unitRef="USD">603000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:OtherLongTermDebtNoncurrent
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-4908"
      unitRef="USD">0</us-gaap:OtherLongTermDebtNoncurrent>
    <us-gaap:OtherLongTermDebtNoncurrent contextRef="E24" decimals="-3" id="ixv-4909" unitRef="USD">0</us-gaap:OtherLongTermDebtNoncurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-4910"
      unitRef="USD">269000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="E24" decimals="-3" id="ixv-4911" unitRef="USD">282000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-4912"
      unitRef="USD">385000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="E24" decimals="-3" id="ixv-4913" unitRef="USD">469000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-4914"
      unitRef="USD">5472000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="E24" decimals="-3" id="ixv-4915" unitRef="USD">5111000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="E25Q1"
      decimals="INF"
      id="ixv-4916"
      unitRef="UsdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="E24"
      decimals="INF"
      id="ixv-4917"
      unitRef="UsdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-4918"
      unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="E24"
      decimals="-3"
      id="ixv-4919"
      unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-4920"
      unitRef="Shares">3281000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-4921"
      unitRef="Shares">3281000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="E24"
      decimals="-3"
      id="ixv-4922"
      unitRef="Shares">3335000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="E24"
      decimals="-3"
      id="ixv-4923"
      unitRef="Shares">3335000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-4924"
      unitRef="USD">33000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="E24" decimals="-3" id="ixv-4925" unitRef="USD">33000</us-gaap:CommonStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-4926"
      unitRef="USD">-11190000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1 contextRef="E24" decimals="-3" id="ixv-4927" unitRef="USD">-11908000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-4928"
      unitRef="USD">0</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="E24" decimals="-3" id="ixv-4929" unitRef="USD">0</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-4930"
      unitRef="USD">128204000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="E24" decimals="-3" id="ixv-4931" unitRef="USD">129302000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-4932"
      unitRef="USD">117047000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="E24" decimals="-3" id="ixv-4933" unitRef="USD">117427000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-4934"
      unitRef="USD">122519000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="E24" decimals="-3" id="ixv-4935" unitRef="USD">122538000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-4936"
      unitRef="USD">9710000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4937"
      unitRef="USD">11340000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-4938"
      unitRef="USD">4172000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4939"
      unitRef="USD">4574000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-4940"
      unitRef="USD">5538000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4941"
      unitRef="USD">6766000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-4942"
      unitRef="USD">2231000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4943"
      unitRef="USD">2617000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-4944"
      unitRef="USD">154000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4945"
      unitRef="USD">266000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-4946"
      unitRef="USD">2385000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4947"
      unitRef="USD">2883000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-4948"
      unitRef="USD">3153000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4949"
      unitRef="USD">3883000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-4950"
      unitRef="USD">705000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4951"
      unitRef="USD">915000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-4952"
      unitRef="USD">3858000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4953"
      unitRef="USD">4798000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-4954"
      unitRef="USD">817000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4955"
      unitRef="USD">842000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-4956"
      unitRef="USD">3041000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4957"
      unitRef="USD">3956000</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Y25Q1"
      decimals="INF"
      id="ixv-4958"
      unitRef="UsdPerShare">0.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Y24Q1"
      decimals="INF"
      id="ixv-4959"
      unitRef="UsdPerShare">1.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Y25Q1"
      decimals="INF"
      id="ixv-4960"
      unitRef="UsdPerShare">0.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Y24Q1"
      decimals="INF"
      id="ixv-4961"
      unitRef="UsdPerShare">1.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-4962"
      unitRef="Shares">3310000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4963"
      unitRef="Shares">3618000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-4964"
      unitRef="Shares">3310000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4965"
      unitRef="Shares">3618000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="Y25Q1"
      decimals="INF"
      id="ixv-4966"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="Y24Q1"
      decimals="INF"
      id="ixv-4967"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="Y25Q1"
      decimals="INF"
      id="ixv-4968"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="Y24Q1"
      decimals="INF"
      id="ixv-4969"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-4970"
      unitRef="USD">718000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4971"
      unitRef="USD">-631000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-4972"
      unitRef="USD">3759000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4973"
      unitRef="USD">3325000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="E24_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4974"
      unitRef="Shares">3335000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4975"
      unitRef="USD">33000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-4976"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-4977"
      unitRef="USD">-11908000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-4978"
      unitRef="USD">129302000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="E24" decimals="-3" id="ixv-4979" unitRef="USD">117427000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Y25Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4980"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y25Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4981"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y25Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-4982"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y25Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-4983"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y25Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-4984"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-4985"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares
      contextRef="Y25Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4986"
      unitRef="Shares">0</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions
      contextRef="Y25Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4987"
      unitRef="USD">0</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions
      contextRef="Y25Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-4988"
      unitRef="USD">0</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions
      contextRef="Y25Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-4989"
      unitRef="USD">0</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions
      contextRef="Y25Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-4990"
      unitRef="USD">0</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-4991"
      unitRef="USD">0</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y25Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4992"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y25Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4993"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y25Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-4994"
      unitRef="USD">82000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y25Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-4995"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y25Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-4996"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-4997"
      unitRef="USD">82000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="Y25Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4998"
      unitRef="Shares">-54000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y25Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4999"
      unitRef="USD">-1000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y25Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-5000"
      unitRef="USD">-82000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y25Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-5001"
      unitRef="USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y25Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-5002"
      unitRef="USD">-3138000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5003"
      unitRef="USD">-3221000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y25Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5004"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y25Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5005"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y25Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-5006"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y25Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-5007"
      unitRef="USD">718000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y25Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-5008"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5009"
      unitRef="USD">718000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y25Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5010"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y25Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5011"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y25Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-5012"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y25Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-5013"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y25Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-5014"
      unitRef="USD">1001000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5015"
      unitRef="USD">1001000</us-gaap:DividendsCommonStockCash>
    <us-gaap:ProfitLoss
      contextRef="Y25Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5016"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y25Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5017"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y25Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-5018"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y25Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-5019"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y25Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-5020"
      unitRef="USD">3041000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5021"
      unitRef="USD">3041000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="E25Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5022"
      unitRef="Shares">3281000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E25Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5023"
      unitRef="USD">33000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E25Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-5024"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E25Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-5025"
      unitRef="USD">-11190000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E25Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-5026"
      unitRef="USD">128204000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-5027"
      unitRef="USD">117047000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="E23_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5028"
      unitRef="Shares">3630000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5029"
      unitRef="USD">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-5030"
      unitRef="USD">593000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-5031"
      unitRef="USD">-10658000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-5032"
      unitRef="USD">138341000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="E23" decimals="-3" id="ixv-5033" unitRef="USD">128313000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5034"
      unitRef="Shares">2000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5035"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y24Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-5036"
      unitRef="USD">96000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y24Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-5037"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y24Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-5038"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5039"
      unitRef="USD">96000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5040"
      unitRef="USD">0</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5041"
      unitRef="USD">0</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions
      contextRef="Y24Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-5042"
      unitRef="USD">0</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions
      contextRef="Y24Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-5043"
      unitRef="USD">0</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions
      contextRef="Y24Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-5044"
      unitRef="USD">0</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5045"
      unitRef="USD">0</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5046"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5047"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-5048"
      unitRef="USD">79000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-5049"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-5050"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5051"
      unitRef="USD">79000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5052"
      unitRef="Shares">-43000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5053"
      unitRef="USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-5054"
      unitRef="USD">-769000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-5055"
      unitRef="USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-5056"
      unitRef="USD">-2221000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5057"
      unitRef="USD">-2990000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5058"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5059"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-5060"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-5061"
      unitRef="USD">-631000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-5062"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5063"
      unitRef="USD">-631000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5064"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5065"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-5066"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-5067"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-5068"
      unitRef="USD">1081000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5069"
      unitRef="USD">1081000</us-gaap:DividendsCommonStockCash>
    <us-gaap:ProfitLoss
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5070"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5071"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-5072"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-5073"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-5074"
      unitRef="USD">3956000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5075"
      unitRef="USD">3956000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="E24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5076"
      unitRef="Shares">3588000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-5077"
      unitRef="USD">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-5078"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-5079"
      unitRef="USD">-11289000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-5080"
      unitRef="USD">138995000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-5081"
      unitRef="USD">127742000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5082"
      unitRef="USD">3041000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5083"
      unitRef="USD">3956000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5084"
      unitRef="USD">200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5085"
      unitRef="USD">156000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5086"
      unitRef="USD">509000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5087"
      unitRef="USD">513000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5088"
      unitRef="USD">-9000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5089"
      unitRef="USD">-8000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5090"
      unitRef="USD">12000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5091"
      unitRef="USD">14000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5092"
      unitRef="USD">-209000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5093"
      unitRef="USD">-192000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5094"
      unitRef="USD">82000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5095"
      unitRef="USD">79000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredTaxExpenseFromStockOptionsExercised
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5096"
      unitRef="USD">0</us-gaap:DeferredTaxExpenseFromStockOptionsExercised>
    <us-gaap:DeferredTaxExpenseFromStockOptionsExercised
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5097"
      unitRef="USD">9000</us-gaap:DeferredTaxExpenseFromStockOptionsExercised>
    <us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5098"
      unitRef="USD">-12000</us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5099"
      unitRef="USD">214000</us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5100"
      unitRef="USD">-275000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5101"
      unitRef="USD">-271000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5102"
      unitRef="USD">26000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5103"
      unitRef="USD">87000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5104"
      unitRef="USD">217000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5105"
      unitRef="USD">230000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5106"
      unitRef="USD">360000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5107"
      unitRef="USD">549000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5108"
      unitRef="USD">1423000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5109"
      unitRef="USD">1320000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5110"
      unitRef="USD">4464000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5111"
      unitRef="USD">5276000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5112"
      unitRef="USD">184000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5113"
      unitRef="USD">22000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5114"
      unitRef="USD">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5115"
      unitRef="USD">27000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5116"
      unitRef="USD">-184000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5117"
      unitRef="USD">5000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5118"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5119"
      unitRef="USD">96000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5120"
      unitRef="USD">3221000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5121"
      unitRef="USD">2990000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDividends
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5122"
      unitRef="USD">1017000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5123"
      unitRef="USD">1089000</us-gaap:PaymentsOfDividends>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5124"
      unitRef="USD">-4238000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5125"
      unitRef="USD">-3983000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5126"
      unitRef="USD">307000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5127"
      unitRef="USD">-358000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5128"
      unitRef="USD">349000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5129"
      unitRef="USD">940000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="E24" decimals="-3" id="ixv-5130" unitRef="USD">82976000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="E23" decimals="-3" id="ixv-5131" unitRef="USD">92868000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-5132"
      unitRef="USD">83325000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-5133"
      unitRef="USD">93808000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5134"
      unitRef="USD">46000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5135"
      unitRef="USD">105000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5136"
      unitRef="USD">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5137"
      unitRef="USD">0</us-gaap:InterestPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="Y25Q1" id="ixv-2905">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. &#160;These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10-K for the year ended December 31, 2024. &#160;In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. &#160;Currency amounts are in thousands except per-share amounts and where noted.&lt;/p&gt;
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="Y25Q1" id="ixv-2908">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(2) Recent Accounting Standards. &lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;i&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. &#160;ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. &#160;The Company is currently evaluating the impact of adopting AUS 2023-09.&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;i&gt;Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/i&gt;, requiring public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. &#160;ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. &#160;The Company is currently evaluating the impact of adopting ASU 2024-03.&lt;/p&gt;
</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:InventoryDisclosureTextBlock contextRef="Y25Q1" id="ixv-2917">&lt;p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:6pt"&gt;&lt;kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt"&gt;(3)&lt;/kbd&gt;&lt;kbd style="margin-left:19.8pt"&gt;&lt;/kbd&gt;Inventories at March 31, 2025 and December 31, 2024 consisted of the following:&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:6pt"&gt;&#160;&lt;/p&gt;
&lt;table style="border-collapse:collapse;margin-left:56.75pt"&gt;&lt;tr style="height:7.2pt"&gt;&lt;td style="width:186.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:27pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;March 31,&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:73.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;December 31,&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="width:186.25pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:27pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;2025&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:73.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;2024&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE;width:186.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Finished goods&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:27pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:72pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$ &#160;1,602 &lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:73.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$ &#160;1,913&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="width:186.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Work-in-process&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:27pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,544&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:73.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,414&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE;width:186.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Raw materials&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:27pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:72pt;border-bottom:0.25pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,502&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:73.35pt;border-bottom:0.25pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,485&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="width:186.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Total &lt;/p&gt;
&lt;/td&gt;&lt;td style="width:27pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt;border-top:0.25pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$ &#160;8,648&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:73.35pt;border-top:0.25pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$ &#160;8,812&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="Y25Q1" id="ixv-2921">&lt;p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:6pt"&gt;&#160;&lt;/p&gt;
&lt;table style="border-collapse:collapse;margin-left:56.75pt"&gt;&lt;tr style="height:7.2pt"&gt;&lt;td style="width:186.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:27pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;March 31,&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:73.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;December 31,&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="width:186.25pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:27pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;2025&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:73.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;2024&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE;width:186.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Finished goods&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:27pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:72pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$ &#160;1,602 &lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:73.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$ &#160;1,913&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="width:186.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Work-in-process&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:27pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,544&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:73.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,414&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE;width:186.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Raw materials&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:27pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:72pt;border-bottom:0.25pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,502&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:73.35pt;border-bottom:0.25pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,485&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="width:186.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Total &lt;/p&gt;
&lt;/td&gt;&lt;td style="width:27pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt;border-top:0.25pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$ &#160;8,648&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:73.35pt;border-top:0.25pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$ &#160;8,812&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-5138"
      unitRef="USD">1602000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="E24" decimals="-3" id="ixv-5139" unitRef="USD">1913000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryWorkInProcess
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-5140"
      unitRef="USD">1544000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="E24" decimals="-3" id="ixv-5141" unitRef="USD">1414000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryRawMaterials
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-5142"
      unitRef="USD">5502000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="E24" decimals="-3" id="ixv-5143" unitRef="USD">5485000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryNet
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-5144"
      unitRef="USD">8648000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="E24" decimals="-3" id="ixv-5145" unitRef="USD">8812000</us-gaap:InventoryNet>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Y25Q1" id="ixv-2984">&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt"&gt;(4)&lt;/kbd&gt;&lt;kbd style="margin-left:18pt"&gt;&lt;/kbd&gt;Stock-Based Compensation. At March 31, 2025, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. &#160;The Company accounts for stock compensation under FASB Accounting Standards Codification (&#x201c;ASC&#x201d;) 718, &lt;i&gt;Compensation - Stock Compensation&lt;/i&gt;. &#160;This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. &#160;In the quarters ended March 31, 2025 and March 31, 2024, the Company recognized $82 and $79, respectively, in stock-based compensation cost.&#160;&lt;/p&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5148"
      unitRef="USD">82000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5149"
      unitRef="USD">79000</us-gaap:StockOptionPlanExpense>
    <us-gaap:ProductWarrantyDisclosureTextBlock contextRef="Y25Q1" id="ixv-2990">&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt"&gt;(5) &lt;/kbd&gt;&lt;kbd style="margin-left:18pt"&gt;&lt;/kbd&gt;Warranty Reserve. &#160;The Company&#x2019;s published warranty is: &#x201c;UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. &#160;During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.&#x201d; &#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2024 or March 31, 2025. &lt;/p&gt;
</us-gaap:ProductWarrantyDisclosureTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="Y25Q1" id="ixv-3001">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(6) 1Q 2025 global revenues (USD) by product category:&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;table style="border-collapse:collapse;border-bottom:0.5pt solid #000000"&gt;&lt;tr&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:58.3pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Domestic&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:62.6pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Outside US&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:19.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Obstetrics&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:58.3pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;832&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:18.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:62.6pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;193&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:19.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,025&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gynecology/Electrosurgery/Urology&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:58.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,329&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:62.6pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,567&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:19.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,896&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Neonatal&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:58.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,622&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:18.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:62.6pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;360&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:19.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,982&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Blood Pressure Monitoring and Accessories&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:58.3pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;800&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:62.6pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,007&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:19.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,807&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:58.3pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,583&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:18.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:62.6pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,127&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:19.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9,710&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:RevenueRecognitionPolicyTextBlock>
    <fil:ScheduleofglobalrevenuesbyproductcategoryTextBlock contextRef="Y25Q1" id="ixv-3003">&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;table style="border-collapse:collapse;border-bottom:0.5pt solid #000000"&gt;&lt;tr&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:58.3pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Domestic&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:62.6pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Outside US&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:19.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Obstetrics&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:58.3pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;832&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:18.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:62.6pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;193&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:19.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,025&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gynecology/Electrosurgery/Urology&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:58.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,329&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:62.6pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,567&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:19.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,896&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Neonatal&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:58.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,622&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:18.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:62.6pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;360&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:19.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,982&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Blood Pressure Monitoring and Accessories&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:58.3pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;800&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:62.6pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,007&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:19.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,807&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:58.3pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,583&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:18.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:62.6pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,127&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:19.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9,710&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</fil:ScheduleofglobalrevenuesbyproductcategoryTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q1_ProductOrService-Obstetrics_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-5150"
      unitRef="USD">832000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q1_ProductOrService-Obstetrics_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-5151"
      unitRef="USD">193000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q1_ProductOrService-Obstetrics"
      decimals="-3"
      id="ixv-5152"
      unitRef="USD">1025000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q1_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-5153"
      unitRef="USD">2329000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q1_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-5154"
      unitRef="USD">2567000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q1_ProductOrService-GynecologyElectrosurgeryUrology"
      decimals="-3"
      id="ixv-5155"
      unitRef="USD">4896000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q1_ProductOrService-Neonatal_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-5156"
      unitRef="USD">1622000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q1_ProductOrService-Neonatal_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-5157"
      unitRef="USD">360000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q1_ProductOrService-Neonatal"
      decimals="-3"
      id="ixv-5158"
      unitRef="USD">1982000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q1_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-5159"
      unitRef="USD">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q1_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-5160"
      unitRef="USD">1007000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q1_ProductOrService-BloodPressureMonitoringAndAccessories"
      decimals="-3"
      id="ixv-5161"
      unitRef="USD">1807000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q1_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-5162"
      unitRef="USD">5583000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q1_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-5163"
      unitRef="USD">4127000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5164"
      unitRef="USD">9710000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:EarningsPerShareTextBlock contextRef="Y25Q1" id="ixv-3136">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(7) Earnings Per Share. Basic earnings per share were calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during each applicable period. &#160;Diluted earnings per share were calculated by assuming the exercise of stock options at the closing price of stock at the end of first quarter 2025 and 2024, as applicable. The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;table style="border-collapse:collapse"&gt;&lt;tr style="height:7.3pt"&gt;&lt;td style="width:184.95pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:179.55pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-indent:3.75pt;margin-left:-13.5pt;text-align:center"&gt;Three months ended March 31&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.3pt"&gt;&lt;td style="width:184.95pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;i&gt; (in thousands)&lt;/i&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:83.85pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;2025&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:83.9pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;2024&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.3pt"&gt;&lt;td style="width:184.95pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;&lt;b&gt;Numerator&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:83.85pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:83.9pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.3pt"&gt;&lt;td style="background-color:#D3F0FE;width:184.95pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Net income&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:83.85pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,041&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:83.9pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,956&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.3pt"&gt;&lt;td style="width:184.95pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;&lt;b&gt;Denominator&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:83.85pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:83.9pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.3pt"&gt;&lt;td style="background-color:#D3F0FE;width:184.95pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Weighted average shares, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:83.85pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,310&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:83.9pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,618&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.3pt"&gt;&lt;td style="width:184.95pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Dilutive effect of stock options&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:83.85pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;-&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:83.9pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;-&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.3pt"&gt;&lt;td style="background-color:#D3F0FE;width:184.95pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Diluted shares&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:83.85pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,310&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:83.9pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,618&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:6.75pt"&gt;&lt;td style="width:184.95pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:83.85pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$0.92&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:83.9pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$1.09&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.3pt"&gt;&lt;td style="background-color:#D3F0FE;width:184.95pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, diluted&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:83.85pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$0.92&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:83.9pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$1.09&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="Y25Q1" id="ixv-3138">&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;table style="border-collapse:collapse"&gt;&lt;tr style="height:7.3pt"&gt;&lt;td style="width:184.95pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:179.55pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-indent:3.75pt;margin-left:-13.5pt;text-align:center"&gt;Three months ended March 31&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.3pt"&gt;&lt;td style="width:184.95pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;i&gt; (in thousands)&lt;/i&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:83.85pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;2025&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:83.9pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;2024&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.3pt"&gt;&lt;td style="width:184.95pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;&lt;b&gt;Numerator&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:83.85pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:83.9pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.3pt"&gt;&lt;td style="background-color:#D3F0FE;width:184.95pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Net income&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:83.85pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,041&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:83.9pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,956&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.3pt"&gt;&lt;td style="width:184.95pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;&lt;b&gt;Denominator&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:83.85pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:83.9pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.3pt"&gt;&lt;td style="background-color:#D3F0FE;width:184.95pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Weighted average shares, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:83.85pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,310&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:83.9pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,618&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.3pt"&gt;&lt;td style="width:184.95pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Dilutive effect of stock options&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:83.85pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;-&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:83.9pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;-&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.3pt"&gt;&lt;td style="background-color:#D3F0FE;width:184.95pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Diluted shares&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:83.85pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,310&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:83.9pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,618&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:6.75pt"&gt;&lt;td style="width:184.95pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:83.85pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$0.92&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:83.9pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$1.09&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.3pt"&gt;&lt;td style="background-color:#D3F0FE;width:184.95pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, diluted&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:83.85pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$0.92&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:83.9pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$1.09&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ProfitLoss
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5167"
      unitRef="USD">3041000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5168"
      unitRef="USD">3956000</us-gaap:ProfitLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5169"
      unitRef="Shares">3310000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5170"
      unitRef="Shares">3618000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5171"
      unitRef="Shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5172"
      unitRef="Shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-5173"
      unitRef="Shares">3310000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-5174"
      unitRef="Shares">3618000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="Y25Q1"
      decimals="INF"
      id="ixv-5175"
      unitRef="UsdPerShare">0.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Y24Q1"
      decimals="INF"
      id="ixv-5176"
      unitRef="UsdPerShare">1.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Y25Q1"
      decimals="INF"
      id="ixv-5177"
      unitRef="UsdPerShare">0.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Y24Q1"
      decimals="INF"
      id="ixv-5178"
      unitRef="UsdPerShare">1.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="Y25Q1" id="ixv-3239">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(8) Segment Information. &#160;The Company operates as one operating segment. &#160;The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) is its chief executive officer, who reviews financial information presented on a consolidated basis. &#160;The CODM uses consolidated gross profit margin, operating margin, and net income to assess financial performance and allocate resources. &#160;These financial metrics are used by the CODM to make key operating decisions such as the allocation of budget between cost of sales, sales and marketing, research and development, and general and administrative expenses.&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;The following table presents selected financial information with respect to the Company&#x2019;s single operating segment for the quarters ended March 31, 2025 and March 31, 2024:&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;p style="font:12pt Times New Roman;margin:0"&gt;&lt;/p&gt;
&lt;table style="border-collapse:collapse;width:288.9pt"&gt;&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:129.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;text-align:center"&gt;&lt;b&gt;Quarter Ended March 31,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;/td&gt;&lt;td style="width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;&lt;b&gt; &#160;&#160;&#160;2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Revenues&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9,710&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;11,340&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Less:&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Standard cost of sales&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,656&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,822&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Other cost of sales&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt;border-bottom:0.25pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;516&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt;border-bottom:0.25pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;753&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gross Profit&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt;border-top:0.25pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,538&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt;border-top:0.25pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;6,765&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gross Profit Margin&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;57.0%&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;59.7%&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Sales &amp;amp; Marketing&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;500&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;411&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Research &amp;amp; Development&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;154&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;266&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Litigation Fees&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;316&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;751&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Amortization&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;509&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;513&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Other General &amp;amp; Administrative&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;906&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;941&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Operating Income&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,153&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,883&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Operating Income Margin&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;32.5%&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;34.2%&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Other Income&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Interest income&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;737&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;891&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Other income (expense)&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt;border-bottom:0.25pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;(32)&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt;border-bottom:0.25pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;24&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Income before income taxes&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt;border-top:0.25pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,858&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt;border-top:0.25pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,798&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Provision for income taxes&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt;border-bottom:0.25pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;817&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt;border-bottom:0.25pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;842&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Net Income&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt;border-top:0.25pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,041&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt;border-top:0.25pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,956&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="Y25Q1" id="ixv-3244">&lt;p style="font:12pt Times New Roman;margin:0"&gt;&lt;/p&gt;
&lt;table style="border-collapse:collapse;width:288.9pt"&gt;&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:129.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;text-align:center"&gt;&lt;b&gt;Quarter Ended March 31,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;/td&gt;&lt;td style="width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;&lt;b&gt; &#160;&#160;&#160;2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Revenues&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9,710&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;11,340&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Less:&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Standard cost of sales&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,656&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,822&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Other cost of sales&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt;border-bottom:0.25pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;516&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt;border-bottom:0.25pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;753&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gross Profit&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt;border-top:0.25pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,538&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt;border-top:0.25pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;6,765&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gross Profit Margin&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;57.0%&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;59.7%&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Sales &amp;amp; Marketing&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;500&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;411&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Research &amp;amp; Development&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;154&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;266&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Litigation Fees&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;316&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;751&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Amortization&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;509&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;513&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Other General &amp;amp; Administrative&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;906&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;941&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Operating Income&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,153&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,883&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Operating Income Margin&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;32.5%&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;34.2%&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Other Income&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Interest income&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;737&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;891&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Other income (expense)&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt;border-bottom:0.25pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;(32)&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt;border-bottom:0.25pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;24&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Income before income taxes&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt;border-top:0.25pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,858&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt;border-top:0.25pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,798&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Provision for income taxes&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt;border-bottom:0.25pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;817&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt;border-bottom:0.25pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;842&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Net Income&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt;border-top:0.25pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,041&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt;border-top:0.25pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,956&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q1_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-5181"
      unitRef="USD">9710000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q1_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-5182"
      unitRef="USD">11340000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <fil:StandardCostOfSales
      contextRef="Y25Q1_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-5183"
      unitRef="USD">3656000</fil:StandardCostOfSales>
    <fil:StandardCostOfSales
      contextRef="Y24Q1_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-5184"
      unitRef="USD">3822000</fil:StandardCostOfSales>
    <fil:OtherCostOfSales
      contextRef="Y25Q1_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-5185"
      unitRef="USD">516000</fil:OtherCostOfSales>
    <fil:OtherCostOfSales
      contextRef="Y24Q1_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-5186"
      unitRef="USD">753000</fil:OtherCostOfSales>
    <us-gaap:GrossProfit
      contextRef="Y25Q1_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-5187"
      unitRef="USD">5538000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Y24Q1_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-5188"
      unitRef="USD">6765000</us-gaap:GrossProfit>
    <fil:GrossProfitMargin
      contextRef="Y25Q1_StScenario-SingleOperatingSeg"
      decimals="INF"
      id="ixv-5189"
      unitRef="Pure">0.57</fil:GrossProfitMargin>
    <fil:GrossProfitMargin
      contextRef="Y24Q1_StScenario-SingleOperatingSeg"
      decimals="INF"
      id="ixv-5190"
      unitRef="Pure">0.597</fil:GrossProfitMargin>
    <us-gaap:SellingAndMarketingExpense
      contextRef="Y25Q1_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-5191"
      unitRef="USD">500000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="Y24Q1_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-5192"
      unitRef="USD">411000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Y25Q1_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-5193"
      unitRef="USD">154000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Y24Q1_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-5194"
      unitRef="USD">266000</us-gaap:ResearchAndDevelopmentExpense>
    <fil:LitigationExpense
      contextRef="Y25Q1_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-5195"
      unitRef="USD">316000</fil:LitigationExpense>
    <fil:LitigationExpense
      contextRef="Y24Q1_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-5196"
      unitRef="USD">751000</fil:LitigationExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Y25Q1_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-5197"
      unitRef="USD">509000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Y24Q1_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-5198"
      unitRef="USD">513000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense
      contextRef="Y25Q1_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-5199"
      unitRef="USD">906000</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense
      contextRef="Y24Q1_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-5200"
      unitRef="USD">941000</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Y25Q1_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-5201"
      unitRef="USD">3153000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Y24Q1_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-5202"
      unitRef="USD">3883000</us-gaap:OperatingIncomeLoss>
    <fil:OperatingIncomeMargin
      contextRef="Y25Q1_StScenario-SingleOperatingSeg"
      decimals="INF"
      id="ixv-5203"
      unitRef="Pure">0.325</fil:OperatingIncomeMargin>
    <fil:OperatingIncomeMargin
      contextRef="Y24Q1_StScenario-SingleOperatingSeg"
      decimals="INF"
      id="ixv-5204"
      unitRef="Pure">0.342</fil:OperatingIncomeMargin>
    <us-gaap:OtherInterestAndDividendIncome
      contextRef="Y25Q1_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-5205"
      unitRef="USD">737000</us-gaap:OtherInterestAndDividendIncome>
    <us-gaap:OtherInterestAndDividendIncome
      contextRef="Y24Q1_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-5206"
      unitRef="USD">891000</us-gaap:OtherInterestAndDividendIncome>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="Y25Q1_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-5207"
      unitRef="USD">-32000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="Y24Q1_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-5208"
      unitRef="USD">24000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Y25Q1_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-5209"
      unitRef="USD">3858000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Y24Q1_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-5210"
      unitRef="USD">4798000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Y25Q1_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-5211"
      unitRef="USD">817000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Y24Q1_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-5212"
      unitRef="USD">842000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="Y25Q1_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-5213"
      unitRef="USD">3041000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q1_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-5214"
      unitRef="USD">3956000</us-gaap:ProfitLoss>
    <us-gaap:SubsequentEventsTextBlock contextRef="Y25Q1" id="ixv-3442">&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;&lt;kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt"&gt;(9)&lt;/kbd&gt;&lt;kbd style="margin-left:18pt"&gt;&lt;/kbd&gt; Subsequent Events.&lt;b&gt; &#160;&lt;/b&gt;UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its March 31, 2025 financial statements. &#160;After March 31, 2025 through May 12, 2025, the Company made additional repurchases of 32,679 shares of its stock in the open market for $1,754, at an average price of $53.67 per share. &#160;&lt;/p&gt;
</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>May 12, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">UTAH MEDICAL PRODUCTS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000706698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">UTMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0342734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,248,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-12575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7043 South 300 West<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Midvale<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">566-1200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Investments</a></td>
<td class="nump">$ 83,325<span></span>
</td>
<td class="nump">$ 82,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts &amp; other receivables, net</a></td>
<td class="nump">3,944<span></span>
</td>
<td class="nump">4,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">8,648<span></span>
</td>
<td class="nump">8,812<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">482<span></span>
</td>
<td class="nump">448<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">96,399<span></span>
</td>
<td class="nump">96,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">9,945<span></span>
</td>
<td class="nump">9,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">13,770<span></span>
</td>
<td class="nump">13,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Other intangible assets</a></td>
<td class="nump">54,650<span></span>
</td>
<td class="nump">53,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Other intangible assets - accumulated amortization</a></td>
<td class="num">(52,245)<span></span>
</td>
<td class="num">(50,907)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangible assets, net</a></td>
<td class="nump">2,405<span></span>
</td>
<td class="nump">2,865<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">122,519<span></span>
</td>
<td class="nump">122,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">914<span></span>
</td>
<td class="nump">696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,410<span></span>
</td>
<td class="nump">3,061<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,324<span></span>
</td>
<td class="nump">3,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Deferred tax liability - Femcare IIA</a></td>
<td class="nump">494<span></span>
</td>
<td class="nump">603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermDebtNoncurrent', window );">Other long term liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term lease liability</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">385<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">5,472<span></span>
</td>
<td class="nump">5,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $.01 par value; authorized - 50,000 shares; issued and outstanding - March 31, 2025, 3,281 shares and December 31, 2024, 3,335 shares</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(11,190)<span></span>
</td>
<td class="num">(11,908)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">128,204<span></span>
</td>
<td class="nump">129,302<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">117,047<span></span>
</td>
<td class="nump">117,427<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 122,519<span></span>
</td>
<td class="nump">$ 122,538<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non-owner sources, including portion attributable to noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS - Parenthetical - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">3,281<span></span>
</td>
<td class="nump">3,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">3,281<span></span>
</td>
<td class="nump">3,335<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">$ 9,710<span></span>
</td>
<td class="nump">$ 11,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">4,172<span></span>
</td>
<td class="nump">4,574<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">5,538<span></span>
</td>
<td class="nump">6,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">2,231<span></span>
</td>
<td class="nump">2,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research &amp; development</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">2,385<span></span>
</td>
<td class="nump">2,883<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">3,153<span></span>
</td>
<td class="nump">3,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">705<span></span>
</td>
<td class="nump">915<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before provision for income taxes</a></td>
<td class="nump">3,858<span></span>
</td>
<td class="nump">4,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">817<span></span>
</td>
<td class="nump">842<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 3,041<span></span>
</td>
<td class="nump">$ 3,956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per common share (basic)</a></td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="nump">$ 1.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per common share (diluted)</a></td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="nump">$ 1.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares outstanding (basic)</a></td>
<td class="nump">3,310<span></span>
</td>
<td class="nump">3,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares outstanding (diluted)</a></td>
<td class="nump">3,310<span></span>
</td>
<td class="nump">3,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation net of taxes of $0 in all periods</a></td>
<td class="nump">$ 718<span></span>
</td>
<td class="num">$ (631)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income</a></td>
<td class="nump">$ 3,759<span></span>
</td>
<td class="nump">$ 3,325<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - Parenthetical - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-21<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Comprehensive Income</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Dec. 31, 2023</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 593<span></span>
</td>
<td class="num">$ (10,658)<span></span>
</td>
<td class="nump">$ 138,341<span></span>
</td>
<td class="nump">$ 128,313<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">3,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options, shares</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions', window );">Common stock received and retired upon exercise of stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Common stock purchased and retired</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(769)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,221)<span></span>
</td>
<td class="num">(2,990)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Common stock purchased and retired, shares</a></td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(631)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(631)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,081)<span></span>
</td>
<td class="num">(1,081)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,956<span></span>
</td>
<td class="nump">3,956<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Mar. 31, 2024</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,289)<span></span>
</td>
<td class="nump">138,995<span></span>
</td>
<td class="nump">127,742<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Mar. 31, 2024</a></td>
<td class="nump">3,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Dec. 31, 2024</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,908)<span></span>
</td>
<td class="nump">129,302<span></span>
</td>
<td class="nump">117,427<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Dec. 31, 2024</a></td>
<td class="nump">3,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions', window );">Common stock received and retired upon exercise of stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares', window );">Common stock received and retired upon exercise of stock options, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Common stock purchased and retired</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(82)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,138)<span></span>
</td>
<td class="num">(3,221)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Common stock purchased and retired, shares</a></td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">718<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,001)<span></span>
</td>
<td class="num">(1,001)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,041<span></span>
</td>
<td class="nump">3,041<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Mar. 31, 2025</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (11,190)<span></span>
</td>
<td class="nump">$ 128,204<span></span>
</td>
<td class="nump">$ 117,047<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Mar. 31, 2025</a></td>
<td class="nump">3,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the monetary amount of Common stock received and retired upon exercise of stock options, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Common stock received and retired upon exercise of stock options, shares (number of shares), during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 3,041<span></span>
</td>
<td class="nump">$ 3,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">509<span></span>
</td>
<td class="nump">513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for losses on/(recovery of) accounts receivable</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of Right-of-Use Assets</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(209)<span></span>
</td>
<td class="num">(192)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxExpenseFromStockOptionsExercised', window );">Tax benefit attributable to exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets', window );">Accounts receivable and other receivables</a></td>
<td class="nump">12<span></span>
</td>
<td class="num">(214)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">360<span></span>
</td>
<td class="nump">549<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities', window );">Total adjustments</a></td>
<td class="nump">1,423<span></span>
</td>
<td class="nump">1,320<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">4,464<span></span>
</td>
<td class="nump">5,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(184)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by/(used in) investing activities</a></td>
<td class="num">(184)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock - options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Common stock purchased and retired</a></td>
<td class="num">(3,221)<span></span>
</td>
<td class="num">(2,990)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Payment of dividends</a></td>
<td class="num">(1,017)<span></span>
</td>
<td class="num">(1,089)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(4,238)<span></span>
</td>
<td class="num">(3,983)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="nump">307<span></span>
</td>
<td class="num">(358)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">349<span></span>
</td>
<td class="nump">940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at beginning of period</a></td>
<td class="nump">82,976<span></span>
</td>
<td class="nump">92,868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at end of period</a></td>
<td class="nump">83,325<span></span>
</td>
<td class="nump">93,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid during the period for income taxes</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the period for interest</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxExpenseFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax expense from write-off of the deferred tax asset related to deductible stock options at exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxExpenseFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables, and operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(1) Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">(1) Basis of Presentation</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. &#160;These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10-K for the year ended December 31, 2024. &#160;In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. &#160;Currency amounts are in thousands except per-share amounts and where noted.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(2) Recent Accounting Standards<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">(2) Recent Accounting Standards</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(2) Recent Accounting Standards. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">In December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. &#160;ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. &#160;The Company is currently evaluating the impact of adopting AUS 2023-09.</p>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;color:#000000">In November 2024, the FASB issued ASU 2024-03, <i>Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</i>, requiring public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. &#160;ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. &#160;The Company is currently evaluating the impact of adopting ASU 2024-03.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org/250/tableOfContent<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(3) Inventories<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">(3) Inventories</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:6pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">(3)</kbd><kbd style="margin-left:19.8pt"></kbd>Inventories at March 31, 2025 and December 31, 2024 consisted of the following:&#160;</p>
<p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:6pt">&#160;</p>
<table style="border-collapse:collapse;margin-left:56.75pt"><tr style="height:7.2pt"><td style="width:186.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:27pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:72pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">March 31,</p>
</td><td style="width:73.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">December 31,</p>
</td></tr>
<tr style="height:7.2pt"><td style="width:186.25pt" valign="top"></td><td style="width:27pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:72pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">2025</span></p>
</td><td style="width:73.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">2024</span></p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE;width:186.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Finished goods</p>
</td><td style="background-color:#D3F0FE;width:27pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:72pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;1,602 </p>
</td><td style="background-color:#D3F0FE;width:73.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;1,913</p>
</td></tr>
<tr style="height:7.2pt"><td style="width:186.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Work-in-process</p>
</td><td style="width:27pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:72pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,544</p>
</td><td style="width:73.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,414</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE;width:186.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Raw materials</p>
</td><td style="background-color:#D3F0FE;width:27pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:72pt;border-bottom:0.25pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,502</p>
</td><td style="background-color:#D3F0FE;width:73.35pt;border-bottom:0.25pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,485</p>
</td></tr>
<tr style="height:7.2pt"><td style="width:186.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Total </p>
</td><td style="width:27pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:72pt;border-top:0.25pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;8,648</p>
</td><td style="width:73.35pt;border-top:0.25pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;8,812</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(4) Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">(4) Stock-Based Compensation</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">(4)</kbd><kbd style="margin-left:18pt"></kbd>Stock-Based Compensation. At March 31, 2025, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. &#160;The Company accounts for stock compensation under FASB Accounting Standards Codification (&#8220;ASC&#8221;) 718, <i>Compensation - Stock Compensation</i>. &#160;This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. &#160;In the quarters ended March 31, 2025 and March 31, 2024, the Company recognized $82 and $79, respectively, in stock-based compensation cost.&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(5) Warranty Reserve<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantyDisclosureTextBlock', window );">(5) Warranty Reserve</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">(5) </kbd><kbd style="margin-left:18pt"></kbd>Warranty Reserve. &#160;The Company&#8217;s published warranty is: &#8220;UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. &#160;During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.&#8221; &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2024 or March 31, 2025. </p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(6) Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">(6) Revenue Recognition</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(6) 1Q 2025 global revenues (USD) by product category:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;border-bottom:0.5pt solid #000000"><tr><td style="width:180pt" valign="top"></td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:58.3pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Domestic</p>
</td><td style="width:18.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:62.6pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Outside US</p>
</td><td style="width:19.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Total</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:58.3pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">832</p>
</td><td style="background-color:#CCEEFF;width:18.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:62.6pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">193</p>
</td><td style="background-color:#CCEEFF;width:19.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,025</p>
</td></tr>
<tr><td style="width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:58.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,329</p>
</td><td style="width:18.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:62.6pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,567</p>
</td><td style="width:19.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,896</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:58.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,622</p>
</td><td style="background-color:#CCEEFF;width:18.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:62.6pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">360</p>
</td><td style="background-color:#CCEEFF;width:19.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,982</p>
</td></tr>
<tr><td style="width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:58.3pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">800</p>
</td><td style="width:18.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:62.6pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,007</p>
</td><td style="width:19.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,807</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt">Total</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:58.3pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,583</p>
</td><td style="background-color:#CCEEFF;width:18.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:62.6pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,127</p>
</td><td style="background-color:#CCEEFF;width:19.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,710</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(7) Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">(7) Earnings Per Share</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(7) Earnings Per Share. Basic earnings per share were calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during each applicable period. &#160;Diluted earnings per share were calculated by assuming the exercise of stock options at the closing price of stock at the end of first quarter 2025 and 2024, as applicable. The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse"><tr style="height:7.3pt"><td style="width:184.95pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" style="width:179.55pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-indent:3.75pt;margin-left:-13.5pt;text-align:center">Three months ended March 31</p>
</td></tr>
<tr style="height:7.3pt"><td style="width:184.95pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><i> (in thousands)</i></p>
</td><td style="width:83.85pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2025</span></p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:83.9pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2024</span></p>
</td></tr>
<tr style="height:7.3pt"><td style="width:184.95pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000"><b>Numerator</b></span></p>
</td><td style="width:83.85pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:83.9pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.3pt"><td style="background-color:#D3F0FE;width:184.95pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Net income</p>
</td><td style="background-color:#D3F0FE;width:83.85pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,041</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:83.9pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,956</p>
</td></tr>
<tr style="height:7.3pt"><td style="width:184.95pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000"><b>Denominator</b></span></p>
</td><td style="width:83.85pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:83.9pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.3pt"><td style="background-color:#D3F0FE;width:184.95pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Weighted average shares, basic</p>
</td><td style="background-color:#D3F0FE;width:83.85pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,310</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:83.9pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,618</p>
</td></tr>
<tr style="height:7.3pt"><td style="width:184.95pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Dilutive effect of stock options</p>
</td><td style="width:83.85pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:83.9pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td></tr>
<tr style="height:7.3pt"><td style="background-color:#D3F0FE;width:184.95pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Diluted shares</p>
</td><td style="background-color:#D3F0FE;width:83.85pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,310</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:83.9pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,618</p>
</td></tr>
<tr style="height:6.75pt"><td style="width:184.95pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, basic</p>
</td><td style="width:83.85pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">$0.92</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:83.9pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">$1.09</p>
</td></tr>
<tr style="height:7.3pt"><td style="background-color:#D3F0FE;width:184.95pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, diluted</p>
</td><td style="background-color:#D3F0FE;width:83.85pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">$0.92</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:83.9pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">$1.09</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(8) Segment Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">(8) Segment Information</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(8) Segment Information. &#160;The Company operates as one operating segment. &#160;The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) is its chief executive officer, who reviews financial information presented on a consolidated basis. &#160;The CODM uses consolidated gross profit margin, operating margin, and net income to assess financial performance and allocate resources. &#160;These financial metrics are used by the CODM to make key operating decisions such as the allocation of budget between cost of sales, sales and marketing, research and development, and general and administrative expenses.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The following table presents selected financial information with respect to the Company&#8217;s single operating segment for the quarters ended March 31, 2025 and March 31, 2024:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:12pt Times New Roman;margin:0"></p>
<table style="border-collapse:collapse;width:288.9pt"><tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" style="width:129.35pt" valign="top"><p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;text-align:center"><b>Quarter Ended March 31,</b></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"></td><td style="width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000"><b> &#160;&#160;&#160;2025</b></span></p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000"><b>2024</b></span></p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Revenues</p>
</td><td style="background-color:#D3F0FE;width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,710</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">11,340</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Less:</p>
</td><td style="width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Standard cost of sales</p>
</td><td style="background-color:#D3F0FE;width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,656</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,822</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Other cost of sales</p>
</td><td style="width:60.3pt;border-bottom:0.25pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">516</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:57.25pt;border-bottom:0.25pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">753</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Gross Profit</p>
</td><td style="background-color:#D3F0FE;width:60.3pt;border-top:0.25pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,538</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt;border-top:0.25pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,765</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Gross Profit Margin</p>
</td><td style="width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">57.0%</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">59.7%</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Sales &amp; Marketing</p>
</td><td style="background-color:#D3F0FE;width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">500</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">411</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Research &amp; Development</p>
</td><td style="width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">154</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">266</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Litigation Fees</p>
</td><td style="background-color:#D3F0FE;width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">316</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">751</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Amortization</p>
</td><td style="width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">509</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">513</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Other General &amp; Administrative</p>
</td><td style="background-color:#D3F0FE;width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">906</span></p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">941</span></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Operating Income</p>
</td><td style="width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,153</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,883</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Operating Income Margin</p>
</td><td style="background-color:#D3F0FE;width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">32.5%</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">34.2%</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Other Income</p>
</td><td style="width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Interest income</p>
</td><td style="background-color:#D3F0FE;width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">737</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">891</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Other income (expense)</p>
</td><td style="width:60.3pt;border-bottom:0.25pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">(32)</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:57.25pt;border-bottom:0.25pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">24</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Income before income taxes</p>
</td><td style="background-color:#D3F0FE;width:60.3pt;border-top:0.25pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,858</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt;border-top:0.25pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,798</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Provision for income taxes</p>
</td><td style="width:60.3pt;border-bottom:0.25pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">817</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:57.25pt;border-bottom:0.25pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">842</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Net Income</p>
</td><td style="background-color:#D3F0FE;width:60.3pt;border-top:0.25pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,041</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt;border-top:0.25pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,956</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(9) Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">(9) Subsequent Events</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">(9)</kbd><kbd style="margin-left:18pt"></kbd> Subsequent Events.<b> &#160;</b>UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its March 31, 2025 financial statements. &#160;After March 31, 2025 through May 12, 2025, the Company made additional repurchases of 32,679 shares of its stock in the open market for $1,754, at an average price of $53.67 per share. &#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(3) Inventories: Schedule of Inventory, Current (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:6pt">&#160;</p>
<table style="border-collapse:collapse;margin-left:56.75pt"><tr style="height:7.2pt"><td style="width:186.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:27pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:72pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">March 31,</p>
</td><td style="width:73.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">December 31,</p>
</td></tr>
<tr style="height:7.2pt"><td style="width:186.25pt" valign="top"></td><td style="width:27pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:72pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">2025</span></p>
</td><td style="width:73.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">2024</span></p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE;width:186.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Finished goods</p>
</td><td style="background-color:#D3F0FE;width:27pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:72pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;1,602 </p>
</td><td style="background-color:#D3F0FE;width:73.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;1,913</p>
</td></tr>
<tr style="height:7.2pt"><td style="width:186.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Work-in-process</p>
</td><td style="width:27pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:72pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,544</p>
</td><td style="width:73.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,414</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE;width:186.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Raw materials</p>
</td><td style="background-color:#D3F0FE;width:27pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:72pt;border-bottom:0.25pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,502</p>
</td><td style="background-color:#D3F0FE;width:73.35pt;border-bottom:0.25pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,485</p>
</td></tr>
<tr style="height:7.2pt"><td style="width:186.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Total </p>
</td><td style="width:27pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:72pt;border-top:0.25pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;8,648</p>
</td><td style="width:73.35pt;border-top:0.25pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;8,812</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock', window );">Schedule Of Global Revenues By Product Category</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;border-bottom:0.5pt solid #000000"><tr><td style="width:180pt" valign="top"></td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:58.3pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Domestic</p>
</td><td style="width:18.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:62.6pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Outside US</p>
</td><td style="width:19.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Total</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:58.3pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">832</p>
</td><td style="background-color:#CCEEFF;width:18.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:62.6pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">193</p>
</td><td style="background-color:#CCEEFF;width:19.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,025</p>
</td></tr>
<tr><td style="width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:58.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,329</p>
</td><td style="width:18.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:62.6pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,567</p>
</td><td style="width:19.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,896</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:58.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,622</p>
</td><td style="background-color:#CCEEFF;width:18.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:62.6pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">360</p>
</td><td style="background-color:#CCEEFF;width:19.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,982</p>
</td></tr>
<tr><td style="width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:58.3pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">800</p>
</td><td style="width:18.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:62.6pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,007</p>
</td><td style="width:19.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,807</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt">Total</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:58.3pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,583</p>
</td><td style="background-color:#CCEEFF;width:18.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:62.6pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,127</p>
</td><td style="background-color:#CCEEFF;width:19.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,710</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Global Revenues by Product Category.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse"><tr style="height:7.3pt"><td style="width:184.95pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" style="width:179.55pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-indent:3.75pt;margin-left:-13.5pt;text-align:center">Three months ended March 31</p>
</td></tr>
<tr style="height:7.3pt"><td style="width:184.95pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><i> (in thousands)</i></p>
</td><td style="width:83.85pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2025</span></p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:83.9pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2024</span></p>
</td></tr>
<tr style="height:7.3pt"><td style="width:184.95pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000"><b>Numerator</b></span></p>
</td><td style="width:83.85pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:83.9pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.3pt"><td style="background-color:#D3F0FE;width:184.95pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Net income</p>
</td><td style="background-color:#D3F0FE;width:83.85pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,041</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:83.9pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,956</p>
</td></tr>
<tr style="height:7.3pt"><td style="width:184.95pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000"><b>Denominator</b></span></p>
</td><td style="width:83.85pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:83.9pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.3pt"><td style="background-color:#D3F0FE;width:184.95pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Weighted average shares, basic</p>
</td><td style="background-color:#D3F0FE;width:83.85pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,310</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:83.9pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,618</p>
</td></tr>
<tr style="height:7.3pt"><td style="width:184.95pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Dilutive effect of stock options</p>
</td><td style="width:83.85pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:83.9pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td></tr>
<tr style="height:7.3pt"><td style="background-color:#D3F0FE;width:184.95pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Diluted shares</p>
</td><td style="background-color:#D3F0FE;width:83.85pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,310</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:83.9pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,618</p>
</td></tr>
<tr style="height:6.75pt"><td style="width:184.95pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, basic</p>
</td><td style="width:83.85pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">$0.92</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:83.9pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">$1.09</p>
</td></tr>
<tr style="height:7.3pt"><td style="background-color:#D3F0FE;width:184.95pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, diluted</p>
</td><td style="background-color:#D3F0FE;width:83.85pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">$0.92</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:83.9pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">$1.09</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(8) Segment Information: Schedule of Segment Reporting Information, by Segment (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><p style="font:12pt Times New Roman;margin:0"></p>
<table style="border-collapse:collapse;width:288.9pt"><tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" style="width:129.35pt" valign="top"><p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;text-align:center"><b>Quarter Ended March 31,</b></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"></td><td style="width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000"><b> &#160;&#160;&#160;2025</b></span></p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000"><b>2024</b></span></p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Revenues</p>
</td><td style="background-color:#D3F0FE;width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,710</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">11,340</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Less:</p>
</td><td style="width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Standard cost of sales</p>
</td><td style="background-color:#D3F0FE;width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,656</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,822</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Other cost of sales</p>
</td><td style="width:60.3pt;border-bottom:0.25pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">516</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:57.25pt;border-bottom:0.25pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">753</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Gross Profit</p>
</td><td style="background-color:#D3F0FE;width:60.3pt;border-top:0.25pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,538</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt;border-top:0.25pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,765</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Gross Profit Margin</p>
</td><td style="width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">57.0%</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">59.7%</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Sales &amp; Marketing</p>
</td><td style="background-color:#D3F0FE;width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">500</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">411</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Research &amp; Development</p>
</td><td style="width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">154</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">266</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Litigation Fees</p>
</td><td style="background-color:#D3F0FE;width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">316</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">751</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Amortization</p>
</td><td style="width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">509</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">513</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Other General &amp; Administrative</p>
</td><td style="background-color:#D3F0FE;width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">906</span></p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">941</span></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Operating Income</p>
</td><td style="width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,153</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,883</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Operating Income Margin</p>
</td><td style="background-color:#D3F0FE;width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">32.5%</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">34.2%</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Other Income</p>
</td><td style="width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Interest income</p>
</td><td style="background-color:#D3F0FE;width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">737</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">891</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Other income (expense)</p>
</td><td style="width:60.3pt;border-bottom:0.25pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">(32)</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:57.25pt;border-bottom:0.25pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">24</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Income before income taxes</p>
</td><td style="background-color:#D3F0FE;width:60.3pt;border-top:0.25pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,858</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt;border-top:0.25pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,798</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Provision for income taxes</p>
</td><td style="width:60.3pt;border-bottom:0.25pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">817</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:57.25pt;border-bottom:0.25pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">842</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Net Income</p>
</td><td style="background-color:#D3F0FE;width:60.3pt;border-top:0.25pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,041</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt;border-top:0.25pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,956</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>(3) Inventories: Schedule of Inventory, Current (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Inventory, Finished Goods, Net of Reserves</a></td>
<td class="nump">$ 1,602<span></span>
</td>
<td class="nump">$ 1,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Inventory, Work in Process, Gross</a></td>
<td class="nump">1,544<span></span>
</td>
<td class="nump">1,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Inventory, Raw Materials, Gross</a></td>
<td class="nump">5,502<span></span>
</td>
<td class="nump">5,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">$ 8,648<span></span>
</td>
<td class="nump">$ 8,812<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(4) Stock-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Obstetrics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">$ 832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Gynecology/Electrosurgery/Urology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">2,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Neonatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Blood Pressure Monitoring and Accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">5,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Obstetrics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Gynecology/Electrosurgery/Urology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">2,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Neonatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Blood Pressure Monitoring and Accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">4,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_ObstetricsMember', window );">Obstetrics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_GynecologyElectrosurgeryUrologyMember', window );">Gynecology/Electrosurgery/Urology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">4,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_NeonatalMember', window );">Neonatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_BloodPressureMonitoringAndAccessoriesMember', window );">Blood Pressure Monitoring and Accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">$ 9,710<span></span>
</td>
<td class="nump">$ 11,340<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fil_DomesticUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fil_DomesticUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_ObstetricsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_ObstetricsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_GynecologyElectrosurgeryUrologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_GynecologyElectrosurgeryUrologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_NeonatalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_NeonatalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_BloodPressureMonitoringAndAccessoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_BloodPressureMonitoringAndAccessoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fil_OutsideUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fil_OutsideUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 3,041<span></span>
</td>
<td class="nump">$ 3,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares, basic</a></td>
<td class="nump">3,310<span></span>
</td>
<td class="nump">3,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive effect of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares outstanding (diluted)</a></td>
<td class="nump">3,310<span></span>
</td>
<td class="nump">3,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per common share (basic)</a></td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="nump">$ 1.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per common share (diluted)</a></td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="nump">$ 1.09<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(8) Segment Information: Schedule of Segment Reporting Information, by Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">$ 9,710<span></span>
</td>
<td class="nump">$ 11,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">5,538<span></span>
</td>
<td class="nump">6,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research &amp; development</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">509<span></span>
</td>
<td class="nump">513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">3,153<span></span>
</td>
<td class="nump">3,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before provision for income taxes</a></td>
<td class="nump">3,858<span></span>
</td>
<td class="nump">4,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">817<span></span>
</td>
<td class="nump">842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">3,041<span></span>
</td>
<td class="nump">3,956<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=fil_SingleOperatingSegmentMember', window );">Single Operating Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">9,710<span></span>
</td>
<td class="nump">11,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_StandardCostOfSales', window );">Standard cost of sales</a></td>
<td class="nump">3,656<span></span>
</td>
<td class="nump">3,822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OtherCostOfSales', window );">Other cost of sales</a></td>
<td class="nump">516<span></span>
</td>
<td class="nump">753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">$ 5,538<span></span>
</td>
<td class="nump">$ 6,765<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_GrossProfitMargin', window );">Gross Profit Margin</a></td>
<td class="nump">57.00%<span></span>
</td>
<td class="nump">59.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and Marketing Expense</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research &amp; development</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_LitigationExpense', window );">Litigation Expense</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">509<span></span>
</td>
<td class="nump">513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSellingGeneralAndAdministrativeExpense', window );">Other Selling, General and Administrative Expense</a></td>
<td class="nump">906<span></span>
</td>
<td class="nump">941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">$ 3,153<span></span>
</td>
<td class="nump">$ 3,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OperatingIncomeMargin', window );">Operating Income Margin</a></td>
<td class="nump">32.50%<span></span>
</td>
<td class="nump">34.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInterestAndDividendIncome', window );">Other Interest and Dividend Income</a></td>
<td class="nump">$ 737<span></span>
</td>
<td class="nump">$ 891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other Operating Income (Expense), Net</a></td>
<td class="num">(32)<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before provision for income taxes</a></td>
<td class="nump">3,858<span></span>
</td>
<td class="nump">4,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">817<span></span>
</td>
<td class="nump">842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 3,041<span></span>
</td>
<td class="nump">$ 3,956<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_GrossProfitMargin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage value of Gross Profit Margin, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_GrossProfitMargin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_LitigationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the monetary amount of Litigation Expense, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_LitigationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OperatingIncomeMargin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage value of Operating Income Margin, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OperatingIncomeMargin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OtherCostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the monetary amount of Other cost of sales, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OtherCostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_StandardCostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the monetary amount of Standard cost of sales, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_StandardCostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInterestAndDividendIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after discount, accretion and premium amortization, of interest income and dividend income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInterestAndDividendIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=fil_SingleOperatingSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=fil_SingleOperatingSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>47</ContextCount>
  <ElementCount>138</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>11</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="utmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="utmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="utmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS - Parenthetical</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS - Parenthetical</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="utmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="utmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - Parenthetical</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - Parenthetical</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="utmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="utmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="utmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>000080 - Disclosure - (1) Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250331/role/idr_Disclosure1BasisOfPresentation</Role>
      <ShortName>(1) Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="utmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>000090 - Disclosure - (2) Recent Accounting Standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250331/role/idr_Disclosure2RecentAccountingStandards</Role>
      <ShortName>(2) Recent Accounting Standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="utmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>000100 - Disclosure - (3) Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250331/role/idr_Disclosure3Inventories</Role>
      <ShortName>(3) Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="utmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>000110 - Disclosure - (4) Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250331/role/idr_Disclosure4StockBasedCompensation</Role>
      <ShortName>(4) Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="utmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>000120 - Disclosure - (5) Warranty Reserve</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250331/role/idr_Disclosure5WarrantyReserve</Role>
      <ShortName>(5) Warranty Reserve</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="utmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>000130 - Disclosure - (6) Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognition</Role>
      <ShortName>(6) Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="utmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>000140 - Disclosure - (7) Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250331/role/idr_Disclosure7EarningsPerShare</Role>
      <ShortName>(7) Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="utmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>000150 - Disclosure - (8) Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformation</Role>
      <ShortName>(8) Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="utmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>000160 - Disclosure - (9) Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250331/role/idr_Disclosure9SubsequentEvents</Role>
      <ShortName>(9) Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="utmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>000170 - Disclosure - (3) Inventories: Schedule of Inventory, Current (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250331/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables</Role>
      <ShortName>(3) Inventories: Schedule of Inventory, Current (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="utmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>000180 - Disclosure - (6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables</Role>
      <ShortName>(6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="utmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>000190 - Disclosure - (7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250331/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables</Role>
      <ShortName>(7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="utmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>000200 - Disclosure - (8) Segment Information: Schedule of Segment Reporting Information, by Segment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables</Role>
      <ShortName>(8) Segment Information: Schedule of Segment Reporting Information, by Segment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="utmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>000210 - Disclosure - (3) Inventories: Schedule of Inventory, Current (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250331/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails</Role>
      <ShortName>(3) Inventories: Schedule of Inventory, Current (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20250331/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="utmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>000220 - Disclosure - (4) Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250331/role/idr_Disclosure4StockBasedCompensationDetails</Role>
      <ShortName>(4) Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20250331/role/idr_Disclosure4StockBasedCompensation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="utmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>000230 - Disclosure - (6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails</Role>
      <ShortName>(6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="utmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>000240 - Disclosure - (7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250331/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails</Role>
      <ShortName>(7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20250331/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="utmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>000250 - Disclosure - (8) Segment Information: Schedule of Segment Reporting Information, by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails</Role>
      <ShortName>(8) Segment Information: Schedule of Segment Reporting Information, by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="utmd-20250331.htm">utmd-20250331.htm</File>
    <File>utmd-20250331.xsd</File>
    <File>utmd-20250331_cal.xml</File>
    <File>utmd-20250331_def.xml</File>
    <File>utmd-20250331_lab.xml</File>
    <File>utmd-20250331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="321">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>75
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "utmd-20250331.htm": {
   "nsprefix": "fil",
   "nsuri": "http://www.utahmed.com/20250331",
   "dts": {
    "inline": {
     "local": [
      "utmd-20250331.htm"
     ]
    },
    "schema": {
     "local": [
      "utmd-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "utmd-20250331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "utmd-20250331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "utmd-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "utmd-20250331_pre.xml"
     ]
    }
   },
   "keyStandard": 130,
   "keyCustom": 8,
   "axisStandard": 4,
   "axisCustom": 0,
   "memberStandard": 4,
   "memberCustom": 7,
   "hidden": {
    "total": 5,
    "http://xbrl.sec.gov/dei/2024": 5
   },
   "contextCount": 47,
   "entityCount": 1,
   "segmentCount": 11,
   "elementCount": 182,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 321,
    "http://xbrl.sec.gov/dei/2024": 29
   },
   "report": {
    "R1": {
     "role": "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation",
     "longName": "000010 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Y25Q1",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y25Q1",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets",
     "longName": "000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "E25Q1",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "E25Q1",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical",
     "longName": "000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS - Parenthetical",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS - Parenthetical",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "E25Q1",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "UsdPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "E25Q1",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "UsdPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome",
     "longName": "000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical",
     "longName": "000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - Parenthetical",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - Parenthetical",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity",
     "longName": "000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "E23_StEqComps-CommonStock",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "E23_StEqComps-CommonStock",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow",
     "longName": "000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.utahmed.com/20250331/role/idr_Disclosure1BasisOfPresentation",
     "longName": "000080 - Disclosure - (1) Basis of Presentation",
     "shortName": "(1) Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.utahmed.com/20250331/role/idr_Disclosure2RecentAccountingStandards",
     "longName": "000090 - Disclosure - (2) Recent Accounting Standards",
     "shortName": "(2) Recent Accounting Standards",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.utahmed.com/20250331/role/idr_Disclosure3Inventories",
     "longName": "000100 - Disclosure - (3) Inventories",
     "shortName": "(3) Inventories",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.utahmed.com/20250331/role/idr_Disclosure4StockBasedCompensation",
     "longName": "000110 - Disclosure - (4) Stock-Based Compensation",
     "shortName": "(4) Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.utahmed.com/20250331/role/idr_Disclosure5WarrantyReserve",
     "longName": "000120 - Disclosure - (5) Warranty Reserve",
     "shortName": "(5) Warranty Reserve",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:ProductWarrantyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:ProductWarrantyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognition",
     "longName": "000130 - Disclosure - (6) Revenue Recognition",
     "shortName": "(6) Revenue Recognition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:RevenueRecognitionPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:RevenueRecognitionPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.utahmed.com/20250331/role/idr_Disclosure7EarningsPerShare",
     "longName": "000140 - Disclosure - (7) Earnings Per Share",
     "shortName": "(7) Earnings Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformation",
     "longName": "000150 - Disclosure - (8) Segment Information",
     "shortName": "(8) Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.utahmed.com/20250331/role/idr_Disclosure9SubsequentEvents",
     "longName": "000160 - Disclosure - (9) Subsequent Events",
     "shortName": "(9) Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.utahmed.com/20250331/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables",
     "longName": "000170 - Disclosure - (3) Inventories: Schedule of Inventory, Current (Tables)",
     "shortName": "(3) Inventories: Schedule of Inventory, Current (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables",
     "longName": "000180 - Disclosure - (6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Tables)",
     "shortName": "(6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Y25Q1",
      "name": "fil:ScheduleofglobalrevenuesbyproductcategoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y25Q1",
      "name": "fil:ScheduleofglobalrevenuesbyproductcategoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.utahmed.com/20250331/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables",
     "longName": "000190 - Disclosure - (7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Tables)",
     "shortName": "(7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables",
     "longName": "000200 - Disclosure - (8) Segment Information: Schedule of Segment Reporting Information, by Segment (Tables)",
     "shortName": "(8) Segment Information: Schedule of Segment Reporting Information, by Segment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.utahmed.com/20250331/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails",
     "longName": "000210 - Disclosure - (3) Inventories: Schedule of Inventory, Current (Details)",
     "shortName": "(3) Inventories: Schedule of Inventory, Current (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "21",
     "firstAnchor": {
      "contextRef": "E25Q1",
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "E25Q1",
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.utahmed.com/20250331/role/idr_Disclosure4StockBasedCompensationDetails",
     "longName": "000220 - Disclosure - (4) Stock-Based Compensation (Details)",
     "shortName": "(4) Stock-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:StockOptionPlanExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R23": {
     "role": "http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails",
     "longName": "000230 - Disclosure - (6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Details)",
     "shortName": "(6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Y25Q1_ProductOrService-Obstetrics_StGeo-DomesticUs",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y25Q1_ProductOrService-Obstetrics_StGeo-DomesticUs",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.utahmed.com/20250331/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails",
     "longName": "000240 - Disclosure - (7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Details)",
     "shortName": "(7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
     "longName": "000250 - Disclosure - (8) Segment Information: Schedule of Segment Reporting Information, by Segment (Details)",
     "shortName": "(8) Segment Information: Schedule of Segment Reporting Information, by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Y25Q1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Y25Q1_StScenario-SingleOperatingSeg",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250331.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r422"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts &amp; other receivables, net",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossBeforeTax1",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive loss",
        "documentation": "Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non-owner sources, including portion attributable to noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r465",
      "r466",
      "r467",
      "r469",
      "r490",
      "r525"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total adjustments",
        "totalLabel": "Total adjustments",
        "documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization {1}",
        "terseLabel": "Amortization",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r167",
      "r169",
      "r414"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r64",
      "r78",
      "r98",
      "r130",
      "r136",
      "r144",
      "r147",
      "r157",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r214",
      "r218",
      "r231",
      "r291",
      "r351",
      "r408",
      "r409",
      "r422",
      "r446",
      "r484",
      "r485",
      "r492"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total current assets",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r81",
      "r98",
      "r157",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r214",
      "r218",
      "r231",
      "r422",
      "r484",
      "r485",
      "r492"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "fil_BloodPressureMonitoringAndAccessoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20250331",
     "localname": "BloodPressureMonitoringAndAccessoriesMember",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Blood Pressure Monitoring and Accessories",
        "documentation": "Represents the Blood Pressure Monitoring and Accessories, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash &amp; Investments",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r75",
      "r398"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash at beginning of period",
        "periodStartLabel": "Cash at beginning of period",
        "periodEndLabel": "Cash at end of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r49",
      "r97"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net increase in cash and cash equivalents",
        "totalLabel": "Net increase in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r49"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r438",
      "r439",
      "r441",
      "r442",
      "r443",
      "r444",
      "r465",
      "r466",
      "r469",
      "r490",
      "r524",
      "r525"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.utahmed.com/20250331",
     "localname": "CommonStockReceivedAndRetiredUponExerciseOfStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock received and retired upon exercise of stock options",
        "documentation": "Represents the monetary amount of Common stock received and retired upon exercise of stock options, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.utahmed.com/20250331",
     "localname": "CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock received and retired upon exercise of stock options, shares",
        "documentation": "Represents the Common stock received and retired upon exercise of stock options, shares (number of shares), during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r339"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r30",
      "r339",
      "r357",
      "r525",
      "r526"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock - $.01 par value; authorized - 50,000 shares; issued and outstanding - March 31, 2025, 3,281 shares and December 31, 2024, 3,335 shares",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r294",
      "r422"
     ]
    },
    "us-gaap_ComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeMember",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income",
        "documentation": "The change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total comprehensive income",
        "totalLabel": "Total comprehensive income",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r83",
      "r85",
      "r89",
      "r287",
      "r301",
      "r302"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of goods sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r251"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred income taxes {1}",
        "terseLabel": "Deferred income taxes",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r66",
      "r464"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred income taxes",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r198",
      "r292"
     ]
    },
    "us-gaap_DeferredTaxExpenseFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxExpenseFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax benefit attributable to exercise of stock options",
        "documentation": "Amount of deferred tax expense from write-off of the deferred tax asset related to deductible stock options at exercise."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liability - Femcare IIA",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r16"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure4StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(4) Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r191",
      "r193",
      "r194",
      "r195",
      "r417"
     ]
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureTextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsCommonStockCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DividendsCommonStockCash",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock dividends",
        "negatedLabel": "Common stock dividends",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "fil_DomesticUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20250331",
     "localname": "DomesticUsMember",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DomesticUsMember",
        "documentation": "Represents the DomesticUsMember, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails",
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per common share (basic)",
        "verboseLabel": "Earnings per common share (basic)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r120",
      "r122",
      "r123",
      "r124",
      "r125",
      "r129",
      "r209",
      "r212",
      "r229",
      "r230",
      "r288",
      "r303",
      "r402"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails",
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per common share (diluted)",
        "verboseLabel": "Earnings per common share (diluted)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r122",
      "r123",
      "r124",
      "r125",
      "r129",
      "r209",
      "r212",
      "r229",
      "r230",
      "r288",
      "r303",
      "r402"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure7EarningsPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(7) Earnings Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r126",
      "r127",
      "r128"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Voluntary filer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r69",
      "r86",
      "r87",
      "r88",
      "r99",
      "r100",
      "r101",
      "r105",
      "r112",
      "r114",
      "r116",
      "r131",
      "r158",
      "r161",
      "r170",
      "r186",
      "r201",
      "r202",
      "r204",
      "r205",
      "r206",
      "r210",
      "r211",
      "r212",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r226",
      "r228",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r243",
      "r246",
      "r300",
      "r312",
      "r313",
      "r314",
      "r326",
      "r376"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other intangible assets - accumulated amortization",
        "negatedLabel": "Other intangible assets - accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r164",
      "r168",
      "r414"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other intangible assets",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r168",
      "r255",
      "r414"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r165",
      "r286",
      "r409",
      "r413",
      "r421",
      "r422",
      "r478",
      "r479"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross profit",
        "totalLabel": "Gross profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r43",
      "r63",
      "r98",
      "r157",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r231",
      "r404",
      "r408",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r484"
     ]
    },
    "fil_GrossProfitMargin": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.utahmed.com/20250331",
     "localname": "GrossProfitMargin",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Profit Margin",
        "documentation": "Represents the percentage value of Gross Profit Margin, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "fil_GynecologyElectrosurgeryUrologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20250331",
     "localname": "GynecologyElectrosurgeryUrologyMember",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gynecology/Electrosurgery/Urology",
        "documentation": "Represents the Gynecology/Electrosurgery/Urology, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income before provision for income taxes",
        "totalLabel": "Income before provision for income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r59",
      "r63",
      "r289",
      "r298",
      "r404",
      "r408",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME",
        "verboseLabel": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - Parenthetical"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r67",
      "r115",
      "r116",
      "r130",
      "r139",
      "r147",
      "r199",
      "r200",
      "r203",
      "r304",
      "r418"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid during the period for income taxes",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r51",
      "r462",
      "r487",
      "r488"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable {1}",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable and other receivables",
        "negatedLabel": "Accounts receivable and other receivables",
        "documentation": "Amount of increase (decrease) in receivables, and operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses {1}",
        "terseLabel": "Accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories {1}",
        "negatedLabel": "Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other intangible assets, net",
        "totalLabel": "Other intangible assets, net",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r480",
      "r481"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid during the period for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r95",
      "r96"
     ]
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure3Inventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(3) Inventories",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Finished Goods, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r400"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails",
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r399",
      "r422"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Raw Materials, Gross",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Work in Process, Gross",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r27",
      "r28",
      "r98",
      "r157",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r215",
      "r218",
      "r219",
      "r231",
      "r338",
      "r403",
      "r446",
      "r484",
      "r492",
      "r493"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total liabilities and stockholders' equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r58",
      "r296",
      "r422",
      "r463",
      "r477",
      "r491"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total current liabilities",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r74",
      "r98",
      "r157",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r215",
      "r218",
      "r219",
      "r231",
      "r422",
      "r484",
      "r492",
      "r493"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "fil_LitigationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.utahmed.com/20250331",
     "localname": "LitigationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Expense",
        "documentation": "Represents the monetary amount of Litigation Expense, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term lease liability",
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r293"
     ]
    },
    "fil_NeonatalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20250331",
     "localname": "NeonatalMember",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Neonatal",
        "documentation": "Represents the Neonatal, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash used in financing activities",
        "totalLabel": "Net cash used in financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash provided by/(used in) investing activities",
        "totalLabel": "Net cash provided by/(used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash provided by operating activities",
        "totalLabel": "Net cash provided by operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r52"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure2RecentAccountingStandards"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(2) Recent Accounting Standards",
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r71",
      "r102",
      "r103",
      "r106",
      "r107",
      "r117",
      "r118",
      "r155",
      "r159",
      "r160",
      "r207",
      "r208",
      "r210",
      "r212",
      "r225",
      "r227",
      "r245",
      "r247",
      "r248",
      "r252",
      "r253",
      "r254",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319"
     ]
    },
    "fil_ObstetricsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20250331",
     "localname": "ObstetricsMember",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Obstetrics",
        "documentation": "Represents the Obstetrics, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total operating expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating income",
        "totalLabel": "Operating income",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r404",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475"
     ]
    },
    "fil_OperatingIncomeMargin": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.utahmed.com/20250331",
     "localname": "OperatingIncomeMargin",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income Margin",
        "documentation": "Represents the percentage value of Operating Income Margin, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Right-of-Use Assets",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure1BasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(1) Basis of Presentation",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r56",
      "r320",
      "r321"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current assets",
        "totalLabel": "Other current assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r422"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome",
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency translation adjustment",
        "verboseLabel": "Foreign currency translation net of taxes of $0 in all periods",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r300"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r232",
      "r239"
     ]
    },
    "fil_OtherCostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.utahmed.com/20250331",
     "localname": "OtherCostOfSales",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other cost of sales",
        "documentation": "Represents the monetary amount of Other cost of sales, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherInterestAndDividendIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherInterestAndDividendIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Interest and Dividend Income",
        "documentation": "Amount, after discount, accretion and premium amortization, of interest income and dividend income classified as other."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_OtherLongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other long term liabilities",
        "documentation": "Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r337"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherOperatingIncomeExpenseNet",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Operating Income (Expense), Net",
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherSellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherSellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Selling, General and Administrative Expense",
        "documentation": "Amount of selling, general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "fil_OutsideUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20250331",
     "localname": "OutsideUsMember",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OutsideUsMember",
        "documentation": "Represents the OutsideUsMember, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock purchased and retired {1}",
        "negatedLabel": "Common stock purchased and retired",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_PaymentsOfDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDividends",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of dividends",
        "negatedLabel": "Payment of dividends",
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment",
        "negatedLabel": "Property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock - options",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r150",
      "r251",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r396",
      "r415",
      "r431",
      "r432",
      "r433",
      "r435",
      "r436",
      "r482",
      "r483",
      "r486",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523"
     ]
    },
    "us-gaap_ProductWarrantyDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductWarrantyDisclosureTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure5WarrantyReserve"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(5) Warranty Reserve",
        "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r150",
      "r251",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r396",
      "r415",
      "r431",
      "r432",
      "r433",
      "r435",
      "r436",
      "r482",
      "r483",
      "r486",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails",
      "http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow",
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome",
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net income",
        "totalLabel": "Net income",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r82",
      "r84",
      "r93",
      "r98",
      "r104",
      "r112",
      "r115",
      "r116",
      "r157",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r209",
      "r212",
      "r213",
      "r216",
      "r217",
      "r230",
      "r231",
      "r289",
      "r299",
      "r325",
      "r359",
      "r374",
      "r375",
      "r419",
      "r420",
      "r445",
      "r459",
      "r484"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r244",
      "r290",
      "r297",
      "r422"
     ]
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for losses on/(recovery of) accounts receivable",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r162"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research &amp; development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r394",
      "r408",
      "r494"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained earnings",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r55",
      "r295",
      "r315",
      "r319",
      "r323",
      "r340",
      "r422"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r99",
      "r100",
      "r101",
      "r105",
      "r112",
      "r114",
      "r116",
      "r158",
      "r161",
      "r170",
      "r201",
      "r202",
      "r204",
      "r205",
      "r206",
      "r210",
      "r211",
      "r212",
      "r220",
      "r222",
      "r223",
      "r226",
      "r228",
      "r241",
      "r243",
      "r312",
      "r314",
      "r326",
      "r525"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails",
      "http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales, net",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r130",
      "r137",
      "r138",
      "r143",
      "r147",
      "r150",
      "r152",
      "r154",
      "r187",
      "r188",
      "r251"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(6) Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r395",
      "r401"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario"
       }
      }
     },
     "auth_ref": [
      "r117",
      "r189",
      "r455",
      "r468"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r36",
      "r37",
      "r38"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r15"
     ]
    },
    "fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.utahmed.com/20250331",
     "localname": "ScheduleofglobalrevenuesbyproductcategoryTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Global Revenues By Product Category",
        "documentation": "Schedule of Global Revenues by Product Category."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r152",
      "r153",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r328",
      "r329",
      "r330",
      "r379",
      "r380",
      "r381",
      "r382",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r397",
      "r416",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r434",
      "r439",
      "r486",
      "r495",
      "r496",
      "r497",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(8) Segment Information",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r130",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r140",
      "r141",
      "r142",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r154",
      "r405",
      "r406",
      "r407",
      "r408",
      "r410",
      "r411",
      "r412"
     ]
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling and Marketing Expense",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Balance, shares",
        "periodStartLabel": "Equity Balance, shares",
        "periodEndLabel": "Equity Balance, shares",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "fil_SingleOperatingSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20250331",
     "localname": "SingleOperatingSegmentMember",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Single Operating Segment",
        "documentation": "Represents the Single Operating Segment, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "fil_StandardCostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.utahmed.com/20250331",
     "localname": "StandardCostOfSales",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Standard cost of sales",
        "documentation": "Represents the monetary amount of Standard cost of sales, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r30",
      "r33",
      "r34",
      "r69",
      "r86",
      "r87",
      "r88",
      "r99",
      "r100",
      "r101",
      "r105",
      "r112",
      "r114",
      "r116",
      "r131",
      "r158",
      "r161",
      "r170",
      "r186",
      "r201",
      "r202",
      "r204",
      "r205",
      "r206",
      "r210",
      "r211",
      "r212",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r226",
      "r228",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r243",
      "r246",
      "r300",
      "r312",
      "r313",
      "r314",
      "r326",
      "r376"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r152",
      "r153",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r328",
      "r329",
      "r330",
      "r379",
      "r380",
      "r381",
      "r382",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r397",
      "r416",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r434",
      "r439",
      "r486",
      "r495",
      "r496",
      "r497",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails",
      "http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r131",
      "r243",
      "r251",
      "r322",
      "r327",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r339",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r358",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r376",
      "r440"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS",
        "verboseLabel": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS - Parenthetical"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r117",
      "r189",
      "r455",
      "r456",
      "r468"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails",
      "http://www.utahmed.com/20250331/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r131",
      "r156",
      "r243",
      "r251",
      "r322",
      "r327",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r339",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r358",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r376",
      "r440"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon exercise of employee stock options, shares",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r29",
      "r30",
      "r55",
      "r192"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon exercise of employee stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r30",
      "r33",
      "r34",
      "r55"
     ]
    },
    "us-gaap_StockOptionPlanExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionPlanExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure4StockBasedCompensationDetails",
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option compensation expense",
        "documentation": "Amount of noncash expense for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock purchased and retired, shares",
        "documentation": "Number of shares that have been repurchased and retired during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r29",
      "r30",
      "r55"
     ]
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock purchased and retired",
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r29",
      "r30",
      "r55"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total stockholders' equity",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r33",
      "r34",
      "r53",
      "r341",
      "r357",
      "r377",
      "r378",
      "r422",
      "r446",
      "r463",
      "r477",
      "r491",
      "r525"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Balance, value",
        "periodStartLabel": "Equity Balance, value",
        "periodEndLabel": "Equity Balance, value",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r69",
      "r70",
      "r87",
      "r99",
      "r100",
      "r101",
      "r105",
      "r112",
      "r114",
      "r158",
      "r161",
      "r170",
      "r186",
      "r201",
      "r202",
      "r204",
      "r205",
      "r206",
      "r210",
      "r211",
      "r212",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r226",
      "r228",
      "r234",
      "r235",
      "r240",
      "r242",
      "r246",
      "r313",
      "r314",
      "r324",
      "r341",
      "r357",
      "r377",
      "r378",
      "r383",
      "r445",
      "r463",
      "r477",
      "r491",
      "r525"
     ]
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure9SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(9) Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r250"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TableTextBlockSupplementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TableTextBlockSupplementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Tables/Schedules"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Details"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive effect of stock options",
        "verboseLabel": "Dilutive effect of stock options",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails",
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares outstanding (diluted)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r125"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.utahmed.com/20250331/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails",
      "http://www.utahmed.com/20250331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares outstanding (basic)",
        "verboseLabel": "Weighted average shares, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r125"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/250/tableOfContent"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-6"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-21"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r460": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r461": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r462": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r463": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r466": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r467": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r468": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r469": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r470": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r473": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r474": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r475": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r476": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r478": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r483": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r485": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r486": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r487": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r488": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r489": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r492": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r493": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r494": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r496": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r497": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r498": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r499": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r500": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r501": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r502": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r503": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r504": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r505": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r506": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
